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ABSTRACT 
O-glycosylation is a common and complex post-translational modification of many 
biomolecules. While this dissertation will focus on the glycosylation with proteins, other types of 
biomolecules are also known to couple with glycans, most notably lipids. Protein glycosylation is 
usually divided into three different kinds of groups based on the first atom which links the glycan 
with the protein: N-type, O-type and the rare C-type. O-Glycosylation, the subject of this 
dissertation, is the glycans attached to the oxygen of the hydroxyl group on serine (Ser) or 
threonine (Thr) residue. 
Chapter 1 describes a strategy for the synthesis of O-mannosyl glycan. O-Mannosylation 
is a vital protein modification involved in brain and muscle development, whereas the biological 
relevance of O-mannosyl glycans remains largely unknown, due to the lack of structurally defined 
glycoforms. An efficient scaffold synthesis/enzymatic extension (SSEE) strategy was thus 
developed to prepare such structures, by combining gram-scale convergent chemical synthesis of 
3 scaffolds and strictly controlled sequential enzymatic extension catalyzed by 
glycosyltransferases. Totally, 45 O-mannosyl glycans were obtained, covering majority of 
identified mammalian structures. Subsequent glycan microarray analysis revealed fine specificities 
of glycan-binding proteins and specific antisera. 
In chapter 2, we try to develop a new method to achieve O-GalNAc glycan from cell. 
Protein O-glycosylation is a universal post-translational modification that plays an essential role 
in many biological regulations. Recently we reported a technology termed Cellular O-Glycome 
Reporter/Amplification (CORA) to amplify and profile mucin-type O-glycans from living cells. 
However, the application and development of the CORA method is litmted by the precursor 
function. Here we described a rapid parallel synthesis of cellular O-glycome precursors via 
microwave assisted reaction. In total, 26 Ac3GalNAc-α-Bn derivatives, including fluorescent and 
other reactive functional groups, were successfully synthesized. Furthermore, subsequent activity 
screening and evaluation of these precursor toward living cell and T-synthase were performed. 
In chapter 3, the first small molecule capable of acting as a dual inhibitor targeting both 
G9a and HDAC was reported. Aberrant enzymatic activities or expression profiles of epigenetic 
regulations are therapeutic targets for cancers. Among these, histone 3 lysine 9 methylation 
(H3K9Me2) and global de-acetylation on histone proteins are associated with multiple cancer 
phenotypes including leukemia, prostatic carcinoma, hepatocellular carcinoma and pulmonary 
carcinoma. In this study, we report the discovery of the first small molecule capable of acting as a 
dual inhibitor targeting both G9a and HDAC. Our structure based design, synthesis, and screening 
for the dual activity of the small molecules led to the discovery of compound 14 which displays 
promising inhibition of both G9a and HDAC in a low micro-molar range in cell based assays. 
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1 FACILE CHEMOENZYMATIC SYNTHESIS OF O-MANNOSYL GLYCANS  
O-Mannosylation is a vital protein modification involved in brain and muscle development, 
whereas the biological relevance of O-mannosyl glycans remains largely unknown, due to the lack 
of structurally defined glycoforms. An efficient scaffold synthesis/ enzymatic extension (SSEE) 
strategy was thus developed to prepare such structures, by combining gram-scale convergent 
chemical synthesis of 3 scaffolds and strictly controlled sequential enzymatic extension catalyzed 
by glycosyltransferases. Totally, 45 O-mannosyl glycans were obtained, covering majority of 
identified mammalian structures. Subsequent glycan microarray analysis revealed fine specificities 
of glycan-binding proteins and specific anti-sera. 
1.1 Introduction  
1.1.1 Biosynthesis of O-mannosyl Glycan 
O-Mannosylation is a vital protein post-translational modification that plays essential roles 
in brain and muscle development and normal tissue function.[1] Alpha-dystroglycan (α-DG) is the 
most studied O-mannosyl protein that is widely distributed in muscle and brain tissues. Abnormal 
O-mannosylation on α-DG disrupts the receptor function of dystroglycan and leads to congenital 
muscular dystrophy.[2] In addition, O-mannosyl glycans have been reported to be involved in other 
human diseases including arenaviral Infection, cancer and metastasis.[3] 
In mammalian brain tissue, O-mannosyl glycans account for up to 30% of all O-linked 
glycans.[4] Regardless of the abundance, studies on mammalian O-mannosylation have been 
mainly focused on α-DG. Recent advances in glycoproteomics enabled discovery of an increased 
number of O-mannosylated proteins and various O-mannosyl glycans.[1b, 5] To date, more than 20 
O-mannosyl glycans have been identified, which are classified into four core types.[5] As illustrated 
in Figure 1.1A, core M0, identified in cadherin family proteins,[6] represents a single structure of 
2 
one mannose (Man) residue α-linked to serine (Ser) or threonine (Thr). Core M1 contains a linear 
β1,2-linked N-acetylglucosamine (GlcNAc), whereas the branched core M2 contains both β1,2- 
and β1,6-linked GlcNAc-residue. Core M3 is a phosphorylated trisaccharide, to which 
glycosaminoglycan-like polysaccharides usually are attached.[5] 
 
Figure 1.1 (A) The 4 cores of mammalian O-mannosyl glycans; (B) identified extensions on core 
M1 and M2. 
All O-Man glycans are initiated by addition of mannose by a pair of mammalian protein 
O-mannosyl-transferases: POMT1 and POMT2, which appear to act as a functional heterodimer 
in vivo.[7] These enzymes have different expression patterns across tissues in humans, and different 
tissue-specific isoforms formed through alternative gene splicing. 
Like most other O-glycan-transferases, both POMT1 and POMT2 are found in the ER (Fig 
1.1), but interestingly they use a unique sugar donor: dolichol phosphate mannose (Dol–P–Man), 
unlike other glycosyltransferases which utilize nucleotide sugars.[1a] After the attachment of the 
first mannosyl residue, glycoproteins are transported to the Golgi apparatus. Both Core M1 and 
Core M2 structures are then extended by addition of GlcNAc through a β1–2 linkage by the UDP–
GlcNAc protein O-mannose β1-2 N-acetylglucosaminyltransferase 1 (POMGNT1).[8] POMGNT1 
works in the Golgi, and appears to be completely independent of the enzymes that catalyze 
3 
formation of the GlcNAcβ1–2Man linkages in N-glycans, since those two enzymes (GnT-I and 
GnT-II) show no reactivity towards O-mannosyl peptides in vitro.[9] The core M1 structure is then 
further elongated by Golgi-resident glycosyltransferases, including galactosyltransferases 
(GALTs), sialyltransferases (SIATs), glucuronyltransferases (GLCATs), sulfotransferase HNK-
1ST and α1-3 fucosyltransferase 9 (FUT9), to give a variety of end structures, but detailed 
mechanisms of how these steps are regulated are not well-understood.[1a] Core M2 glycans, thought 
to exist only in the brain, have a branched trisaccharide core: GlcNAcβ1–6(GlcNAcβ1–2)Man–
Ser/Thr. After synthesis of the Core M1 dimer, a branching GlcNAcβ1–6 can be added to form 
Core M2 structures. This is done by the brain-specific N-acetylglucosaminyltransferase IX (GnT-
IX) enzyme,[10] which is also involved in the synthesis of highly branched complex-type N-
glycans.[11] 
 
Figure 1.2 Biosynthesis of representative O-mannosyl glycan in the ER and Golgi apparatus. 
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1.1.2 Functional effect of O-mannosylation 
Understanding the works of O-mannosylation on the biophysical and biological properties 
on a protein or peptide is an important research area as well. Given the well documented structural 
effects of O-GalNAc type glycans on mucin domains in other systems, it was of significant interest 
to investigate how the presence of both O-Man and O-GalNAc glycans on the mucin domain of α-
DG might affect the structure of the protein. As with O-GalNAc glycosylation, biophysical and 
structural studies of synthetic model systems allowed for quick and robust conclusions to be drawn. 
For example, by synthesizing a series of glycopeptides derived from the α-DG mucin region and 
containing up to four consecutive O-Man residues, it was possible to conclude that the 
glycopeptides existed in a mostly unordered structure.[12] Interestingly, when the glycans were 
switched to O-GalNAc, the same sequence was considerably more ordered, as would be expected 
given the previous work on mucin-domain structures.[13] This comparison held across three 
different biophysical characterization methods: circular dichroism (CD), NMR and hydrogen–
deuterium exchange (HDX).[12] Combined with the well-documented importance of O-Man 
glycans in the functioning of α-DG,[1] these observations led to a proposed model where the O-
GalNAc glycans provide the mucin domain with a defined, rigid structure that supports optimal 
display of the functionally important end-groups of the O-Man glycans.[12, 14] The results of 
structural studies of the glycopeptide bearing a negatively charged 6-O-phosphomannose residue 
also supported this assertion. As with previous work on the structural effects of O-mannosylation, 
the authors found little structural difference between the unglycosylated peptide and the 
phosphomannose-containing glycopeptide.[15] Replacing the mannose derivative with an O-
GalNAc, however, resulted in significant changes in the NMR spectra of the glycopeptide. 
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In addition to the studies of the effects of O-glycosylation on unstructured mucin domains, 
many groups, including our own, have undertaken research programs to get this knowledge with 
respect to folded peptides and proteins. One example of this type of research is the work done by 
the Tan group on a Family 1 carbohydrate-binding module (CBM) of a fungal cellulase. The CBM 
is a small, 36-residue peptide domain and is responsible for recognition and binding of cellulose. 
It is naturally glycosylated by several O-glycans, which have been implicated as critical in the 
functions of this domain.[16] In order to characterize the specific effects of O-mannosylation on the 
CBM, a library of CBM glycoforms bearing mono- and oligo-mannose chains at each of the three 
possible glycosylation sites were chemically synthesized. By comparing the individual members 
of this glycoform library, the Tan group was able to show that O-mannosylated CBM was more 
stable and bound tighter to cellulose.[17] Particularly intriguingly, the authors found that 
glycosylation at Ser3, more so than at either of the other two sites, was the single most important 
factor in the thermostability of the glycoforms. 
 The core M1 and M2 are typically extended and have been identified with structures 
including N-acetyllactosamine (Gal- β1,4-GlcNAc, LN), 3-sialyl-N-acetyllactosamine (Neu5Ac-
α2,3-Gal-β1,4-GlcNAc, 3SLN), Lewis X [Gal-β1,4-(Fuc-α1,3-)GlcNAc, LeX], sialyl-LeX 
(sLeX), and the human natural killer-1 (3-sulfo-GlcA-β1,3-Gal-β1,4-Glc, HNK-1) epitopes (Fig 
1.1B).[1b] These terminal epitopes largely diversify core M1 and M2 based glycans and in fact, the 
majority of identified structures belong to these two core types.[1b] Additionally, it was found that 
the structures centered on core M1 and M2 account for 15% and 5% of all brain O-linked glycans, 
respectively.[4] Despite the abundance of core M1 and M2 structures, very little is known about 
their functional relevance.[5] Therefore, structurally well-defined O-mannosyl glycans not only 
6 
serve as ideal standards to identify and characterize such glycoforms, but also provide unique 
probes to uncover their biological roles. 
To date, only a few O-mannosyl glycans were prepared.[18] A core M1 tetrasaccharide (Fig 
1.2, M102) was firstly synthesized in 1999,[18c, 18d] and later two lower homologs (M100, M101). 
Most recently, Cao and co-workers prepared six core M1 structures (M100, M101, M102, M104, 
M105, and M102G) employing a chemoenzymatic approach.[18a] Glycopeptides harboring basic 
O-mannosyl structures (e.g., M101,[19] M102,[20] core M0,[18e] M000,[21] or core M3[22]) were also 
generated. Nevertheless, the majority of O-mannosyl glycans (especially core M2 branched 
structures) are still not accessible, which hampered in-depth understanding of O-mannosylation. 
Here an efficient strategy was developed employing scaffold synthesis/enzymatic extension 
(SSEE) to prepare 45 structurally well-defined core M1 and M2 based O-mannosyl glycans (Fig 
2), covering all identified glycoforms with the exception of the HNK-1 epitope.[1b] 
 
Figure 1.3 The 45 core M1 and M2 O-mannosyl glycans prepared in this study. 
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1.2 Results and discussion 
1.2.1 Convergent synthesis of scaffold structures 
Considering the structural signatures of O-mannosyl glycans, it is concluded that all core 
M1 and M2 structures can be enzymatically elaborated from the following three scaffolds, M100, 
M201 and M301 (Fig 1.2). We envisioned that the protected Man derivative 1 (Fig 1.3A) would 
serve as a versatile precursor for the synthesis of these scaffolds. It has a free hydroxyl group at 
the C-2 position and the 4,6-hydroxyl groups are protected as the benzylidene acetal. This 
arrangement allows performing chemical glycosylation at the C-2 position followed by the C-6 
position with the deprotection of the acetal protecting group. 
As shown in Figure 1.3, the three scaffolds required for the enzymatic extension were 
synthesized in a convergent approach and were assembled by three simple building blocks, 1, 2 
and 3 and the Fmoc-Thr(OH)-OtBu 4. To prepare the glyco-amino acid M100, donor 2 was 
chemically glycosylated to the glycosyl acceptor 1 at the C-2 position to obtain the disaccharide 5 
in 85% yield. An N-phenyltrifluoroacetimidate donor was used instead of the typical 
trichloroacetimidate, as the latter can generate over 50% of a glucosamine thioether by-product 
through thioether migration. Typical deprotection and protection strategies were employed to 
convert the benzylidene acetal, 4-methoxybenzyl ether (PMB), and trichloroethoxycarbonyl 
(Troc) protecting groups on 5 to acetyl (Ac) groups to afford 6 over three steps, with a total yield 
of 80%. The obtained thiophenyl glycosyl donor 6 was coupled to the protected threonine amino 
acid 4 at 0 °C in the presence of N-iodosuccinimide (NIS) and AgOTf to obtain the protected 
glyco-amino acid derivative 7 in excellent yield. The t-butyl (tBu) and Ac groups were then 
removed successively, followed by reintroduction of the partially cleaved 
8 
fluorenylmethyloxycarbonyl (Fmoc) group to provide the final product 8 (M100) in gram-amounts 
with a total yield of 90% over three steps.  
b2
ab4
b6
Thr
b2
a
b4
b6
Thr
b2
aThr
 
Figure 1.4 (A) The four building blocks; (B) The synthetic scheme for the assembly of the three O-
mannosyl scaffold structures. 
Reagents and conditions: (a) TMSOTf, DCM, -60 °C, 5: 85%; 10: 79%; 14: 75%; 16: 82%; (b) (i) TFA, DCM; (ii) 
Zn, AcOH; (iii) Ac2O, Py, 80% over three steps; (c) NIS, AgOTf, DCM/Et2O=1:1, 0 °C, 7: 93%; 12: 89%; 18: 83%; 
(d) (i) TFA, DCM; (ii) NaOMe, MeOH; (iii) FmocOSu, NaHCO3, Acetone/H2O=3:1, 8: 90%; 13: 85%; 19: 87%; (e) 
(i) DDQ, DCM/PBS Buffer=9:1; (ii) Ac2O, Py; (iii) EtSH, TsOH, DCM, 9: 77%; 15: 81%; (f) (i) Zn, AcOH; (ii) Ac2O, 
Py, 11: 87%; 17: 82%. 
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To synthesize M301, the PMB group on the disaccharide 5 was initially converted to Ac, 
followed by deprotection of the benzylidene acetal to achieve the diol 9. Glycosylation of 9 with 
the glycosyl donor 3 yielded the protected target tetrasaccharide 10 in 79% yield. Successively, 
the Troc protecting groups were converted to Ac groups and provided compound 11, which was 
used as glycosyl donor for coupling with the amino acid 4 to obtain the tetrasaccharide 12 in 89% 
yield. Complete deprotections of tBu and Ac groups were performed under standard reaction 
conditions and reprotection of the partially Fmoc deprotected amine afforded gram-amounts of 
compound 13 (M301), in a total yield of 85% over three steps. Similarly, 19 (M201) was prepared, 
by coupling of disaccharide donor 3 to the C-2 position of acceptor 1 followed by coupling of 2 to 
the C-6 position., Then coupling of the obtained oligosaccharide thiosglycoside 18 with amino 
acid 4 gave the desired glycosylated-amino acid 19 in a total yield of 29% over 11 steps. 
1.2.2 Enzymatic extension of scaffold structures 
To note the Fmoc was reintroduced to facilitate product detection and purification, as Fmoc 
has both UV (260 nm) and fluorescence (Ex. 260 nm, Em. 310 nm) absorbance.[23] The bulky 
hydrophobic group also enhanced retention and separation of hydrophilic O-mannosyl glycans on 
reversed phase chromatography. Herein, HPLC was used to detect, purify and quantify 
enzymatically extended O-mannosyl glycans.  
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Figure 1.5 Enzymatic extension of core M1 and core M2 structures. 
Reagents and conditions: (a) NmLgtB, UDP-Gal, Mg2+; (b) PmST1-M144D, NmCSS, Neu5Ac, CTP, Mg2+; (c) 
Pd26ST, NmCSS, Neu5Ac, CTP, Mg2+; (d) Hp3FT, GDP-Fuc, Mg2+; (e) PmST1-M144D, NmCSS, Neu5Gc, CTP, 
Mg2+; (f) Pd26ST, NmCSS, Neu5Gc, CTP, Mg2+; (g) GlcAT-P, UDP-GlcA, Mg2+; (h) PmST1m, NmCSS, Neu5Ac, 
CTP, Mg2+; (i) bGalD. 
Four robust bacterial GTs and a human b1,3-glucuronyltransferase (GlcAT-P) were used 
to extend the scaffold M100 to eight core M1 O-mannosyl glycans (Fig 1.4A). The bacterial GTs 
include, b1,4-galactosyltransferase from Neisseria meningitidis (NmLgtB),[24] mutant M144D of 
a2,3-sialyltransferase 1 from Pasteurella multocida (PmST1-M144D) with decreased donor 
hydrolysis plus reduced sialidase activity,[25] a2,6-sialyltransferase from Photobacterium 
damselae (Pd26ST),[26] and C-terminal 66 amino acids truncated a1,3-fucosyltransferase from 
Helicobacter pylori (Hp3FT) with increased solubility.[27] These GTs are all highly active and 
recognize minimal motifs (e.g., GlcNAc for NmLgtB, LN for Pd26ST and Hp3FT, LN or LeX for 
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PmST1-M144D) on oligosaccharide acceptors, and were previously applied for preparing complex 
glycans.[28]  
As illustrated in Figure 1.4, M101 was prepared by the NmLgtB-catalyzed reaction, 
containing M100 (10 mM), uridine 5'-diphosphogalactose (UDP-Gal) (15 mM), MgCl2 (10 mM), 
and an appropriate amount of NmLgtB. After overnight incubation, an m/z peak of 867.2972 was 
observed on the ESI mass spectrum, corresponding to M101 [M-H]-. Meanwhile, on the HPLC-
UV260 nm profile, a new peak (TR = 21.71 min) was observed, of which the area underneath 
increased while the peak corresponding to M100 (TR = 23.32 min) became smaller over time. After 
over 90% conversion (monitored by HPLC-UV260 nm with a 4.6 × 250 mm Inertsil ODS-4 column), 
M101 was isolated by HPLC using a semi-preparative column (Inertsil ODS-4, 20 × 250 mm). 
The purified M101 was then lyophilized, and further extended to afford M102 and M104, 
catalyzed by PmST1-M144D and Hp3FT, respectively (Fig 1.4). To make glycosylation reactions 
more efficient and less costly, the one-pot two-enzyme (OPTE)[29] approach was adopted when 
adding sialic acid residues. For example, in the PmST1-M144D-catalyzed reaction to generate 
M102, Neu5Ac, cytidine 5'-triphosphate (CTP), MgCl2, and N. meningitidis CMP-sialic acid 
synthetase (NmCSS)[30] were added to achieve in situ generation of the sugar donor CMP-Neu5Ac. 
Finally, M105 was prepared from M104 via the same OPTE approach. Employing a bacterial 
a2,6-sialyltransferase (Pd26ST), we were also able to generate a not yet identified structure, 
M103, harboring the 6-sialyl-N-acetyllactosamine (Neu5Ac-a2,6-Gal-b1,4-GlcNAc, 6SLN) 
epitope (Fig 4), which may serve as an ideal standard for mining such structures. 
Core M1 glycans terminated with N-glycolylneuraminic acid (Neu5Gc) (e.g. 3SGcLN, Fig 
1.1) were also observed on animal a-DG.[4, 31] Structures with a Neu5Gc residue (M102G and 
M103G) were thus prepared, using PmST1-M144D- and Pd26ST-catalyzed OPTE system similar 
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to the synthesis of M102 and M103. The HNK-1 epitope is a unique sulfated trisaccharide that 
highly expressed in the nervous system and plays critical roles in neuronal plasticity and 
diseases.[32] We optimized the codon and cloned the b-glucuronosyltransferase gene (GlcAT-P) 
for heterogeneous expression in E. coli. Even though pure soluble proteins were not obtained, we 
were able to synthesize a precursor structure of the HNK-1 epitope on core M1 (Fig 1.4, M106) 
using GlcAT-P-containing cell lysate. Research in obtaining a 3-sulfotransferase for generating 
HNK-1 epitope is undergoing. 
Core M2 O-mannosyl glycans can be classified into symmetric (with same motifs on both 
b1,2- and b1,6-branches, e.g., M0X0) and asymmetric (with different motifs on the branches, e.g., 
M2XX and M3XX) structures. To generate symmetric structures, chemically prepared M201 was 
firstly galactosylated by NmLgtB to afford M010. Similar as described for the synthesis of core 
M1 glycans, M020, M030 and M040 were then prepared starting from M010 via reactions 
catalyzed by PmST1-M144D, Pd26ST, and Hp3FT, respectively. On the other hand, M050 was 
prepared starting from M040 via the PmST1-M144D-catalyzed reaction (Fig 1.4B). Specifically, 
M000 was generated by treating M201 with a b-galactosidase from Streptococcus pneumoniae 
(bGalD). [31] 
The synthesis of asymmetric core M2 O-mannosyl glycans was performed starting with 
M201 or M301, by enzymatic extension of the Gal-containing branch first and then the other, in a  
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Figure 1.6 Enzymatic extension of M301 to generate core M2 O-mannosyl glycans. 
Reagents and conditions: (a) NmLgtB, UDP-Gal, Mg2+; (b) PmST1-M144D, NmCSS, Neu5Ac, CTP, Mg2+; (c) 
Pd26ST, NmCSS, Neu5Ac, CTP, Mg2+; (d) Hp3FT, GDP-Fuc, Mg2+; (h) PmST1m, NmCSS, Neu5Ac, CTP, Mg2+ 
strictly controlled sequential manner. The synthesis of M2XX is illustrated in Figure 1.4B. Such 
synthetic routes were designed according to substrate specificities of corresponding GTs to avoid 
undesirable glycosylation. With M234 as an example, the scaffold M201 was first fucosylated to 
form M204, followed by galactosylation on the b1,6-branch to provide M214. Such a synthetic 
sequence eliminates the addition of Fuc onto the b1,6-branch, as Hp3FT requires an LN 
disaccharide motif for its activity.[27] Lastly, M234 was formed by the Pd26ST-catalyzed reaction, 
which attaches a Neu5Ac residue selectively onto the terminal Gal on the b1,6-branch, as a1,3-
fucosylation prevents Pd26ST-catalyzed a2,6-sialylation[33] on the b1,2-branch. The synthetic 
scheme of M3XX is shown in Figure 1.5. It should be noted that M224 and M324 were 
synthesized from M214 and M314 (Fig 1.4B, Fig 1.5) by using mutant E271F/R313Y of PmST1 
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(PmST1m) instead of PmST1-M144D, which greatly prefers the LN disaccharide over the LeX 
trisaccharide,[34] to avoid undesired sialylation. Collectively, all 36 possible combinations of core 
M2 glycans that harboring LN, 3SLN, 6SLN, LeX or sLeX motifs were prepared. These glycans 
were purified by HPLC, and characterized by ESI/MALDI-MS & NMR to confirm the structures. 
1.2.3 Microarray analysis 
The synthesized O-mannosyl glycans are well-defined and closely related glycoforms (Fig 
1.2), providing unique probes for mining fine specificities of glycan-binding proteins (GBPs). As 
shown in Figure 1.6A, microarray analysis showed that both Ricinus communis lectin I (RCA-I) 
and Erythrina crystagalli lectin (ECA) strongly bound to M010, consistent with its primary 
specificity towards terminal LN epitope.[35] Moreover, ECA exhibited a broader specificity 
towards all O-mannosyl glycans harboring a free terminal LN (M101, M201, M21X, M301, and 
M31X), whereas RCA-I seems to prefer terminal LN on the b1,6-branch (M301 and M21X) over 
the b1,2-branch (M101, M201, M314 and M215) (Fig 1.6A). Such a branch preference was also 
found for the anti-CD15s antibody (specific to sLeX epitope), which bound to glycans that contain 
sLeX on the b1,6-branch (M050, M3X5) but not to that with sLeX only on the b1,2-branch (M105, 
M2X5) (Fig 1.6B). On the other hand, Aleuria aurantia lectin (AAL, specific to a-Fuc) exhibited 
a preference towards the b1,2-branch, as well as other fine specificities (Fig 1.7).  
ConA, an a-Man specific lectin commonly used for enriching tryptic O-mannosyl peptides, 
strongly bound to M100 but not to other natural core M1 or any core M2 structures. It thus can be 
speculated that detection or enrichment of O-mannosyl glycans using ConA may miss a substantial 
amount of complex structures (Fig 1.8). Interestingly, weak bindings of ConA to unnatural a2,6-
sialylated core M1 glycans (M103, M103G) was observed (Fig 1.8), suggesting that such 
modification may result in conformational changes that facilitated ConA binding. 
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Figure 1.7 Microarray analysis and evaluation of binding to spotted O-mannosyl glycans 
 
Anti-glycan antibodies, on the other hand, may present as better detection tools. For 
example, anti-serum from two rabbits (26559, 26560) that immunized with a core M2 glycan 
(M000) conjugate bound to a broad range of core M2-containing glycopeptides regardless of 
varied peptide sequences.[21] We further evaluated the anti-sera toward synthesized O-mannosyl 
glycans. Our results showed that both sera exhibit binding specificities towards core M2 O-
mannosyl glycans that containing at least one free terminal GlcNAc residue (M000, M20X, 
M30X) as well as the core M1 disaccharide M100 (Fig 1.6C, Fig 1.9). Moreover, antisera from 
rabbit 26560 exhibited comparable bindings to all those glycans, whereas anti-sera from rabbit 
26559 showed stronger binding to glycans contain a free GlcNAc on the b1,6-branch (M20X) 
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compared with binding to the b1,2-branch (M100, M30X) (Fig 1.9). The results imply that 
antibodies generated from different hosts may posses certain individual heterogeneity (or 
individual difference). Nevertheless, our results revealed fine specificities of the anti-sera towards 
O-mannosyl glycans. Comparing with ConA, these anti-sera are advantageous in the detection of 
branched O-mannosyl glycans. 
 
1.3 Conclusion  
In summary, by combining convergent chemical synthesis with a strictly programmed 
enzymatic synthesis in a stepwise manner, an efficient scaffold synthesis/enzymatic extension 
(SSEE) strategy was developed to access 45 mammalian O-mannosyl glycans. Such unique 
glycoforms provide not only standards for identifying O-mannosyl glycans and revealing their 
biological roles, but also ideal probes for mining fine details of protein-glycan interactions.  
1.4 Experiment Section 
1.4.1 Chemical synthesis 
All chemicals were purchased as reagent grade and used without further purification. 
Anhydrous dichloromethane (CH2Cl2), acetonitrile (CH3CN), tetrahydrofuran (THF), N,N-
dimethyl formamide (DMF), diethyl ether (Et2O), toluene, and methanol (MeOH) were purchased 
from a commercial source without further distillation. Pulverized Molecular Sieves MS-4 Å 
(Aldrich) for glycosylation was activated by heating at 350 oC for 3 h. Reactions were monitored 
by analytical thin-layer chromatography (TLC) in EM silica gel 60 F254 plates and visualized 
under UV (254 nm) and/or by staining with acidic ceric ammonium molybdate or p-anisadehyde. 
Flash chromatography was performed on silica gel (Merck) of 40-63μm particle size and P2 gel 
(Biorad). 1H and 13C NMR spectra were recorded on a Bruker AVANCE 400 (400 MHz), and 
17 
Bruker AVANCE 600 (600 MHz) spectrometer at 25 oC. All 1H Chemical shifts (in ppm) were 
assigned according to CDCl3 (δ= 7.24 ppm) and D2O (δ = 4.79 ppm) and all 
13C NMR was 
calibrated with CDCl3 (δ = 77.00 ppm). Coupling constants (J) are reported in hertz (Hz). Splitting 
patterns are described using the following abbreviations: s, singlet; brs, broad singlet; d, doublet; 
t, triplet; q, quartet; dd, doublet of doublet; m, multiplet. 1H NMR spectra are reported in the 
following order: chemical shift, multiplicity, coupling constant(s), and number(s) of protons. All 
NMR signals were assigned on the basis of 1H NMR, COSY, HSQC, HMQC, and 13C NMR 
experiments. HPLC-MS experiments were performed on an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 
high-performance liquid chromatography system (Thermo Fisher). Samples were transmitted into 
MS with a silica column. LTQ-Orbitrap Elite mass spectrometer was operated in the data-
dependent mode. A full-scan survey MS experiment (m/z range was set according to the molecular 
weight of O-mannose glycan; automatic gain control target, 1,000,000 ions; resolution at 400 m/z, 
240,000; maximum ion accumulation time, 200 ms) was acquired by the Orbitrap mass 
spectrometer. MALDI-TOF MS analyses were performed on UltrafleXtreme MALDI TOF/TOF 
Mass Spectrometer (Bruker). Scan range of MS was set according to the molecular weight of O-
mannose glycans, and reflector mode was used for O-mannose glycan analysis. Mass spectra were 
obtained in both positive and negative extraction mode with the following voltage settings: ion 
source 1 (19.0 kV), ion source 2 (15.9 kV), and lens (9.3 kV). The reflector voltage was set to 20 
kV. The laser was pulsed at 7 Hz and the pulsed ion extraction time was set at 400 ns. The laser 
power was kept in the range of 40–90%. Fmoc-Thr(OH)-OtBu (4) was purchased from Sigma-
Aldrich. 
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Glycosylation of N-phenyltrifluoroacetimidate donor (A) 
A mixture of donor (1.2 mmol), acceptor (1 mmol) and 4 Å molecular sieves in dry 
CH2Cl2 was stirred at room temperature under argon for 1 h. TMSOTf (0.2 mmol) was added at -
60 °C. The reaction mixture was stirred at -60 °C for 1 h before it was quenched with a few 
drops of triethylamine. The resulting mixture was filtered. The filtrate was concentrated in vacuo 
and purified on a silica gel column to produce the product. 
 
Glycosylation of thioether donor procedure (B) 
 A mixture of thioether donor (1 mmol), amino acid acceptor 4 (1.5-2 mmol) and 4 Å 
molecular sieves in dry Et2O/CH2Cl2 (1:1, v/v) were stirred at room temperature under argon for 
1 h. NIS (1.5 mmol) and AgOTf (0.2 mmol) were added at 0 °C. The reaction mixture was 
stirred for 10 h before it was quenched with a few drops of triethylamine. The resulting mixture 
was filtered. The filtrate was diluted with CH2Cl2 and washed with 5% aqueous Na2S2O3, 
saturated aqueous NaHCO3, brine, dried over Na2SO4, and concentrated in vacuo. The residue 
was purified on a silica gel column to produce the product. 
 
Global deprotection of Ac and tBu and reintroducing of Fmoc (C) 
Oligosaccharide glycosyl amino acid derivative (1 mmol) was dissolved in TFA/CH2Cl2 
(1:1, v/v) and stirred at room temperature under argon for 4 h. The mixture was concentrated in 
vacuo and the residue was dissolved in MeOH, and NaOMe in MeOH was added until pH was 
10. After stirring at room temperature for 2 h, the solution was neutralized with ion-exchange 
resin (H+), then filtered and concentrated in vacuo. The crude product, NaHCO3 (4 mmol) and 
9-fluorenylmethyl-Nsuccimidylcarbonate (3 mmol) were dissolved in H2O/acetone (1:1, v/v) and 
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this mixture was stirred at room temperature. After 2 h, the mixture was concentrated in vacuo 
and purified on a silica gel column to afford the product. 
 
Transformation of PMB to Ac and cleavage of benzylidene (D) 
A solution of oligosaccharide (1 mmol) in a mixture of CH2Cl2/H2O (30:1, v/v) was 
treated with DDQ (1.2 mmol) in ice bath and stirred at 25 °C for 3 h. Triethylamine was added 
and the solvent was removed in vacuo. The residue was dissolved in CH2Cl2 was cooled down to 
0 °C, followed by slow addition of acetic anhydride (3 mmol) and TEA (5 mmol). The reaction 
mixture was stirred at room temperature overnight and concentrated in vacuo. The crude product 
was dissolved in anhydrous MeOH, followed by addition of TsOH (0.1 mmol) and EtSH (6 
mmol). The reaction mixture was stirred at rt. for 6 h and then quenched with triethylamine and 
concentrated in vacuo. The mixture was purified with silica column to get the product.  
 
Transformation of NHTroc to NHAc (E) 
N-Troc protected oligosaccharide (1 mmol) was dissolved in AcOH at room temperature, 
followed by addition of Zn dust (<10 micron, 10 mmol). After being stirred at 40 °C for 24 h, the 
mixture was concentrated in vacuo to give a residue for the next step without further purification. 
To a solution of the residue in pyridine was added Ac2O. After being stirred at room temperature 
for 12 h, the solution was diluted with ethyl acetate and washed with aqueous HCl (1 M), 
saturated aqueous NaHCO3, and brine solution. The organic layer was dried over Na2SO4, 
filtered, and concentrated in vacuo to give a residue, which was purified by silica gel column 
chromatography to generate NHAc containing compound. 
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Preparation of the versatile precursor 1. 
 
4,6-O-benzylidene-1-thio-α-D-Mannopyranoside[36] (13.40 g, 37.2 mmol), dibutyltin 
oxide (10.23 g, 40.9 mmol) and toluene (250 mL) were refluxed for 3 h, followed by concentration 
in vacuo. The residue, tetrabutylammonium iodide (15.09 g, 40.9 mmol), 4-Methoxybenzyl 
chloride (6.39 mL, 40.9 mmol), and toluene (250 mL) were stirred at 70 °C overnight. Toluene 
was removed by concentration in vacuo and the residue was diluted with ethyl acetate (300 mL). 
The resulting solution was washed with water and saturated aqueous NaHCO3, dried over Na2SO4, 
filtered, and concentrated in vacuo. The resulting residue was purified by silica gel column 
chromatography (hexane/ethyl acetate, 4:1, v/v) to afford precursor 1 (16.26 g, 91%) as white 
foams. Rf = 0.28 (hexane/ethyl acetate, 4:1, v/v);
 1H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 7.6, 
1.8 Hz, 2H), 7.46 – 7.34 (m, 5H), 7.35 – 7.25 (m, 5H), 6.88 (d, J = 8.7 Hz, 2H), 5.61 (s, 1H), 5.57 
(s, 1H), 4.81 (d, J = 11.4 Hz, 1H), 4.66 (d, J = 11.4 Hz, 1H), 4.33 (td, J = 9.8, 4.9 Hz, 1H), 4.25 – 
4.11 (m, 3H), 3.93 (dd, J = 9.5, 3.4 Hz, 1H), 3.84 (t, J = 10.3 Hz, 1H), 3.80 (s, 3H), 2.95 (d, J = 
1.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 159.47, 137.42, 133.27, 131.65, 129.74, 129.61, 
129.10, 128.94, 128.20, 127.63, 126.05, 113.90, 101.57, 87.76, 78.92, 75.35, 72.87, 71.32, 68.48, 
64.57, 55.23; MALDI-MS: [M+Na]+ C27H28O6SNa calculated for 503.1504, found 503.1515. 
  
Preparation of N-phenyltrifluoroacetimidate donor 2. 
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1,3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranose 
(5.70 g, 10.9 mmol) was dissolved in THF (100 mL) followed by the addition of benzylamine 
(2.10 mL, 19.6 mmol). After the reaction mixture was stirred at room temperature for 8 h under 
dry atmosphere, it was evaporated and the residue was diluted with ethyl acetate and washed 
successively with 1 M aqueous HCl, saturated aqueous NaHCO3, and brine. The organic layer was 
dried over MgSO4, filtrated and concentrated under high vacuum. The crude product was 
dissolved in CH2Cl2 (200 mL), then 2,2,2-Trifluoro-N-phenylacetimidoyl Chloride (3.42 mL, 21.8 
mmol) and 1,8-diazabicyclo-[5,4,0]-7-undecene (2.44 mL, 16.4 mmol) were added at 0 °C under 
dry atmosphere. After the reaction mixture was stirred at room temperature for 2 h, it was 
evaporated followed by purification by silica gel column chromatography (hexane/ethyl acetate 
4/1) to afford imidate donor 2 (5.50 g, 77% over two steps) as a white foams, which were found 
unstable and used immediately in the subsequent glycosylation without further characterization. 
 
Preparation of N-phenyltrifluoroacetimidate donor 3. 
 
Phenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-acetyl-2-deoxy-2-
(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranoside[37] (5.10 g, 5.9 mmol) was dissolved 
in Actone/H2O (10:1, v/v, 60 mL) at -30 °C and N-Bromosuccinimide (5.25 g, 29.5 mmol) was 
added to the solution. After stirred at -30 °C for 2 h, the reaction was quenched with 5% aqueous 
Na2S2O3 (10 mL) and saturated aqueous NaHCO3 (10 mL). The mixture was diluted with ethyl 
acetate and washed with brine. The organic layer was dried over NaSO4, filtered, and concentrated. 
The residue was dissolved in CH2Cl2 (100 mL), then 2,2,2-Trifluoro-N-phenylacetimidoyl 
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Chloride (1.85 mL, 11.8 mmol) and 1,8-diazabicyclo-[5,4,0]-7-undecene (1.32 mL, 8.9 mmol) 
were added at 0 °C under dry atmosphere. After the reaction mixture was stirred at room 
temperature for 2 h, it was evaporated followed by purification by silica gel column 
chromatography (hexane/acetone 4/1) to afford imidate donor 3 (4.29 g, 75% over two steps) as a 
white foams, which were found instable and used immediately in the subsequent glycosylation 
without further characterization. 
 
Phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-
glucopyranosyl-(1→2)-4,6-O-benzylidene-3-(4-Methoxybenzyl)-1-thio-α-D-
Mannopyranoside (5) 
Compound 1 (3.37 g, 7.0 mmol) was glycosylated with fresh-made donor 2 (5.50 g, 8.43 
mmol) by following general procedure A to get the desired compound 5 (5.63 g, 85%) as white 
foam. Rf = 0.30 (hexane/ethyl acetate, 3:1, v/v); 
1H NMR (400 MHz, CDCl3) δ 7.60 – 7.49 (m, 
2H), 7.49 – 7.37 (m, 5H), 7.37 – 7.30 (m, 5H), 6.94 – 6.84 (m, 2H), 5.64 (s, 1H), 5.54 (dd, J = 
10.7, 9.3 Hz, 1H), 5.48 (d, J = 1.4 Hz, 1H), 5.37 – 5.30 (m, 1H), 5.14 – 5.01 (m, 2H), 4.78 (d, J = 
11.2 Hz, 1H), 4.74 – 4.63 (m, 2H), 4.52 (d, J = 12.5 Hz, 1H), 4.40 (dd, J = 3.3, 1.6 Hz, 1H), 4.35 
– 4.11 (m, 5H), 3.96 (dd, J = 9.8, 3.2 Hz, 1H), 3.88 – 3.78 (m, 4H), 3.77 – 3.70 (m, 1H), 3.44 (dt, 
J = 10.9, 8.1 Hz, 1H), 2.05 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
170.63, 170.27, 169.58, 159.40, 137.50, 133.42, 131.72, 129.87, 129.66, 129.23, 128.94, 128.25, 
127.91, 126.06, 113.87, 101.55, 87.40, 78.75, 76.40, 74.40, 72.49, 72.09, 68.80, 68.49, 65.32, 
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62.16, 60.42, 55.26, 21.06, 20.71, 20.65, 20.58; MALDI-MS: [M+Na]+ C42H46Cl3NO15SNa 
calculated for 964.1552, found 964.1538.  
 
Phenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→2)-3,4,6-tri-
O-acetyl-1-thio-α-D-Mannopyranoside (6) 
Compound 5 (2.83 g, 3.0 mmol) was dissolved in TFA/CH2Cl2 (10:1, v/v, 50 mL) and 
stirred at room temperature under argon for 1 h. CH2Cl2 (100 mL) was added to dilute the reaction 
and then neutralized with saturated aqueous NaHCO3. The organic layer was separated and washed 
with brine. After dried over anhydrous Na2SO4 and concentrated, the residue was treated by 
following general procedure E to afford compound 6 (1.74 g, 80%) as white foam. Rf = 0.30 
(hexane/acetone, 3:1, v/v); 1H NMR (400 MHz, CDCl3) δ 7.58 – 7.42 (m, 2H), 7.41 – 7.24 (m, 
3H), 5.73 (d, J = 7.9 Hz, 1H), 5.51 (t, J = 9.9 Hz, 1H), 5.45 (s, 1H), 5.30 (t, J = 10.0 Hz, 1H), 5.12 
– 4.95 (m, 2H), 4.53 – 4.41 (m, 2H), 4.33 – 4.20 (m, 2H), 4.11 – 3.97 (m, 2H), 3.72 (dd, J = 10.2, 
5.1 Hz, 1H), 3.59 (dt, J = 11.5, 8.1 Hz, 1H), 2.11 – 2.07 (m, 6H), 2.05 (s, 3H), 2.03 (s, 3H), 2.02 
– 1.99 (m, 6H), 1.86 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.78, 170.67, 170.62, 170.50, 
170.35, 169.56, 169.51, 133.14, 131.55, 129.18, 127.87, 98.40, 85.07, 75.47, 71.84, 71.47, 70.46, 
69.53, 68.83, 66.20, 62.71, 62.05, 55.63, 23.19, 20.75, 20.72, 20.70, 20.67, 20.63; [M+Na]+ 
C32H41NO16SNa calculated for 750.2044, found 750.2032. 
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Nα-9-Fluorenylmethyloxycarbonyl-O-[2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranosyl-(1→2)-3,4,6-tri-O-acetyl-α-D-mannopyranosyl]-L-threonine tertbutyl ester 
(7) 
Compound 6 (1.74 g, 2.4 mmol) was glycosylated with compound 4 (1.43 g, 3.6 mmol) by 
following general procedure B to get the desired compound 7 (2.27 g, 93%) as white foam. Rf = 
0.29 (hexane/acetone, 3:1, v/v); 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 7.4 Hz, 2H), 7.72 – 
7.54 (m, 2H), 7.47 – 7.29 (m, 4H), 5.76 (d, J = 7.9 Hz, 1H), 5.56 (d, J = 9.0 Hz, 1H), 5.43 (t, J = 
9.8 Hz, 1H), 5.23 (t, J = 9.7 Hz, 1H), 5.10 – 4.94 (m, 2H), 4.91 – 4.80 (m, 2H), 4.58 – 4.14 (m, 
8H), 4.14 – 4.05 (m, 2H), 4.05 – 3.88 (m, 2H), 3.72 – 3.51 (m, 2H), 2.08 (s, 6H), 2.07 (s, 3H), 2.04 
(s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.95 (s, 3H), 1.53 (s, 9H), 1.32 (d, J = 5.6 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 170.65, 170.60, 170.56, 169.47, 169.32, 156.52, 143.84, 143.74, 141.31, 
127.78, 127.11, 125.18, 120.04, 99.00, 98.89, 82.67, 74.15, 71.86, 71.65, 69.95, 69.21, 68.79, 
67.36, 66.09, 62.89, 62.10, 58.92, 55.31, 47.17, 28.03, 23.24, 20.75, 20.71, 20.64, 17.88; [M+Na]+ 
C49H62N2O21Na calculated for 1037.3743, found 1037.3752. 
 
25 
Nα-9-Fluorenylmethyloxycarbonyl-O-[2-acetamido-2-deoxy-β-D-glucopyranosyl-
(1→2)-α-D-mannopyranosyl]-L-threonine (8, M100) 
Compound 7 (2.13 g, 2.1 mmol) was treated by following general procedure C to afford 
compound 8 (1.34 g, 90%) as white foam. Rf = 0.40 (ethyl acetate/methanol/H2O, 4:2:0.5, v/v); 
1H 
NMR (400 MHz, D2O) δ 7.74 – 7.60 (m, 2H), 7.60 – 7.40 (m, 2H), 7.40 – 7.18 (m, 4H), 4.60 (dd, 
J = 10.7, 4.9 Hz, 1H), 4.42 – 4.27 (m, 2H), 4.23 (d, J = 6.3 Hz, 1H), 4.12 – 3.96 (m, 1H), 3.83 – 
3.71 (m, 4H), 3.71 – 3.42 (m, 7H), 3.42 – 3.30 (m, 3H), 3.27 (s, 1H), 1.96 (s, 3H), 0.94 (d, J = 6.1 
Hz, 3H); 13C NMR (100 MHz, D2O) δ 174.87, 158.05, 143.91, 143.49, 140.96, 140.91, 127.96, 
127.41, 124.90, 124.78, 120.09, 100.01, 98.04, 77.19, 75.59, 73.28, 73.05, 69.84, 69.26, 67.22, 
65.92, 61.60, 60.52, 55.26, 47.10, 22.35, 18.33; [M-H]- C33H41N2O15 calculated for 705.2585, 
found 705.2470. 
 
Phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-
glucopyranosyl-(1→2)-3-O-acetyl-1-thio-α-D-Mannopyranoside (9) 
Compound 5 (3.58 g, 3.8 mmol) was treated by following general procedure C to afford 
compound 9 (2.27 g, 77%) as white foam. Rf = 0.33 (hexane/acetone, 4:1, v/v); 
1H NMR (400 
MHz, CDCl3) δ 7.42 (d, J = 6.5 Hz, 2H), 7.36 – 7.19 (m, 3H), 6.00 (d, J = 8.2 Hz, 1H), 5.35 (s, 
1H), 5.25 (t, J = 9.9 Hz, 1H), 4.99 (t, J = 9.5 Hz, 1H), 4.88 (d, J = 9.6 Hz, 1H), 4.71 – 4.56 (m, 
2H), 4.52 – 4.37 (m, 2H), 4.33 – 4.15 (m, 2H), 4.15 – 3.97 (m, 2H), 3.87 (t, J = 10.5 Hz, 1H), 3.80 
– 3.45 (m, 4H), 2.93 (d, J = 8.7 Hz, 1H), 2.10 (s, 3H), 2.08 (s, 3H), 2.00 (s, 3H), 1.98 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 170.99, 170.89, 170.77, 169.52, 154.57, 133.42, 131.69, 129.27, 
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127.94, 100.41, 95.00, 85.81, 76.94, 74.56, 73.42, 73.20, 71.77, 71.35, 68.58, 64.12, 62.12, 61.50, 
56.05, 20.91, 20.68, 20.59; [M+Na]+ C29H36Cl3NO15SNa calculated for 798.0769, found 798.0778. 
 
Phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-
glucopyranosyl-(1→2)-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-acetyl-
2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl]-(1→6)-3-O-acetyl-1-
thio-α-D-mannopyranoside (10) 
Compound 9 (2.10 g, 2.7 mmol) was glycosylated with fresh-made donor 3 (3.05 g, 3.2 
mmol) by following general procedure A to get the desired compound 10 (3.26 g, 79%) as white 
foam. Rf = 0.35 (hexane/acetone, 2:1, v/v); 
1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 6.7 Hz, 2H), 
7.39 – 7.24 (m, 3H), 6.32 (d, J = 8.4 Hz, 1H), 6.05 (d, J = 8.4 Hz, 1H), 5.45 (s, 1H), 5.43 – 5.31 
(m, 3H), 5.09 (dd, J = 10.3, 7.9 Hz, 1H), 5.05 – 4.91 (m, 3H), 4.86 (dd, J = 9.8, 2.6 Hz, 1H), 4.78 
(d, J = 8.2 Hz, 1H), 4.76 – 4.62 (m, 3H), 4.59 – 4.44 (m, 3H), 4.41 (s, 1H), 4.26 (dd, J = 12.3, 5.4 
Hz, 1H), 4.20 – 4.00 (m, 6H), 3.96 (d, J = 10.9 Hz, 1H), 3.92 – 3.81 (m, 2H), 3.79 – 3.65 (m, 2H), 
3.61 (dd, J = 8.7, 3.8 Hz, 1H), 3.49 (dq, J = 17.4, 8.7 Hz, 2H), 3.00 (s, 1H), 2.15 (s, 3H), 2.13 (s, 
6H), 2.09 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.01 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 170.77, 170.68, 170.50, 170.40, 170.19, 170.12, 169.52, 169.11, 
155.08, 154.61, 133.76, 130.97, 129.19, 127.63, 101.24, 100.97, 99.16, 95.48, 95.35, 85.16, 76.47, 
74.73, 74.52, 73.30, 72.72, 72.47, 71.97, 71.14, 70.99, 70.74, 69.15, 68.88, 67.77, 66.67, 63.87, 
62.07, 60.93, 56.75, 56.14, 21.03, 20.94, 20.88, 20.72, 20.69, 20.63, 20.60, 20.50; [M+Na]+ 
C56H70Cl6N2O32SNa calculated for 1547.1661, found 1547.1603. 
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Phenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-glucopyranosyl-(1→2)-[2,3,4,6-
tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-2-acetamido-3,6-di-O-acetyl-2-deoxy-β-D-
glucopyranosyl-(1→6)]-3,4-di-O-acetyl-1-thio-α-D-mannopyranoside (11) 
Compound 10 (3.10 g, 2.0 mmol) was treated by following general procedure C to afford 
compound 11 (2.30 g, 87%) as white foam. Rf = 0.22 (hexane/acetone, 3:2, v/v); 
1H NMR (400 
MHz, CDCl3) δ 7.46 – 7.36 (m, 2H), 7.35 – 7.26 (m, 3H), 7.26 – 7.20 (m, 1H), 6.46 (d, J = 10.0 
Hz, 1H), 5.89 (dd, J = 10.7, 9.2 Hz, 1H), 5.68 (d, J = 1.1 Hz, 1H), 5.50 – 5.37 (m, 2H), 5.34 (d, J 
= 2.8 Hz, 1H), 5.14 – 4.99 (m, 3H), 4.99 – 4.82 (m, 2H), 4.54 – 4.36 (m, 3H), 4.26 (dd, J = 12.2, 
5.9 Hz, 1H), 4.22 – 4.11 (m, 3H), 4.11 – 4.00 (m, 4H), 3.95 (dd, J = 12.1, 2.2 Hz, 1H), 3.85 (t, J = 
7.1 Hz, 1H), 3.80 – 3.66 (m, 2H), 3.53 (ddd, J = 9.7, 5.0, 1.8 Hz, 1H), 3.15 (d, J = 10.8 Hz, 1H), 
3.02 – 2.89 (m, 1H), 2.14 (s, 3H), 2.11 (s, 3H), 2.08 (s, 6H), 2.07 (s, 3H), 2.05 (s, 3H), 2.04 (d, J 
= 3.8 Hz, 3H), 2.02 (d, J = 4.8 Hz, 6H), 1.99 (s, 3H), 1.98 (s, 3H), 1.95 (s, 3H), 1.88 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 172.69, 172.18, 170.86, 170.60, 170.31, 170.29, 170.08, 170.00, 
169.93, 169.78, 169.08, 133.09, 130.04, 129.24, 127.24, 102.96, 101.07, 96.29, 83.45, 77.41, 
77.09, 76.78, 76.15, 74.31, 72.83, 72.75, 71.88, 70.88, 70.62, 70.55, 70.43, 69.98, 69.53, 69.15, 
68.44, 66.51, 65.77, 62.35, 62.07, 60.57, 56.92, 53.49, 23.28, 23.25, 21.02, 20.89, 20.80, 20.67, 
20.64, 20.61, 20.58, 20.52, 20.48; [M+Na]+ C56H74N2O31SNa calculated for 1325.3894, found 
1325.3935. 
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Nα-9-Fluorenylmethyloxycarbonyl-O-{2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-
glucopyranosyl-(1→2)-[2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-2-acetamido-
3,6-di-O-acetyl-2-deoxy-β-D-glucopyranosyl]-(1→6)-3,4-di-O-acetyl-α-D-mannopyranosyl}-
L-threonine tertbutyl ester (12) 
Compound 11 (2.00 g, 1.5 mmol) was glycosylated with compound 4 (1.19 g, 3.0 mmol) 
by following general procedure B to get the desired compound 12 (2.12 g, 89%) as white foam. Rf 
= 0.24 (hexane/acetone, 3:2, v/v); 1H NMR (600 MHz, CDCl3) δ 7.80 – 7.74 (m, 2H), 7.69 – 7.52 
(m, 2H), 7.44 – 7.37 (m, 2H), 7.37 – 7.30 (m, 3H), 6.44 (d, J = 10.0 Hz, 1H), 5.95 – 5.85 (m, 1H), 
5.60 (d, J = 9.3 Hz, 1H), 5.43 – 5.31 (m, 3H), 5.17 – 5.01 (m, 3H), 4.96 (dd, J = 10.4, 3.4 Hz, 1H), 
4.94 – 4.83 (m, 2H), 4.54 – 4.42 (m, 3H), 4.42 – 4.23 (m, 5H), 4.23 – 4.02 (m, 7H), 3.97 – 3.83 
(m, 2H), 3.83 – 3.70 (m, 2H), 3.70 – 3.60 (m, 1H), 3.60 – 3.52 (m, 1H), 3.14 (d, J = 11.3 Hz, 1H), 
2.91 (dd, J = 17.8, 7.9 Hz, 1H), 2.16 (s, 3H), 2.12 (s, 3H), 2.11 (s, 3H), 2.09 (s, 3H), 2.09 (s, 3H), 
2.07 (t, J = 2.7 Hz, 6H), 2.05 (s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 1.99 (s, 3H), 1.97 (s, 3H), 1.95 (s, 
3H), 1.52 (s, 9H), 1.31 – 1.24 (m, 3H); 13C NMR (150 MHz, CDCl3) δ 172.57, 172.20, 170.87, 
170.63, 170.32, 170.11, 170.04, 169.97, 169.93, 169.89, 169.10, 169.03, 156.59, 143.95, 143.79, 
141.29, 127.71, 127.11, 127.08, 125.25, 119.98, 119.95, 102.90, 101.11, 98.35, 96.47, 82.46, 
78.01, 76.15, 72.90, 72.80, 72.71, 71.80, 70.91, 70.64, 70.62, 70.07, 69.85, 69.17, 69.09, 68.32, 
67.25, 66.52, 65.79, 62.39, 61.97, 60.57, 59.03, 56.99, 53.51, 47.20, 28.11, 23.30, 23.28, 21.04, 
29 
20.93, 20.85, 20.81, 20.69, 20.63, 20.61, 20.58, 20.50, 18.06; [M+Na]+ C73H95N3O36Na calculated 
for 1612.5593, found 1612.5678. 
 
Nα-9-Fluorenylmethyloxycarbonyl-O-{2-acetamido-2-deoxy-β-glucopyranosyl-
(1→2)-[β-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-β-D-glucopyranosyl]-(1→6)-α-
D-mannopyranosyl}-L-threonine (13, M301) 
Compound 12 (1.90 g, 1.2 mmol) was treated by following general procedure C to afford 
compound 13 (1.11 g, 85%) as white foam. Rf = 0.30 (ethyl acetate/methanol/H2O, 4:2:0.5, v/v); 
1H NMR (400 MHz, MeOD) δ 7.79 (d, J = 7.5 Hz, 2H), 7.74 – 7.58 (m, 2H), 7.44 – 7.27 (m, 4H), 
4.55 (d, J = 7.7 Hz, 1H), 4.50 – 4.31 (m, 5H), 4.23 (t, J = 6.7 Hz, 1H), 4.18 – 4.02 (m, 2H), 4.01 – 
3.84 (m, 5H), 3.84 – 3.51 (m, 14H), 3.51 – 3.30 (m, 6H), 2.08 (s, 3H), 2.06 (s, 3H), 1.22 (d, J = 
5.9 Hz, 2H); 13C NMR (100 MHz, MeOD) δ 173.40, 172.73, 157.41, 144.06, 143.80, 141.18, 
127.42, 126.85, 124.88, 119.55, 103.81, 101.78, 98.66, 79.69, 79.33, 76.38, 75.74, 75.04, 73.89, 
73.41, 72.46, 71.20, 70.54, 69.85, 68.93, 68.64, 67.77, 66.59, 61.16, 60.88, 60.39, 55.28, 47.08, 
22.35, 22.12, 18.44; [M-H]- C47H64N3O25 calculated for 1071.3907, found  1071.3741. 
 
30 
Phenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-acetyl-2-deoxy-
2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl-(1→2)-4,6-O-benzylidene-3-
(4-Methoxybenzyl)-1-thio-α-D-Mannopyranoside (14) 
Compound 1 (1.8 g, 3.8 mmol) was glycosylated with fresh-made donor 3 (4.23 g, 4.5 
mmol) by following general procedure A to get the desired compound 14 (3.46 g, 75%) as white 
foam. Rf = 0.33 (hexane/acetone, 3:1, v/v); 
1H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 7.6, 1.8 
Hz, 2H), 7.46 – 7.25 (m, 10H), 6.87 (d, J = 8.7 Hz, 2H), 5.62 (s, 1H), 5.48 (s, 1H), 5.43 – 5.23 (m, 
3H), 5.12 (dd, J = 10.4, 7.9 Hz, 1H), 4.97 (dd, J = 10.4, 3.4 Hz, 1H), 4.81 (d, J = 8.2 Hz, 1H), 4.75 
– 4.62 (m, 3H), 4.59 – 4.45 (m, 3H), 4.34 (d, J = 1.7 Hz, 1H), 4.30 – 4.03 (m, 6H), 3.94 – 3.86 (m, 
2H), 3.85 – 3.72 (m, 5H), 3.65 – 3.51 (m, 2H), 2.15 (s, 3H), 2.06 (s, 3H), 2.06 (s, 6H), 2.04 (s, 
3H), 1.97 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.40, 170.33, 170.15, 170.08, 169.09, 159.30, 
153.99, 137.55, 133.40, 131.49, 130.00, 129.44, 129.24, 128.90, 128.23, 127.84, 126.10, 113.80, 
101.53, 100.98, 99.17, 95.32, 86.79, 78.47, 76.24, 74.48, 74.23, 73.00, 71.90, 71.38, 70.97, 70.75, 
69.13, 68.46, 66.69, 65.30, 62.24, 60.94, 55.98, 55.26, 20.82, 20.79, 20.66, 20.63, 20.61, 20.52; 
[M+Na]+ C54H62Cl3NO23SNa calculated for 1252.2397, found 1252.2444.  
 
Phenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-acetyl-2-deoxy-
2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl-(1→2)-3-O-acetyl-1-thio-α-D-
Mannopyranoside (15) 
Compound 14 (3.3 g, 2.7 mmol) was treated by following general procedure C to afford 
compound 15 (2.31 g, 81%) as white foam. Rf = 0.22 (hexane/acetone, 2:1, v/v); 
1H NMR (400 
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MHz, CDCl3) δ 7.40 (d, J = 6.6 Hz, 2H), 7.34 – 7.21 (m, 3H), 6.07 (d, J = 9.1 Hz, 1H), 5.35 (s, 
1H), 5.32 (d, J = 3.1 Hz, 1H), 5.10 – 4.99 (m, 2H), 4.94 (dd, J = 10.4, 3.3 Hz, 1H), 4.87 (dd, J = 
9.9, 2.6 Hz, 1H), 4.72 (d, J = 11.9 Hz, 1H), 4.52 – 4.42 (m, 2H), 4.38 (d, J = 11.7 Hz, 3H), 4.31 – 
4.19 (m, 1H), 4.15 – 3.98 (m, 4H), 3.94 – 3.78 (m, 2H), 3.78 – 3.63 (m, 3H), 3.63 – 3.53 (m, 1H), 
3.43 (d, J = 3.9 Hz, 1H), 2.97 (d, J = 8.7 Hz, 1H), 2.11 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 2.03 (s, 
3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.94 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.12, 170.46, 
170.42, 170.15, 170.13, 169.44, 154.88, 133.34, 131.56, 129.27, 127.88, 101.17, 100.94, 95.06, 
85.69, 76.09, 74.58, 73.61, 73.28, 72.73, 71.63, 70.83, 70.69, 69.19, 66.66, 63.99, 62.23, 61.48, 
60.91, 55.97, 20.87, 20.78, 20.75, 20.64, 20.58, 20.47; [M+Na]+ C41H52Cl3NO23SNa calculated for 
1086.1614, found 1086.1658. 
 
Phenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-acetyl-2-deoxy-
2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-acetyl-2-
deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-glucopyranosyl-(1→6)]-3-O-acetyl-1-thio-
α-D-Mannopyranosyl (16) 
Compound 15 (2.10 g, 2.0 mmol) was glycosylated with fresh-made donor 2 (1.54 g, 2.4 
mmol) by following general procedure A to get the desired compound 16 (2.75 g, 82%) as white 
foam. Rf = 0.25 (hexane/acetone, 2:1, v/v); 
1H NMR (400 MHz, CDCl3) δ 7.39 (dd, J = 7.5, 1.7 
Hz, 2H), 7.34 – 7.21 (m, 3H), 6.96 (d, J = 7.0 Hz, 1H), 5.93 (d, J = 9.7 Hz, 1H), 5.73 (t, J = 10.0 
Hz, 1H), 5.43 (s, 1H), 5.33 (d, J = 3.2 Hz, 1H), 5.18 – 4.89 (m, 6H), 4.81 (dd, J = 10.0, 2.7 Hz, 
1H), 4.72 – 4.53 (m, 3H), 4.50 – 4.38 (m, 3H), 4.36 (s, 1H), 4.24 (dd, J = 12.3, 4.4 Hz, 1H), 4.16 
32 
– 4.03 (m, 4H), 4.03 – 3.89 (m, 4H), 3.85 (t, J = 6.6 Hz, 1H), 3.83 – 3.65 (m, 3H), 3.65 – 3.56 (m, 
1H), 3.17 (dd, J = 18.1, 8.0 Hz, 1H), 2.12 (s, 3H), 2.11 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.04 (s, 
6H), 2.01 (s, 3H), 2.01 (s, 3H), 1.95 (s, 3H), 1.94 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.80, 
170.59, 170.51, 170.42, 170.14, 170.10, 169.76, 169.29, 154.95, 133.57, 130.98, 129.18, 127.65, 
101.23, 100.94, 100.49, 96.05, 94.96, 85.58, 77.60, 76.27, 75.19, 74.19, 73.55, 72.93, 72.63, 71.62, 
71.44, 70.96, 70.87, 70.45, 69.34, 69.09, 67.65, 66.80, 63.26, 62.51, 62.13, 61.26, 57.10, 55.69, 
21.02, 20.88, 20.81, 20.75, 20.64, 20.60, 20.57, 20.55, 20.48; [M+Na]+ C56H70Cl6N2O32SNa 
calculated for 1547.1661, found 1547.1738. 
 
Phenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-2-acetamido-3,6-di-O-
acetyl-2-deoxy-β-D-glucopyranosyl-(1→2)-[2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-
glucopyranosyl-(1→6)]-3,4-di-O-acetyl-1-thio-α-D-Mannopyranoside (17) 
Compound 16 (2.50 g, 1.6 mmol) was treated by following general procedure C to afford 
compound 17 (1.75 g, 82%) as white foam. Rf = 0.22 (hexane/acetone, 3:2, v/v); 
1H NMR (400 
MHz, CDCl3) δ 7.46 – 7.36 (m, 2H), 7.36 – 7.26 (m, 2H), 7.26 – 7.19 (m, 1H), 7.10 (d, J = 6.9 Hz, 
1H), 6.55 (d, J = 9.9 Hz, 1H), 5.84 (dd, J = 10.6, 8.9 Hz, 1H), 5.74 (s, 1H), 5.50 – 5.38 (m, 2H), 
5.33 (d, J = 2.8 Hz, 1H), 5.15 – 4.98 (m, 4H), 4.94 (dd, J = 10.4, 3.4 Hz, 1H), 4.48 (d, J = 7.9 Hz, 
1H), 4.37 – 3.97 (m, 11H), 3.85 (t, J = 7.0 Hz, 1H), 3.77 – 3.55 (m, 3H), 3.19 (d, J = 10.9 Hz, 1H), 
2.90 (dt, J = 10.5, 8.1 Hz, 1H), 2.15 (s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.08 (s, 3H), 
2.05 (s, 3H), 2.03 (s, 6H), 2.02 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H), 1.95 (s, 3H), 1.91 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 172.73, 172.09, 171.03, 170.70, 170.63, 170.53, 170.35, 170.26, 
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170.10, 169.92, 169.37, 169.32, 168.87, 133.13, 129.74, 129.24, 127.13, 103.01, 100.62, 96.29, 
83.11, 77.85, 74.47, 72.98, 72.86, 71.86, 70.99, 70.57, 70.47, 70.36, 69.49, 69.07, 68.55, 68.49, 
66.62, 65.93, 62.44, 61.96, 60.78, 57.07, 53.41, 23.32, 23.16, 21.08, 21.05, 20.70, 20.69, 20.67, 
20.61, 20.57, 20.55, 20.52, 20.48; [M+Na]+ C56H74N2O31SNa calculated for 1325.3894, found 
1325.3946. 
 
Nα-9-Fluorenylmethyloxycarbonyl-O-{2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-
(1→4)-2-acetamido-3,6-di-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→2)-[2-acetamido-3,4,6-
tri-O-acetyl-2-deoxy-β-glucopyranosyl-(1→6)]-3,4-di-O-acetyl-α-D-Mannopyranosyl}-L-
threonine tertbutyl ester (18) 
Compound 17 (1.57 g, 1.2 mmol) was glycosylated with compound 4 (0.98 g, 2.4 mmol) 
by following general procedure B to get the desired compound 18 (1.56 g, 83%) as white foam. Rf 
= 0.23 (hexane/acetone, 3:2, v/v); 1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.4 Hz, 2H), 7.71 – 
7.51 (m, 2H), 7.49 – 7.25 (m, 5H), 7.05 (d, J = 7.0 Hz, 1H), 6.51 (d, J = 9.6 Hz, 1H), 5.87 – 5.72 
(m, 1H), 5.57 (d, J = 9.3 Hz, 1H), 5.41 – 5.28 (m, 3H), 5.19 – 5.01 (m, 4H), 5.01 – 4.87 (m, 2H), 
4.59 – 4.41 (m, 3H), 4.41 – 3.96 (m, 16H), 3.90 – 3.81 (m, 1H), 3.81 – 3.70 (m, 1H), 3.70 – 3.55 
(m, 3H), 3.17 (d, J = 11.2 Hz, 1H), 2.88 (dd, J = 17.5, 8.1 Hz, 1H), 2.18 (s, 3H), 2.16 (s, 3H), 2.12 
(s, 3H), 2.12 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.05 (s, 3H), 2.04 (s, 6H), 2.02 (s, 
3H), 1.97 (s, 3H), 1.94 (s, 3H), 1.52 (s, 9H), 1.27 (d, J = 8.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) 
δ 172.45, 172.04, 171.00, 170.70, 170.62, 170.57, 170.35, 170.22, 170.12, 169.82, 169.38, 169.01, 
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156.57, 143.95, 143.78, 141.28, 127.70, 127.10, 125.25, 119.98, 102.88, 101.06, 98.03, 96.56, 
82.47, 78.21, 77.93, 72.88, 72.79, 71.91, 71.03, 70.88, 70.52, 69.85, 69.50, 69.22, 69.11, 68.61, 
68.38, 67.25, 66.53, 65.93, 62.51, 62.00, 60.61, 58.98, 57.02, 53.84, 53.48, 47.19, 29.28, 28.13, 
23.28, 23.18, 21.09, 20.72, 20.68, 20.63, 20.59, 20.53, 17.95; [M+Na]+ C73H95N3O36Na calculated 
for 1612.5593, found 1612.5663. 
 
Nα-9-Fluorenylmethyloxycarbonyl-O-{β-D-galactopyranosyl-(1→4)-2-acetamido-2-
deoxy-β-D-glucopyranosyl-(1→2)-[2-acetamido-2-deoxy-β-glucopyranosyl-(1→6)]-α-D-
Mannopyranosyl}-L-threonine (19, M201) 
Compound 18 (1.90 g, 1.2 mmol) was treated by following general procedure C to afford 
compound 19 (1.09 g, 87%) as white foam. Rf = 0.30 (ethyl acetate/methanol/H2O, 4:2:0.5, v/v); 
1H NMR (400 MHz, D2O) δ 7.68 – 7.56 (m, 2H), 7.56 – 7.36 (m, 2H), 7.36 – 7.16 (m, 5H), 4.59 
– 4.51 (m, 1H), 4.47 (d, J = 8.4 Hz, 1H), 4.43 – 4.23 (m, 4H), 4.18 (d, J = 6.4 Hz, 1H), 4.09 (d, J 
= 10.3 Hz, 1H), 3.98 (d, J = 4.8 Hz, 1H), 3.90 – 3.80 (m, 4H), 3.80 – 3.55 (m, 16H), 3.55 – 3.42 
(m, 5H), 3.41 – 3.24 (m, 5H), 1.97 (s, 3H), 1.95 (s, 4H), 0.95 (d, J = 6.1 Hz, 3H); 13C NMR (100 
MHz, D2O) δ 174.59, 174.15, 158.00, 143.88, 143.45, 140.96, 140.90, 127.97, 127.43, 124.80, 
120.11, 102.90, 101.16, 99.84, 98.22, 78.31, 77.18, 76.85, 75.90, 75.31, 74.56, 73.93, 72.48, 71.95, 
70.94, 70.06, 69.21, 68.56, 67.59, 65.98, 61.02, 60.87, 59.88, 55.57, 54.82, 48.89, 47.09, 22.50, 
22.33, 18.49; [M+Na]+ C47H65N3O25Na calculated for 1094.3805, found 1094.3876. 
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1.4.2 Enzymatic extension 
Materials and enzymes 
N-Acetylneuraminic acid(Neu5Ac), N-Glycolylneuraminic acid (Neu5Gc) and cytidine 5'-
triphosphate (CTP) were purchased from Carbosynth Limited. Sugar nucleotides uridine 5’-
diphospho-galactose (UDP-Gal)[38], guanosine 5’-diphospho-L-fucose (GDP-Fuc)[39], uridine 5′-
diphosphoglucuronic acid(UDP-GlcA)[40] were prepared as described previously reported. 
Enzymes including CMP-sialic acid synthetase from Neisseria meningitidis (NmCSS),[30] mutant 
M144D of a2,3-sialyltransferase  1 from Pasteurella multocida (PmST1-M144D),[25] mutant 
E271F/R313Y of PmST1 (PmST1m),[34] a2,6-sialyltransferase from Photobacterium damselae 
(Pd2,6ST),[26] b1,4-galactosyltransferase from N. meningitidis (NmLgtB),[24] and C-terminal 66 
amino acid truncated a1,3-fucosyltransferase from Helicobacter pylori (Hp3FT)[41] were 
expressed and purified as previously described. All enzymes were desalted against 50 mM Tris-
HCl, and 20% glycerol, and stored at -20 °C for long-term use. b-galactosidase (bGalD) from 
Streptococcus pneumoniae was purchased from Prozyme, CA.  
 
Cloning and expression of human GlcAT-P 
The human β1,3-glucuronyltransferase gene (GlcAT-P) gene (GenBank: AB029396.1) 
was codon optimized, synthesized and cloned into vector pET15b vector (Genescript, NJ). The 
recombinant plasmid harboring GlcAT-P was transformed into E. coli BL21 (DE3) for 
hetergenous expression. The recombinant strain was cultured in LB medium at 37 °C with brief 
shaking (180 rpm) untill OD600nm reached 0.6 to 0.8, followed by addition of isopropyl-b-D-
thiogalactopyranoside (IPTG) to a final concentration of 0.2 mM. After 20 h induction at 16 °C, 
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the cells were harvested by centrifuging at 4000 rpm for 30 min. The target protein was expressed 
as inclusion body. E. coli cell lysate was used to in GlcAT-P-catalyzed reactions.   
Optimized GlcAT gene sequence 
CATCAATCCACCCTGGCACCGCTGCTGGCAGTCCATAAGGACGAAGGTTCCG
ATCCGCGTCGTGAGACCCCGCCGGGCGCAGACCCGCGTGAGTACTGCACCAGCGAT
CGTGACATCGTGGAAGTGGTGCGTACCGAATACGTTTACACCCGTCCGCCGCCGTGG
AGCGATACCCTGCCGACCATCCACGTGGTTACCCCGACCTACAGCCGTCCGGTGCAG
AAGGCTGAGCTGACCCGTATGGCTAACACCCTGCTGCACGTTCCGAACCTGCACTGG
CTGGTTGTGGAAGATGCGCCGCGTCGTACCCCGCTGACCGCTCGTCTGCTGCGTGAC
ACCGGTCTGAACTACACCCACCTGCACGTGGAAACCCCGCGTAACTACAAACTGCG
TGGTGACGCTCGTGACCCGCGTATCCCGCGTGGTACCATGCAGCGTAACCTGGCTCT
GCGTTGGCTGCGTGAAACCTTCCCGCGTAACAGCAGCCAGCCGGGCGTGGTTTACTT
CGCGGACGATGACAACACCTACAGCCTGGAACTGTTCGAGGAAATGCGTAGCACCC
GTCGTGTGAGCGTTTGGCCGGTGGCTTTCGTTGGTGGCCTGCGTTACGAGGCGCCGC
GTGTGAACGGTGCTGGCAAGGTGGTTCGTTGGAAAACCGTTTTCGATCCGCACCGTC
CGTTCGCGATCGACATGGCGGGTTTCGCTGTGAACCTGCGTCTGATCCTGCAGCGTA
GCCAGGCTTACTTCAAGCTGCGTGGCGTGAAAGGTGGCTACCAGGAGAGCAGCCTG
CTGCGTGAACTGGTTACCCTGAACGACCTGGAACCGAAGGCGGCTAACTGCACCAA
AATCCTGGTGTGGCACACCCGTACCGAGAAGCCGGTGCTGGTGAATGAAGGCAAGA
AAGGTTTTACCGACCCGTCCGTTGAGATT 
General HPLC methods 
HPLC method for monitoring reactions and purity analysis of final products: An analytical 
GL Science Inertsil ODS-4 column (100 Å, 5 μm, 4.6 mm × 250 mm) was used for separation, 
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monitored by a UV detector (260 nm) or fluorescent detector (Ex 260nm, Em 310 nm).[23] The 
running solvents are solvent A(H2O with 0.1% TFA) and solvent B (acetonitrile with 0.1% TFA). 
The running condition is gradient elution with solvent B% linear increased from 20% to 40% 
within 25 mins, with a total flow rate of 1 mL/min. 
HPLC method for purifying final products: An analytical GL Science Inertsil ODS-4 
column (100 Å, 5 μm, 4.6 mm × 250 mm) was used for separating small reactions with 3 mg or 
less products, and a semipreparative Inertsil ODS-4 column (100 Å, 5 μm, 20 mm × 250 mm) was 
used for separating products with over 5 mgs. The method for using the analytical column is same 
as above and monitored by a UV detector (260 nm). The method for using the semipreparative 
column is similar as that for the analytical column, with the only difference of flow rate at 18.9 
mL/min instead. Commonly, the analytical column enabled up to 1 mg product separation per run, 
while the semipreparative one enabled up to 15 mg product separation per run. 
 
HPLC quantification of purified glycans 
Firstly, 10 mg M201 was weighted out accurately and diluted to 1 µM as standard solution. 
Then different volumes of standard solution, 1 μL, 2 μL, 3 μL, 4 μL, 6 μL, 8 μL, 10 μL, 20 μL, 30 
μL, 40 μL, 60 μL, 80 μL, were injected into the HPLC by the method mentioned above using 
fluorescent (Ex. 260 nm, Em. 310 nm) in three replicates. The peak area of each injection was 
recorded and calculated to make the standard curve. All the purified glycans was quantified by the 
same condition as built the standard curve.  
 
b1,4-galactosylation by NmLgtB 
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Reaction mixtures contain Tris-HCl (100 mM, pH 7.5), an acceptor O-mannosyl glycan 
(10 mM), UDP-Gal (15 mM), MgCl2 (10 mM), and an appropriate amount of NmLgtB. Reactions 
were incubated at 37 °C overnight and monitored by HPLC and/or MALDI-MS. After over 90% 
acceptor was converted, the reaction was quenched by freezing at -80 °C for 30 min, thaw and 
brief centrifugation to remove protein precipitants. The sample was then concentrated and subject 
for HPLC separation, product-containing fractions were pooled and lyophilized for 
characterization and next step use. The purity and quantification of each glycan was confirmed by 
HPLC as described above. NmLgtB-catalyzed reactions give 90-96% yields (HPLC purified glycan 
product/starting glycan substrate × 100%) 
 
One-pot two-enzyme a2,3-sialylation catalyzed by PmST1-M144D or PmST1m 
Reaction mixtures contain Tris-HCl (100 mM, pH 7.5), an acceptor glycan (10 mM), CTP 
(15 mM), Neu5Ac or Neu5Gc (15 mM), MgCl2 (10 mM), and appropriate amount of NmCSS and 
PmST1-M144D (or PmST1m). PmST1-M144D-catalyzed reactions were incubated at 37 °C 
overnight and monitored by HPLC and/or MALDI-TOF. After over 90% acceptor was converted, 
the reaction was quenched, concentrated and subject for HPLC separation. PmST1m-catalyzed 
reactions were incubated at 37 °C for 30 min, quenched, and concentrated for HPLC separation.  
Product-containing fractions were pooled and lyophilized for characterization and next step use. 
PmST1-catalyzed reactions give 85-92% yields (HPLC purified glycan product/starting glycan 
substrate × 100%). 
 
One-pot two-enzyme a2,6-sialylation catalyzed by Pd26ST 
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Reaction mixtures contain Tris-HCl (100 mM, pH 7.5), an acceptor glycan (10 mM), CTP 
(15 mM), Neu5Ac or Neu5Gc (15 mM), MgCl2 (10 mM), and appropriate amount of NmCSS and 
Pd26ST. Reactions were incubated at 37 °C overnight and monitored by HPLC and/or MALDI-
TOF. After over 90% acceptor was converted, reactions were quenched, concentrated before 
HPLC separation. Product-containing fractions were pooled and lyophilized for characterization 
and next step use. Pd26ST-catalyzed reactions give 89-94% yields (HPLC purified glycan 
product/starting glycan substrate × 100%). 
 
a1,3-fucosylation catalyzed by Hp3FT 
Reaction mixtures contain Tris-HCl (100 mM, pH 7.5), an acceptor glycan (10 mM), GDP-
Fuc (15 mM), MgCl2 (10 mM), and appropriate amount of Hp3FT. Reactions were incubated at 
37 °C overnight and were monitored by HPLC and/or MALDI-TOF. After over 90% acceptor was 
converted, reactions were quenched, concentrated before HPLC separation. Product-containing 
fractions were pooled and lyophilized for characterization and next step use. Hp3FT-catalyzed 
reactions give 85-86% yields (HPLC purified glycan product/starting glycan substrate × 100%). 
 
GlcAT-P-catalyzed addition of GlcA 
The reaction mixture contains Tris-HCl (100 mM, pH 7.5), M101 (10 mM), UDP-GlcA 
(15 mM), MgCl2 (10 mM), and appropriate amount of GlcAT-P cell lysis. Reaction was incubated 
at 37 °C overnight. The reaction was monitored by HPLC until 90% M101 was converted. The 
reaction was then quenched andconcentrated for HPLC separation. Product-containing fractions 
were pooled and lyophilized for characterization. The reaction gives a yield of 90% (HPLC purified 
glycan product/starting glycan substrate × 100%). 
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b-galactosidase-catalyzed reaction 
The reaction was performed according to the instruction using commercial b-galactosidase 
in the presence of M201. The reaction was monitored and product was purified by HPLC. The 
reaction gives a yield of 96% (HPLC purified glycan product/starting glycan substrate × 100%) 
 
1.4.3 Glycan Microarray preparation, assay and data 
Method for removing Fmoc 
O-mannosyl glycans (50 ug) were dissolved in 200 uL H2O, and 30 uL triethylamine was 
added to remove the Fmoc group at room temperature for 4 h. The reactions were then lyophilized 
and hexane extraction was used to remove free Fmoc. 
 
Method for microarray preparation 
O-mannosyl glycans microarray was prepared as previously reported,[42] briefly, 8 
subarrays was printed on N-hydroxysuccinimide (NHS)-derivatized slides by Z Biotech (Aurora, 
CO, USA). Within each subarray, each glycan was printed in six replicates with print buffer, and 
print buffer was also printed as a negative control. In addition, Biotin-PEG2-Amine (0.01 mg/mL) 
(positive control 1), Rabbit IgG (0.1 mg/mL) (positive control 2) were printed in six replicates 
with print buffer to serve as a positive control. A marker containing human IgG conjugate with 
Cy3 (0.01 mg/mL) and human IgG conjugate with Alexa 647 (0.01 mg/mL) was also printed in 
the replicates of six.  
 
Method for microarray assay  
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Materials: All biotinylated lectins were purchased from EYLabs (San Mateo, CA). Cy5- 
streptavidin, Cy3- streptavidin, goat anti-rabbit IgG-Alexa Fluor 647 conjugate, goat anti-mouse 
IgG-Alexa Fluor 647 conjugate were purchased from ThermoFisher Scientific (Waltham, MA). 
Mouse anti-human CD15s (sialyl-lewis X) antibody was purchased from BD Biosciences 
(Franklin Lakers, NJ). Mab(IIH6) was a kind gift from Dr. Kevin Campbell (HHMI, University of 
Iowa).[43] 
Procedures: Microarray slides were rehydrated for 30 min in blocking buffer (50 mM 
ethanolamine in 50 mM sodium borate, pH 9.2) and wash with H2O before assay. All assay were 
performed as previously reported.[42]  Plant lectins, including Concanavalin A from Canavalia 
ensiformis (Con A, 10 µg/mL), Aleuria aurantia lectin (AAL, 10 µg/mL), Ricinus Communis 
lectin I (RCA-I, 10 µg/mL),  Erythrina cristagalli Lectin (ECA, 10 µg/mL) were applied with 
appropriate concentrations, and detected by Cy3-streptavidin or Cy5-streptavidin (1 µg/mL). Anti-
CD15s antibody (10 µg/mL), and IIH6 antibody (1:200 dilution) antibody were also tested. The 
primary antibodies were bound by goat anti-mouse IgG-Alexa Fluor 647 conjugate (5 µg/mL). 
Twelve subarrays were assayed with rabbit serums from Dr. Ulrika Westerlind. Goat anti-rabbit 
IgG-Alexa Fluor 647 conjugate (5 µg/mL) was used to bound with the primary antibodies. After 
binding, the slides were scanned with a microarray scanner (GenePix 4000B). 
 
Results and analysis 
Firstly, binding specificities Aleuria aurantia lectin (AAL, specific to a-linked Fuc) was 
profiled. As shown in Figure S2, AAL bound to all O-mannosyl glycans with an a1,3-linked Fuc 
residue (Fig 6A). Meanwhile, weaker bindings were observed towards M3X4 and M3X5 (contain 
one Fuc on the b1,6-branch) than M2X4 and M2X5 (contain one Fuc on the b1,2-branch) with the 
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exception of M345 and M245 (contain Fuc residues on both branches), indicating AAL possesses 
a branch preference towards the b1,2-branch. In addition, AAL showed higher bindings to glycans 
that contain the LeX epitope (e.g., M104, M040, M204, M214, M304, M314) than those contain 
the sLeX epitope (e.g., M105, M050, M205, M215, M305, M315), suggesting a same-chain 
glycosylation (a2,3-sialylation) influence. Besides ECA and RCA-I’s branch preferences, When 
comparing binding specificities of RCA-I towards M212, M213, M214 and M215, a series of 
glycans with the same b1,6-branch (LN disaccharide) but differs in the b1,2-branch, an apparent 
preference of M213>M214>M215>M212 was observed, suggesting a side-chain influence on 
RCA-I binding. Such influences were also found for ECA (Fig 1.6A) and AAL (varied bindings 
to M104, M204, M214, M224, M234), but in different orders.  
As expected, a a-DG antibody (IIH6) failed to bind any core M1 and branched core M2 
structures, as it is specific for core M3 glycans.[43] 
 
Figure 1.8 Microarray analysis towards Aleuria aurantia lectin. 
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Figure 1.9 Microarray analysis towards Concanavalin A from Canavalia ensiformis 
 
 
 
 
Figure 1.10 Microarray analysis and binding profile of O-mannosyl glycans towards rabbit 
26559 
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Figure 1.11 Microarray analysis towards mouse IIH6 antibody 
 
1.4.4 NMR and MS analysis of purified O-mannosyl glycan 
M100    
1H NMR (400 MHz, D2O) δ 7.74 – 7.60 (m, 2H), 7.60 – 7.40 (m, 2H), 7.40 – 7.18 (m, 4H), 
4.60 (dd, J = 10.7, 4.9 Hz, 1H), 4.42 – 4.27 (m, 2H), 4.23 (d, J = 6.3 Hz, 1H), 4.12 – 3.96 (m, 1H), 
3.83 – 3.71 (m, 4H), 3.71 – 3.42 (m, 7H), 3.42 – 3.30 (m, 3H), 3.27 (s, 1H), 1.96 (s, 3H), 0.94 (d, 
J = 6.1 Hz, 3H); 13C NMR (100 MHz, D2O) δ 174.87, 158.05, 143.91, 143.49, 140.96, 140.91, 
127.96, 127.41, 124.90, 124.78, 120.09, 100.01, 98.04, 77.19, 75.59, 73.28, 73.05, 69.84, 69.26, 
67.22, 65.92, 61.60, 60.52, 55.26, 47.10, 22.35, 18.33; ESI-MS, calculated: 706.2585; found [M-
H]- 705.2470; MALDI-MS: calculated for 729.2483, found [M+Na]+729.2478.
 
 
M101   
1H NMR (600 MHz, D2O) δ 7.71 – 7.55 (m, 2H), 7.71 – 7.55 (m, 2H), 7.51 – 7.29 (m, 4H), 
4.77 (d, J = 4.9 Hz, 1H), 4.75 (d, J = 4.8 Hz, 1H), 4.65 (m, 1H), 4.63 (m, 1H), 4.57 (dd, J = 11.0, 
4.6 Hz, 1H), 4.38 (d, J = 7.8 Hz, 1H), 4.35 (d, J = 5.5 Hz, 1H), 4.29 – 4.20 (m, 2H), 3.95 (d, J = 
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2.1 Hz, 1H), 3.86 (m, 2H), 3.81 – 3.57 (m, 10H), 3.57 – 3.42 (m, 4H), 3.38 (t, J = 9.7 Hz, 1H), 
1.96 (s, 3H), 0.96 (d, J = 6.4 Hz, 3H). ESI-MS, calculated: 868.3113; found [M-H]- 867.2972; 
MALDI-MS, found [M+Na]+ 891.305, [M+K]+ 907.279. 
 
M102   
1H NMR (600 MHz, D2O) δ 7.90 – 7.73 (m, 2H), 7.71 – 7.50 (m, 2H), 7.45 – 7.25 (m, 4H), 
4.65 (s, 1H), 4.59 (s, 1H), 4.54 (dd, J = 11.0, 4.6 Hz, 1H), 4.41 (d, J = 7.8 Hz, 1H), 4.30 (d, J = 
7.1 Hz, 1H), 4.23 (s, 1H), 4.17 (d, J = 5.6 Hz, 1H), 4.00 (d, J = 12.5 Hz, 1H), 3.89 – 3.66 (m, 8H), 
3.65 – 3.36 (m, 16H), 3.32 (t, J = 9.6 Hz, 1H), 2.64 (dd, J = 12.4, 4.4 Hz, 1H), 1.91 (s, 3H), 1.90 
(s, 3H), 1.69 (t, J = 12.1 Hz, 1H), 0.91 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 1159.4068; found 
[M-H]- 1158.3877. 
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M102G  
1H NMR (600 MHz, D2O) δ 7.86 – 7.73 (m, 2H), 7.67 – 7.49 (m, 2H), 7.41 – 7.25 (m, 4H), 
4.64 – 4.60 (m, 1H), 4.57 – 4.50 (m, 1H), 4.40 (d, J = 8.0 Hz, 1H), 4.28 (d, J = 6.7 Hz, 1H), 4.23 
(s, 2H), 4.17 (d, J = 6.7 Hz, 1H), 4.03 – 3.97 (m, 3H), 3.94 (s, 1H), 3.86 – 3.35 (m, 24H), 3.31 (t, 
J = 9.7 Hz, 1H), 2.64 (d, J = 8.4 Hz, 1H), 1.88 (s, 3H), 1.69 (t, J = 12.1 Hz, 1H), 0.90 (d, J = 6.2 
Hz, 3H). ESI-MS, calculated: 1175.4017; found [M-H]- 1174.3850; MALDI-MS, found [M+Na]+ 
1198.394, [M+K]+ 1214.375. 
 
M103    
1H NMR (600 MHz, D2O) δ 7.83 – 7.72 (m, 2H), 7.63 – 7.49 (m, 2H), 7.42 – 7.25 (m, 4H), 
4.69 (s,1H), 4.68 (s,1H), 4.53 (dd, J = 11.0, 3.4 Hz, 1H), 4.35 – 4.25 (m, 2H), 4.20 (s, 2H), 4.02 
(s, 1H), 3.89 (t, J = 9.4 Hz, 1H), 3.86 – 3.67 (m, 7H), 3.67 – 3.37 (m, 15H), 3.34 (t, J = 9.4 Hz, 
1H), 2.53 (d, J = 8.7 Hz, 1H), 1.92 (s, 3H), 1.91 (s, 3H), 1.64 (t, J = 12.2 Hz, 1H), 0.92 (d, J = 6.0 
Hz, 3H). ESI-MS, calculated: 1159.4068; found [M-H]- 1158.3878. 
 
M103G  
1H NMR (600 MHz, D2O) δ 7.89 – 7.74 (m, 2H), 7.71 – 7.53 (m, 2H), 7.49 – 7.29 (m, 4H), 
4.74 (s, 1H), 4.67 – 4.60 (m, 1H), 4.62 – 4.54 (m, 1H), 4.40 – 4.30 (m, 2H), 4.24 (d, J = 5.1 Hz, 
2H), 4.08 (s, 1H), 4.04 (s, 2H), 3.95 (t, J = 9.5 Hz, 1H), 3.89 – 3.71 (m, 10H), 3.71 – 3.34 (m, 
14H), 2.59 (dd, J = 12.5, 4.4 Hz, 1H), 2.03 – 1.93 (m, 3H), 1.70 (t, J = 12.2 Hz, 1H), 0.97 (d, J = 
6.4 Hz, 3H). ESI-MS, calculated: 1175.4017; found [M-H]- 1174.3792MALDI-MS, found 
[M+Na]+ 1198.391, [M+K] + 1214.372.  
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M104   
1H NMR (600 MHz, D2O) δ 7.83 – 7.60 (m, 2H), 7.60 – 7.40 (m, 2H), 7.38 – 7.18 (m, 4H), 
5.04 (d, J = 3.8 Hz, 1H), 4.76 (d, J = 6.8 Hz, 1H), 4.64 – 4.54 (m, 1H), 4.43 (s, 1H), 4.36 (d, J = 
7.6 Hz, 2H), 4.25 (s, 1H), 4.12 (s, 1H), 4.05 (s, 1H), 3.90 – 3.70 (m, 9H), 3.70 – 3.32 (m, 11H), 
1.94 (s, 3H), 1.11 (d, J = 6.2 Hz, 3H), 0.98 (d, J = 5.8 Hz, 3H). ESI-MS, calculated: 1014.3693; 
found [M-H]- 1013.3524. 
 
M105    
1H NMR (600 MHz, D2O) δ 7.85 – 7.73 (m, 2H), 7.68 – 7.48 (m, 2H), 7.42 – 7.23 (m, 4H), 
4.96 (d, J = 3.2 Hz, 1H), 4.65 (s, 1H), 4.64 (s, 1H), 4.53 (dd, J = 10.9, 4.5 Hz, 2H), 4.36 (d, J = 
7.9 Hz, 1H), 4.28 (d, J = 8.0 Hz, 1H), 4.25 – 4.14 (m, 2H), 4.00 – 3.88 (m, 2H), 3.87 – 3.60 (m, 
13H), 3.60 – 3.34 (m, 14H), 3.28 (t, J = 9.6 Hz, 1H), 2.62 (d, J = 8.0 Hz, 1H), 1.89 (s, 3H), 1.88 
(s, 3H), 1.67 (t, J = 12.1 Hz, 1H), 1.03 (d, J = 6.2 Hz, 3H), 0.90 (d, J = 6.1 Hz, 3H). ESI-MS, 
calculated: 1305.4647; found [M-H]- 1304.4440. 
 
M106   
1H NMR (600 MHz, D2O) δ 7.84 – 7.64 (m, 2H), 7.64 – 7.44 (m, 2H), 7.41 – 7.19 (m, 4H), 
4.65 (s, 1H), 4.58 (d, J = 7.9 Hz, 1H), 4.50 (dd, J = 11.0, 4.7 Hz, 1H), 4.36 (d, J = 7.8 Hz, 1H), 
4.32 – 4.23 (m, 1H), 4.22 – 4.12 (m, 2H), 4.02 (d, J = 2.9 Hz, 1H), 3.92 (d, J = 2.1 Hz, 1H), 3.83 
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– 3.51 (m, 15H), 3.51 – 3.36 (m, 5H), 3.36 – 3.24 (m, 2H), 1.88 (s, 3H), 0.90 (d, J = 6.3 Hz, 3H). 
ESI-MS, calculated: 1044.3434; found [M-H]- 1043.3264. 
 
M000    
1H NMR (600 MHz, D2O) δ 7.94 – 7.79 (m, 2H), 7.71 – 7.54 (m, 2H), 7.50 – 7.29 (m, 4H), 
4.76 (dd, J = 10.8, 4.9 Hz, 1H), 4.67 (s, 1H), 4.56 (dd, J = 11.0, 4.7 Hz, 1H), 4.47 (d, J = 8.5 Hz, 
1H), 4.34 (d, J = 8.3 Hz, 1H), 4.27 (s, 1H), 4.18 (d, J = 6.1 Hz, 1H), 4.12 (d, J = 10.4 Hz, 1H), 
4.01 (s, 1H), 3.86 (d, J = 12.3 Hz, 1H), 3.80 (d, J = 10.9 Hz, 1H), 3.75 – 3.43 (m, 10H), 3.43 – 
3.24 (m, 5H), 1.96 (s, 3H), 1.94 (s, 3H), 0.96 (d, J = 6.4 Hz, 3H). ESI-MS, calculated: 909.3379; 
found [M-H]- 908.3226; MALDI-MS, found [M+Na]+ 932.324, [M+K]+ 948.318. 
 
M010     
1H NMR (600 MHz, D2O) δ 7.91 – 7.72 (m, 2H), 7.72 – 7.49 (m, 2H), 7.49 – 7.27 (m, 4H), 
4.74 (d, J = 3.3 Hz, 1H), 4.66 (d, J = 4.5 Hz, 1H), 4.60 – 4.51 (m, 1H), 4.51 – 4.43 (m, 2H), 4.41 
– 4.35 (m, 2H), 4.34 – 4.24 (m, 2H), 4.20 (d, J = 5.8 Hz, 2H), 4.11 (d, J = 10.8 Hz, 1H), 4.03 (d, J 
= 14.8 Hz, 1H), 4.00 – 3.79 (m, 4H), 3.79 – 3.39 (m, 21H), 3.31 (t, J = 10.0 Hz, 1H), 1.96 (s, 3H), 
1.94 (s, 3H), 0.99 (d, J = 4.8 Hz, 3H). ESI-MS, calculated: 1233.4435; found [M+H]+ 1234.4497, 
[M+Na]+ 1256.4307. 
 
M020   
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1H NMR (600 MHz, D2O) δ 7.92 – 7.78 (m, 2H), 7.72 – 7.54 (m, 2H), 7.52 – 7.29 (m, 4H), 
4.76 – 4.74 (m, 1H), 4.68 – 4.66 (m, 1H), 4.59 – 4.50 (m, 2H), 4.52 – 4.44 (m, 2H), 4.40 (d, J = 
7.7 Hz, 1H), 4.35 (d, J = 7.5 Hz, 1H), 4.28 (s, 2H), 4.20 (d, J = 6.4 Hz, 1H), 4.17 – 4.00 (m, 4H), 
3.98 – 3.39 (m, 38H), 3.30 (t, J = 10.3 Hz, 1H), 2.68 (dd, J = 12.6, 4.0 Hz, 2H), 1.96 (s, 9xH), 1.92 
(s, 3H), 1.78 (t, J = 12.5 Hz, 2H), 0.99 (d, J = 6.1 Hz, 3H). ESI-MS, calculated: 1815.6344; found 
[M-H]- 1814.6297, [M-2H]2- 906.8041. 
 
M030    
1H NMR (600 MHz, D2O) δ 7.90 – 7.78 (m, 2H), 7.71 – 7.54 (m, 2H), 7.50 – 7.29 (m, 4H), 
4.62 – 4.53 (m, 1H), 4.50 (d, J = 8.4 Hz, 2H), 4.42 – 4.33 (m, 2H), 4.33 – 4.25 (m, 2H), 4.22 (d, J 
= 4.7 Hz, 1H), 4.17 – 4.05 (m, 2H), 4.00 – 3.42 (m, 40H), 3.31 (t, J = 9.8 Hz, 1H), 2.62 – 2.56 (m, 
2H), 1.98 (s, 3H), 1.96 (s, 3H), 1.96 (s, 3H), 1.95 (s, 3H), 1.68 (t, J = 12.2 Hz, 2H), 1.00 (d, J = 
6.4 Hz, 3H). ESI-MS, calculated: 1815.6344; found [M-H]- 1814.6103, [M-2H]2- 906.7999. 
 
M040     
1H NMR (600 MHz, D2O) δ 7.71 – 7.54 (m, 2H), 7.54 – 7.32 (m, 2H), 7.23 (m, J = 31.1 
Hz, 4H), 4.99 – 4.92 (m, 2H), 4.61 (d, J = 7.0 Hz, 1H), 4.48 (d, J = 9.1 Hz, 1H), 4.44 – 4.35 (m, 
1H), 4.35 – 4.21 (m, 3H), 4.18 (d, J = 7.1 Hz, 1H), 4.14 (d, J = 5.5 Hz, 1H), 4.03 (d, J = 34.7 Hz, 
3H), 3.90 – 3.16 (m, 35H), 1.88 (s, 3H), 1.85 (s, 3H), 1.08 – 0.98 (m, 6H), 0.93 (d, J = 5.0 Hz, 
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3H). ESI-MS, calculated: 1525.5594; found [M-H]- 1524.5373; MALDI-MS, found [M+Na]+ 
1548.517, [M+K]+ 1564.491. 
 
M050   
1H NMR (600 MHz, D2O) δ 7.87 – 7.72 (m, 2H), 7.67 – 7.48 (m, 2H), 7.44 – 7.26 (m, 4H), 
5.00 – 4.91 (m, 2H), 4.64 – 4.63 (m, 1H), 4.62 – 4.58 (m, 2H), 4.54 – 4.46 (m, 2H), 4.46 – 4.35 
(m, 3H), 4.35 – 4.27 (m, 2H), 4.23 (s, 2H), 4.14 (d, J = 5.5 Hz, 1H), 4.10 – 3.91 (m, 5H), 3.91 – 
3.61 (m, 21H), 3.61 – 3.31 (m, 22H), 3.23 (t, J = 9.9 Hz, 1H), 2.66 – 2.56 (m, 2H), 1.89 (s, 6H), 
1.88 (s, 3H), 1.85 (s, 3H), 1.68 (t, J = 12.0 Hz, 2H), 1.08 – 0.99 (m, 6H), 0.91 (d, J = 5.7 Hz, 3H). 
ESI-MS, calculated: 2107.7502; found [M-2H]2- 1052.8568. 
 
M201    
1H NMR (400 MHz, D2O) δ 7.68 – 7.56 (m, 2H), 7.56 – 7.36 (m, 2H), 7.36 – 7.16 (m, 5H), 
4.59 – 4.51 (m, 1H), 4.47 (d, J = 8.4 Hz, 1H), 4.43 – 4.23 (m, 4H), 4.18 (d, J = 6.4 Hz, 1H), 4.09 
(d, J = 10.3 Hz, 1H), 3.98 (d, J = 4.8 Hz, 1H), 3.90 – 3.80 (m, 4H), 3.80 – 3.55 (m, 16H), 3.55 – 
3.42 (m, 5H), 3.41 – 3.24 (m, 5H), 1.97 (s, 3H), 1.95 (s, 4H), 0.95 (d, J = 6.1 Hz, 3H); 13C NMR 
(100 MHz, D2O) δ 174.59, 174.15, 158.00, 143.88, 143.45, 140.96, 140.90, 127.97, 127.43, 
124.80, 120.11, 102.90, 101.16, 99.84, 98.22, 78.31, 77.18, 76.85, 75.90, 75.31, 74.56, 73.93, 
72.48, 71.95, 70.94, 70.06, 69.21, 68.56, 67.59, 65.98, 61.02, 60.87, 59.88, 55.57, 54.82, 48.89, 
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47.09, 22.50, 22.33, 18.49. ESI-MS, calculated: 1071.3907; found [M-H]- 1070.3732; MALDI-
MS,  found [M+Na]+ 1094.372, [M+K]+ 1110.358. 
 
M202    
 
1H NMR (600 MHz, D2O) δ 7.63 – 7.47 (m, 2H), 7.47 – 7.26 (m, 2H), 7.26 – 7.07 (m, 4H), 
4.63 (s, 1H), 4.50 – 4.34 (m, 3H), 4.31 – 4.19 (m, 2H), 4.15 (s, 1H), 4.08 – 3.97 (m, 3H), 3.93 (d, 
J = 11.3 Hz, 1H), 3.90 – 3.50 (m, 21H), 3.50 – 3.35 (m, 5H), 3.35 – 3.20 (m, 3H), 2.63 (d, J = 8.5 
Hz, 1H), 1.90 (s, 6H), 1.87 (s, 3H), 1.75 (t, J = 12.2 Hz, 1H), 0.93 (d, J = 5.5 Hz, 3H). ESI-MS, 
calculated: 1362.4861; found [M-H]- 1361.4659, [M-2H]2- 680.2284; MALDI-MS; found 
[M+Na]+ 1385.436, [M+K]+ 1401.414. 
 
M203    
1H NMR (600 MHz, D2O) δ 7.92 – 7.78 (m, 2H), 7.72 – 7.54 (m, 2H), 7.49 – 7.30 (m, 4H), 
4.63 – 4.55 (m, 2H), 4.47 (d, J = 8.6 Hz, 1H), 4.37 (m, 2H), 4.29 (m, 1H), 4.20 (m, 1H), 4.14 (d, 
J = 10.0 Hz, 1H), 4.07 (s, 1H), 3.94 (m, 2H), 3.91 – 3.43 (m, 33H), 3.43 – 3.27 (m, 4H), 2.59 (dd, 
J = 12.5, 4.5 Hz, 1H), 1.98 (s, 3H), 1.96 (s, 3H), 1.94 (s, 3H), 1.68 (t, J = 12.2 Hz, 1H), 0.97 (d, J 
= 6.4 Hz, 3H). ESI-MS, calculated: 1362.4861; found [M-H]- 1361.4653, [M-2H]2- 680.2283; 
MALDI-MS; found [M-H]- 1361.438. 
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M204    
1H NMR (600 MHz, D2O) δ 7.90 – 7.68 (m, 2H), 7.67 – 7.50 (m, 2H), 7.46 – 7.26 (m, 4H), 
5.03 (d, J = 3.5 Hz, 1H), 4.66 (s, 1H), 4.59 (d, J = 11.8 Hz, 1H), 4.54 – 4.42 (m, 2H), 4.36 (d, J = 
7.8 Hz, 2H), 4.27 – 4.16 (m, 2H), 4.11 (d, J = 10.2 Hz, 2H), 3.99 (s, 1H), 3.94 – 3.55 (m, 18H), 
3.55 – 3.26 (m, 8H), 1.96 (s, 3H), 1.94 (s, 3H), 1.10 (d, J = 6.4 Hz, 3H), 0.96 (d, J = 6.1 Hz, 3H). 
ESI-MS, calculated: 1217.4486; found [M-H]- 1216.4292; MALDI-MS; found [M+Na]+ 
1240.478,, [M+K]+ 1256.458.  
 
M205    
1H NMR (600 MHz, D2O) δ 7.84 – 7.72 (m, 2H), 7.66 – 7.48 (m, 2H), 7.43 – 7.26 (m, 4H), 
4.98 (d, J = 3.8 Hz, 1H), 4.61 (s, 1H), 4.56 – 4.50 (m, 1H), 4.45 – 4.35 (m, 2H), 4.31 (d, J = 8.0 
Hz, 1H), 4.24 – 4.17 (m, 1H), 4.14 (dd, J = 6.4, 2.1 Hz, 1H), 4.07 (d, J = 10.1 Hz, 1H), 4.02 (s, 
1H), 3.98 (dd, J = 9.8, 2.8 Hz, 1H), 3.88 – 3.68 (m, 11H), 3.68 – 3.64 (m, 2H), 3.64 – 3.50 (m, 
10H), 3.50 – 3.37 (m, 7H), 3.37 – 3.22 (m, 4H), 2.65 (dd, J = 12.4, 4.4 Hz, 1H), 1.91 (s, 3H), 1.90 
(s, 3H), 1.88 (s, 3H), 1.71 (t, J = 12.2 Hz, 1H), 1.05 (d, J = 6.5 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H). 
ESI-MS, calculated: 1508.5440; found [M-H]- 1507.5277. 
 
M212    
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1H NMR (600 MHz, D2O) δ 7.93 – 7.79 (m, 2H), 7.72 – 7.55 (m, 2H), 7.50 – 7.30 (m, 4H), 
4.78 (d, J = 5.7 Hz, 1H), 4.64 (d, J = 3.2 Hz, 1H), 4.55 (d, J = 10.7 Hz, 2H), 4.52 – 4.43 (m, 2H), 
4.43 – 4.33 (m, 2H), 4.33 – 4.24 (m, 2H), 4.20 (d, J = 4.9 Hz, 1H), 4.16 – 3.98 (m, 3H), 3.98 – 
3.38 (m, 32H), 3.30 (t, J = 9.8 Hz, 1H), 2.68 (dd, J = 12.5, 4.4 Hz, 1H), 1.96 (s, 6H), 1.93 (s, 3H), 
1.75 (t, J = 12.2 Hz, 1H), 1.00 (d, J = 6.0 Hz, 3H). ESI-MS, calculated: 1524.5390; found [M-H]- 
1523.5161, [M-2H]2- 761.2533; MALDI-MS; found [M+Na]+ 1547.593. 
 
M213    
1H NMR (600 MHz, D2O) δ 7.88 – 7.75 (m, 2H), 7.68 – 7.51 (m, 2H), 7.49 – 7.29 (m, 4H), 
4.78 – 4.72 (m, 1H), 4.70 – 4.65 (m, 1H), 4.61 – 4.51 (m, 1H), 4.47 (d, J = 10.6 Hz, 1H), 4.42 – 
4.33 (m, 2H), 4.30 (d, J = 7.7 Hz, 1H), 4.28 – 4.18 (m, 2H), 4.12 (s, 2H), 3.99 – 3.38 (m, 35H), 
3.31 (t, J = 9.9 Hz, 1H), 2.57 (dd, J = 12.7, 4.3 Hz, 1H), 1.98 (s, 3H), 1.96 (s, 3H), 1.93 (s, 3H), 
1.73 (t, J = 12.2 Hz, 1H), 1.00 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 1524.5390; found [M-H]- 
1523.5166, [M-2H]2- 761.2534; MALDI-MS; found [M-H]- 1523.553 . 
 
M214    
1H NMR (600 MHz, D2O) δ 7.94 – 7.78 (m, 2H), 7.72 – 7.54 (m, 2H), 7.54 – 7.30 (m, 4H), 
5.03 (d, J = 3.8 Hz, 1H), 4.77 – 4.75 (m, 1H), 4.67 (s, 1H), 4.49 (d, J = 7.9 Hz, 1H), 4.36 (d, J = 
7.8 Hz, 2H), 4.31 (d, J = 7.7 Hz, 1H), 4.27 (s, 1H), 4.21 (d, J = 5.5 Hz, 1H), 4.11 (d, J = 11.3 Hz, 
1H), 4.03 (s, 1H), 3.97 – 3.38 (m, 33H), 3.30 (t, J = 10.0 Hz, 1H), 1.96 (s, 3H), 1.94 (s, 3H), 1.11 
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(d, J = 6.2 Hz, 3H), 0.99 (d, J = 6.3 Hz, 3H). ESI-MS, calculated: 1379.5014; found [M-H]- 
1378.4804. 
 
M215    
1H NMR (600 MHz, D2O) δ 7.91 – 7.80 (m, 2H), 7.71 – 7.55 (m, 2H), 7.49 – 7.31 (m, 4H), 
5.03 (d, J = 3.9 Hz, 1H), 4.77 – 4.75 (m, 1H), 4.68 – 4.65 (m, 1H), 4.56 (dd, J = 10.9, 5.0 Hz, 1H), 
4.51 – 4.41 (m, 2H), 4.38 (d, J = 8.1 Hz, 1H), 4.34 – 4.25 (m, 2H), 4.21 (dd, J = 6.3, 2.2 Hz, 1H), 
4.15 – 4.06 (m, 2H), 4.03 (dd, J = 9.8, 3.0 Hz, 1H), 3.96 – 3.76 (m, 12H), 3.76 – 3.42 (m, 26H), 
3.30 (t, J = 9.8 Hz, 1H), 2.70 (dd, J = 12.4, 4.6 Hz, 1H), 1.96 (s, 3H), 1.95 (s, 3H), 1.93 (s, 3H), 
1.75 (t, J = 12.1 Hz, 1H), 1.10 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.3 Hz, 3H). ESI-MS, calculated: 
1670.5969; found [M-H]- 1669.5942, [M-2H]2- 834.2878. 
 
M223    
1H NMR (600 MHz, D2O) δ 7.91 – 7.77 (m, 2H), 7.63 (ddd, J = 28.7, 16.5, 7.2 Hz, 2H), 
7.54 – 7.27 (m, 4H), 4.57 (dd, J = 11.0, 5.1 Hz, 1H), 4.48 (d, J = 8.4 Hz, 1H), 4.42 (d, J = 7.9 Hz, 
1H), 4.40 – 4.34 (m, 2H), 4.34 – 4.25 (m, 1H), 4.25 – 4.18 (m, 1H), 4.17 – 4.00 (m, 3H), 4.00 – 
3.41 (m, 40H), 3.31 (t, J = 9.8 Hz, 1H), 2.69 (dd, J = 12.5, 4.5 Hz, 1H), 2.59 (dd, J = 12.5, 4.5 Hz, 
1H), 1.98 (s, 3H), 1.96 (s, 6H), 1.93 (s, 3H), 1.76 (t, J = 12.2 Hz, 1H), 1.69 (t, J = 12.2 Hz, 1H), 
1.00 (d, J = 6.3 Hz, 3H). ESI-MS, calculated: 1815.6344; found [M-H]- 1814.6084, [M-2H]2- 
906.7991. 
 
55 
M224   
1H NMR (600 MHz, D2O) δ 7.94 – 7.81 (m, 2H), 7.78 – 7.56 (m, 2H), 7.50 – 7.30 (m, 4H), 
5.07 – 4.99 (m, 2H), 4.54 – 4.46 (m, 2H), 4.46 – 4.33 (m, 2H), 4.29 (s, 1H), 4.26 – 4.14 (m, 1H), 
4.08 (d, J = 10.8 Hz, 1H), 4.05 – 3.98 (m, 1H), 3.92 (t, J = 12.1 Hz, 1H), 3.89 – 3.55 (m, 28H), 
3.55 – 3.38 (m, 9H), 3.28 (t, J = 9.8 Hz, 1H), 2.69 (dd, J = 12.3, 4.4 Hz, 1H), 2.00 – 1.86 (m, 9H), 
1.73 (t, J = 12.1 Hz, 1H), 1.15 – 1.02 (m, 6H), 0.94 (d, J = 6.3 Hz, 3H). ESI-MS, calculated: 
1670.5969; found [M-H]- 1669.5733, [M-2H]2- 834.2812 
. 
M225   
1H NMR (600 MHz, D2O) δ 7.93 – 7.80 (m, 2H), 7.72 – 7.55 (m, 2H), 7.53 – 7.33 (m, 4H), 
5.03 (d, J = 4.0 Hz, 1H), 4.61 – 4.53 (m, 2H), 4.52 – 4.35 (m, 5H), 4.30 (s, 2H), 4.24 – 4.15 (m, 
1H), 4.05 (m, 4H), 3.98 – 3.38 (m, 39H), 3.37 – 3.25 (m, 2H), 3.23 – 3.15 (m, 1H), 2.74 – 2.65 
(m, 2H), 1.96 (s, 6H), 1.95 (s, 3H), 1.93 (s, 3H), 1.92 (s, 3H), 1.74 (t, J = 11.9 Hz, 2H), 1.10 (d, J 
= 6.5 Hz, 3H), 0.99 (d, J = 6.4 Hz, 3H). ESI-MS, calculated: 1961.6923; found [M-2H]2- 979.8275. 
 
M234    
1H NMR (600 MHz, D2O) δ 7.92 – 7.78 (m, 2H), 7.72 – 7.55 (m, 2H), 7.53 – 7.32 (m, 4H), 
5.03 (d, J = 3.8 Hz, 1H), 4.56 (d, J = 12.5 Hz, 1H), 4.51 (d, J = 8.3 Hz, 1H), 4.45 – 4.33 (m, 3H), 
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4.29 (s, 2H), 4.21 (d, J = 6.3 Hz, 1H), 4.15 – 4.02 (m, 2H), 4.02 – 3.35 (m, 38H), 3.35 – 3.26 (m, 
1H), 2.60 (dd, J = 12.2, 4.6 Hz, 1H), 1.97 (s, 3H), 1.96 (s, 3H), 1.95 (s, 3H), 1.70 – 1.63 (m, 1H), 
1.10 (d, J = 6.3 Hz, 3H), 0.99 (d, J = 5.4 Hz, 3H). ESI-MS, calculated: 1670.5969; found [M-H]- 
1669.5733, [M-2H]2- 834.2816; MALDI-MS; found [M-H]- 1669.520. 
 
M235    
1H NMR (600 MHz, D2O) δ 7.92 – 7.79 (m, 2H), 7.78 – 7.54 (m, 2H), 7.51 – 7.32 (m, 4H), 
5.03 (d, J = 4.0 Hz, 1H), 4.62 – 4.56 (m, 2H), 4.50 (d, J = 8.1 Hz, 1H), 4.49 – 4.44 (m, 1H), 4.43 
(d, J = 8.0 Hz, 1H), 4.41 – 4.34 (m, 1H), 4.32 – 4.27 (m, 2H), 4.21 (d, J = 5.2 Hz, 1H), 4.15 – 4.05 
(m, 2H), 4.02 (dd, J = 10.1, 2.7 Hz, 1H), 3.99 – 3.39 (m, 46H), 3.35 – 3.27 (m, 1H), 2.69 (dd, J = 
12.4, 4.5 Hz, 1H), 2.60 (dd, J = 12.1, 4.3 Hz, 1H), 1.96 (s, 3H), 1.96 (s, 3H), 1.92 (s, 3H), 1.75 (t, 
J = 12.3 Hz, 1H), 1.71 – 1.64 (m, 1H), 1.10 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 6.0 Hz, 3H). ESI-MS, 
calculated: 1961.6923; found [M-2H]2- 979.8283. 
 
M245    
1H NMR (600 MHz, D2O) δ 7.87 – 7.75 (m, 2H), 7.68 – 7.48 (m, 2H), 7.46 – 7.26 (m, 4H), 
4.96 (d, J = 3.2 Hz, 2H), 4.60 – 4.58 (m, 2H), 4.48 – 4.39 (m, 3H), 4.36 (d, J = 7.6 Hz, 2H), 4.31 
(d, J = 9.5 Hz, 2H), 4.22 (d, J = 5.9 Hz, 2H), 4.16 – 4.15 (m, 1H), 4.13 (d, J = 5.7 Hz, 1H), 4.02 
(d, J = 10.4 Hz, 1H), 3.95 (d, J = 9.9 Hz, 2H), 3.88 – 3.61 (m, 18H), 3.61 – 3.49 (m, 9H), 3.49 – 
3.29 (m, 9H), 3.27 – 3.17 (m, 2H), 2.62 (dd, J = 12.2, 3.7 Hz, 1H), 1.89 (s, 6H), 1.87 (s, 3H), 1.66 
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(t, J = 12.3 Hz, 1H), 1.03 (d, J = 6.0 Hz, 6H), 0.91 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 
1816.6548; found [M-H]- 1815.6307, [M-2H]2- 907.3100. 
 
M301    
 1H NMR (400 MHz, MeOD) δ 7.79 (d, J = 7.5 Hz, 2H), 7.74 – 7.58 (m, 2H), 7.44 – 7.27 
(m, 4H), 4.55 (d, J = 7.7 Hz, 1H), 4.50 – 4.31 (m, 5H), 4.23 (t, J = 6.7 Hz, 1H), 4.18 – 4.02 (m, 
2H), 4.01 – 3.84 (m, 5H), 3.84 – 3.51 (m, 14H), 3.51 – 3.30 (m, 6H), 2.08 (s, 3H), 2.06 (s, 3H), 
1.22 (d, J = 5.9 Hz, 2H); 13C NMR (100 MHz, MeOD) δ 173.40, 172.73, 157.41, 144.06, 143.80, 
141.18, 127.42, 126.85, 124.88, 119.55, 103.81, 101.78, 98.66, 79.69, 79.33, 76.38, 75.74, 75.04, 
73.89, 73.41, 72.46, 71.20, 70.54, 69.85, 68.93, 68.64, 67.77, 66.59, 61.16, 60.88, 60.39, 55.28, 
47.08, 22.35, 22.12, 18.44. ESI-MS, calculated: 1071.3907; found [M-H]- 1070.3777; MALDI-
MS; found [M+Na]+ 1094.388. 
 
M302    
1H NMR (600 MHz, D2O) δ 7.79 – 7.66 (m, 2H), 7.61 – 7.42 (m, 2H), 7.38 – 7.22 (m, 4H), 
4.68 – 4.58 (m, 1H), 4.58 – 4.47 (m, 1H), 4.47 – 4.36 (m, 1H), 4.33 (d, J = 7.8 Hz, 1H), 4.29 (t, J 
= 7.7 Hz, 1H), 4.22 (d, J = 7.6 Hz, 1H), 4.20 – 3.96 (m, 3H), 3.93 – 3.80 (m, 1H), 3.80 – 3.34 (m, 
30H), 3.34 – 3.20 (m, 3H), 2.63 (dd, J = 12.4, 4.1 Hz, 1H), 1.91 (s, 6H), 1.87 (s, 3H), 1.74 (t, J = 
12.2 Hz, 1H), 0.94 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 1362.4861; found [M-H]- 1361.4634, 
[M-2H]2- 680.2272; MALDI-MS; found [M+H]+ 1363.4380, [M+Na]+ 1385.418. 
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M303    
1H NMR (600 MHz, D2O) δ 7.92 – 7.73 (m, 2H), 7.73 – 7.49 (m, 2H), 7.49 – 7.29 (m, 4H), 
4.68 (s, 1H), 4.60 – 4.43 (m, 2H), 4.36 (d, J = 7.9 Hz, 1H), 4.29 (d, J = 6.5 Hz, 1H), 4.28 – 4.18 
(m, 3H), 4.18 – 4.05 (m, 3H), 4.04 – 3.88 (m, 4H), 3.88 – 3.41 (m, 21H), 3.41 – 3.26 (m, 4H), 2.59 
(dd, J = 12.4, 3.8 Hz, 1H), 1.99 (s, 3H), 1.98 (s, 3H), 1.96 (s, 3H), 1.75 (t, J = 12.1 Hz, 1H), 1.02 
(d, J = 6.3 Hz, 3H). ESI-MS, calculated: 1362.4861; found [M-H]- 1361.4637, [M-2H]2- 680.2274; 
MALDI-MS; found [M-H]- 1361.427. 
 
M304    
1H NMR (600 MHz, D2O) δ 7.87 – 7.73 (m, 2H), 7.74 – 7.51 (m, 2H), 7.51 – 7.29 (m, 4H), 
5.02 (d, J = 3.9 Hz, 1H), 4.75 (d, J = 7.1 Hz, 1H), 4.65 – 4.54 (m, 1H), 4.54 – 4.44 (m, 2H), 4.41 
– 4.32 (m, 1H), 4.27 (d, J = 7.8 Hz, 1H), 4.21 (d, J = 4.7 Hz, 2H), 4.16 – 4.02 (m, 2H), 3.90 (d, J 
= 10.4 Hz, 1H), 3.89 – 3.29 (m, 26H), 1.96 (s, 3H), 1.93 (s, 3H), 1.10 (d, J = 6.5 Hz, 3H), 1.00 (d, 
J = 6.3 Hz, 3H). ESI-MS, calculated: 1217.4486; found [M+H]+ 1218.4589, [M+Na]+ 1240.4386; 
MALDI-MS, found [M-H]- 1216.436. 
 
M305    
1H NMR (600 MHz, D2O) δ 7.77 – 7.59 (m, 2H), 7.59 – 7.37 (m, 2H), 7.37 – 7.15 (m, 4H), 
4.98 (d, J = 3.4 Hz, 1H), 4.66 (s, 1H), 4.54 (s, 1H), 4.51 – 4.39 (m, 2H), 4.39 – 4.26 (m, 3H), 4.26 
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– 3.95 (m, 5H), 3.95 – 3.20 (m, 32H), 2.66 (dd, J = 12.6, 4.4 Hz, 1H), 1.93 (s, 6H), 1.89 (s, 3H), 
1.80 (t, J = 12.2 Hz, 1H), 1.06 (d, J = 6.2 Hz, 3H), 0.97 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 
1508.544; found [M-H]- 1507.5194, [M-2H]2- 753.2551. 
 
M312    
1H NMR (600 MHz, D2O) δ 7.92 – 7.73 (m, 2H), 7.73 – 7.56 (m, 2H), 7.54 – 7.33 (m, 4H), 
4.80 – 4.74 (m, 1H), 4.65 – 4.58 (m, 1H), 4.59 – 4.46 (m, 4H), 4.38 (d, J = 7.8 Hz, 2H), 4.34 – 
4.23 (m, 2H), 4.19 (d, J = 5.0 Hz, 1H), 4.11 (d, J = 10.3 Hz, 1H), 3.99 (s, 1H), 3.95 – 3.78 (m, 
7H), 3.78 – 3.42 (m, 26H), 3.39 – 3.26 (m, 1H), 2.61 (dd, J = 12.4, 4.4 Hz, 1H), 1.97 (s, 6H), 1.96 
(s, 3H), 1.66 (t, J = 11.9 Hz, 1H), 0.99 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 1524.5390; found 
[M-H]- 1523.5249, [M-2H]2- 761.2589. 
 
M313    
1H NMR (600 MHz, D2O) δ 7.94 – 7.82 (m, 2H), 7.75 – 7.57 (m, 2H), 7.52 – 7.31 (m, 4H), 
4.75 – 4.73 (m, 1H), 4.69 – 4.67 (m, 1H), 4.52 (d, J = 7.7 Hz, 2H), 4.44 – 4.35 (m, 2H), 4.35 – 
4.25 (m, 2H), 4.18 (d, J = 6.4 Hz, 1H), 4.11 (d, J = 10.4 Hz, 1H), 3.98 – 3.89 (m, 2H), 3.89 – 3.78 
(m, 6H), 3.78 – 3.42 (m, 28H), 3.33 – 3.26 (m, 1H), 2.61 (dd, J = 12.8, 4.3 Hz, 1H), 1.98 (s, 6H), 
1.96 (s, 3H), 1.65 (t, J = 11.9 Hz, 1H), 0.96 (d, J = 5.7 Hz, 3H). ESI-MS, calculated: 1524.5390; 
found [M-H]- 1523.5148, [M-2H]2- 761.2527; MALDI-MS; found [M+H]+ 1525.527, [M+Na]+ 
1547.527. 
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M314    
1H NMR (600 MHz, D2O) δ 7.89 – 7.78 (m, 2H), 7.70 – 7.53 (m, 2H), 7.49 – 7.28 (m, 4H), 
5.02 (d, J = 3.8 Hz, 1H), 4.76 – 4.74 (m, 1H), 4.69 – 4.67 (m, 1H), 4.54 – 4.46 (m, 2H), 4.35 (d, J 
= 8.2 Hz, 2H), 4.32 – 4.17 (m, 4H), 4.09 (d, J = 10.0 Hz, 1H), 4.04 (s, 1H), 3.91 (d, J = 11.2 Hz, 
2H), 3.88 – 3.69 (m, 10H), 3.69 – 3.46 (m, 14H), 3.46 – 3.26 (m, 6H), 1.96 (s, 3H), 1.93 (s, 3H), 
1.10 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.3 Hz, 3H). ESI-MS, calculated: 1379.5014; found [M-H]- 
1378.4948. 
 
M315    
1H NMR (600 MHz, D2O) δ 7.88 – 7.74 (m, 2H), 7.69 – 7.50 (m, 2H), 7.47 – 7.30 (m, 4H), 
5.01 (d, J = 3.4 Hz, 1H), 4.83 – 4.79 (m, 1H), 4.65 – 4.63 (m, 1H), 4.53 – 4.31 (m, 5H), 4.29 – 
4.17 (m, 3H), 4.16 – 4.00 (m, 3H), 3.98 – 3.37 (m, 37H), 3.31 (t, J = 10.4 Hz, 1H), 2.69 (dd, J = 
12.7, 4.4 Hz, 1H), 1.96 (s, 3H), 1.95 (s, 3H), 1.91 (s, 3H), 1.81 (t, J = 12.3 Hz, 1H), 1.09 (d, J = 
6.0 Hz, 3H), 0.99 (d, J = 6.3 Hz, 3H). ESI-MS, calculated: 1670.5969; found [M-H]- 1669.5717, 
[M-2H]2- 834.2809; MALDI-MS; found [M+H]+ 1669.519. 
 
M323    
1H NMR (600 MHz, D2O) δ 7.90 – 7.76 (m, 2H), 7.67 – 7.52 (m, 2H), 7.48 – 7.29 (m, 4H), 
4.74 – 4.72 (m, 1H),4.69 – 4.67 (m, 1H), 4.54 (d, J = 14.9 Hz, 2H), 4.50 (d, J = 8.1 Hz, 1H), 4.46 
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(d, J = 7.8 Hz, 1H), 4.36 (d, J = 7.8 Hz, 1H), 4.32 – 4.18 (m, 3H), 4.16 – 4.03 (m, 3H), 4.05 – 3.36 
(m, 40H), 3.31 (t, J = 9.8 Hz, 1H), 2.80 – 2.63 (m, 1H), 2.62 – 2.53 (m, 1H), 1.96 (s, 9H), 1.95 (s, 
3H), 1.80 (t, J = 12.1 Hz, 1H), 1.77 – 1.68 (m, 1H), 1.01 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 
1815.6344; found [M-H]- 1814.6059, [M-2H]2- 906.7983. 
 
M324    
1H NMR (600 MHz, D2O) δ 7.90 – 7.78 (m, 2H), 7.71 – 7.54 (m, 2H), 7.52 – 7.30 (m, 4H), 
5.01 (d, J = 3.8 Hz, 1H), 4.58 – 4.52 (m, 2H), 4.49 (d, J = 8.0 Hz, 1H), 4.45 (d, J = 7.7 Hz, 2H), 
4.35 (d, J = 8.1 Hz, 2H), 4.27 (d, J = 6.8 Hz, 2H), 4.20 (d, J = 5.5 Hz, 1H), 4.14 – 4.02 (m, 3H), 
3.99 – 3.55 (m, 28H), 3.54 – 3.44 (m, 5H), 3.44 – 3.36 (m, 2H), 3.31 (t, J = 9.7 Hz, 1H), 2.68 (dd, 
J = 11.9, 3.4 Hz, 1H), 1.96 (s, 3H), 1.95 (s, 3H), 1.92 (s, 3H), 1.80 (t, J = 12.5 Hz, 1H), 1.09 (d, J 
= 6.5 Hz, 3H), 0.99 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 1670.5969; found [M-H]- 1669.5715, 
[M-2H]2- 834.2804; MALDI-MS, found [M+Na]+ 1693.566, [M+K]+ 1709.538. 
 
M325    
1H NMR (600 MHz, D2O) δ 7.92 – 7.78 (m, 2H), 7.74 – 7.53 (m, 2H), 7.48 – 7.30 (m, 4H), 
5.02 (d, J = 4.0 Hz, 1H), 4.55 (dd, J = 8.8, 4.4 Hz, 1H), 4.53 – 4.42 (m, 3H), 4.37 (dd, J = 17.1, 
7.9 Hz, 2H), 4.34 – 4.24 (m, 2H), 4.24 – 4.15 (m, 1H), 4.15 – 3.99 (m, 4H), 3.99 – 3.39 (m, 42H), 
3.31 (t, J = 9.7 Hz, 1H), 2.75 – 2.62 (m, 2H), 1.96 (s, 3H), 1.95 (s, 3H), 1.92 (s, 6H), 1.77 (t, J = 
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12.4 Hz, 2H), 1.09 (d, J = 6.3 Hz, 3H), 0.99 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 1961.6923; 
found [M-H]- 1960.6640, [M-2H]2- 979.8271. 
 
M334    
1H NMR (600 MHz, D2O) δ 7.91 – 7.78 (m, 2H), 7.72 – 7.53 (m, 2H), 7.52 – 7.29 (m, 4H), 
5.02 (d, J = 3.7 Hz, 1H), 4.58 – 4.51 (m, 2H), 4.49 (d, J = 7.2 Hz, 1H), 4.41 – 4.33 (m, 2H), 4.31 
– 4.17 (m, 3H), 4.16 – 4.05 (m, 2H), 4.01 – 3.44 (m, 36H), 3.44 – 3.37 (m, 2H), 3.31 (t, J = 9.9 
Hz, 1H), 2.57 (dd, J = 12.7, 2.6 Hz, 1H), 1.97 (s, 3H), 1.96 (s, 3H), 1.92 (s, 3H), 1.73 (t, J = 12.3 
Hz, 1H), 1.09 (d, J = 6.4 Hz, 3H), 1.00 (d, J = 6.3 Hz, 3H). ESI-MS, calculated: 1670.5969; found 
[M-H]- 1669.5713, [M-2H]2- 834.2806; MALDI-MS, found [M+Na]+ 1693.567, [M+K]+ 
1709.894. 
 
M335    
1H NMR (600 MHz, D2O) δ 7.93 – 7.79 (m, 2H), 7.74 – 7.56 (m, 2H), 7.51 – 7.31 (m, 4H), 
5.02 (d, J = 3.7 Hz, 1H), 4.60 – 4.53 (m, 1H), 4.53 – 4.43 (m, 2H), 4.43 – 4.34 (m, 2H), 4.34 – 
4.25 (m, 1H), 4.21 (d, J = 2.7 Hz, 1H), 4.17 – 4.06 (m, 2H), 4.01 (d, J = 9.6 Hz, 1H), 3.93 (d, J = 
10.0 Hz, 2H), 3.90 – 3.38 (m, 46H), 3.31 (t, J = 9.8 Hz, 1H), 2.70 (dd, J = 12.3, 4.5 Hz, 1H), 2.59 
(dd, J = 12.4, 4.4 Hz, 1H), 1.98 (s, 3H), 1.96 (s, 6H), 1.92 (s, 3H), 1.76 (t, J = 11.9 Hz, 1H), 1.72 
– 1.64 (m, 1H), 1.09 (d, J = 6.5 Hz, 3H), 0.99 (d, J = 6.2 Hz, 3H). ESI-MS, calculated: 1961.6923; 
found [M-H]- 1960.6671, [M-2H]2- 979.8270. 
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M345   
1H NMR (600 MHz, D2O) δ 7.94 – 7.79 (m, 2H), 7.77 – 7.54 (m, 2H), 7.51 – 7.30 (m, 4H), 
5.03 (d, J = 4.1 Hz, 2H), 4.57 – 4.52 (m, 1H), 4.52 – 4.43 (m, 1H), 4.37 (dd, J = 14.6, 7.7 Hz, 2H), 
4.33 – 4.25 (m, 1H), 4.21 (dd, J = 6.3, 2.3 Hz, 1H), 4.13 – 4.07 (m, 1H), 4.07 – 3.98 (m, 1H), 3.93 
(d, J = 10.7 Hz, 1H), 3.90 – 3.54 (m, 32H), 3.54 – 3.38 (m, 10H), 3.31 (t, J = 9.7 Hz, 1H), 2.70 
(dd, J = 12.5, 4.5 Hz, 1H), 1.96 (s, 3H), 1.95 (s, 3H), 1.92 (s, 3H), 1.77 (t, J = 12.1 Hz, 1H), 1.15 
– 1.05 (m, 6H), 0.99 (d, J = 6.3 Hz, 3H). ESI-MS, calculated: 1816.6548; found [M-H]- 1815.6285, 
[M-2H]2- 907.3094. 
 
 
 
 
 
 
 
 
 
 
 
64 
2 DESIGN, SYNTHESIS AND ACTIVITY STUDIES OF CELLULAR O-GLYCOME 
PRECURSOR 
Protein O-glycosylation is a universal post-translational modification that plays an essential role 
in many biological regulations. Recently we reported a technology termed Cellular O-Glycome 
Reporter/Amplification (CORA) to amplify and profile mucin-type O-glycans from living cells. 
However, the application and development of the CORA method is litmted by the precursor 
function. Here we discussed a rapid parallel synthesis of cellular O-glycome precursors via 
microwave assisted reaction. In total, 26 Ac3GalNAc-α-Bn derivatives, including fluorescent and 
other reactive functional groups, were successfully synthesized. Furthermore, subsequent activity 
screening and evaluation of these precursors toward living cell and T-synthase were performed. 
2.1 Introduction 
2.1.1 Biosynthesis of O-GalNAc protein 
Protein glycosylation is a widespread post-translational modification that play a key role 
in diverse fundamental cellular processes[44]. The highly regulated repertoire of cellular glycans, 
by binding to lectins and sterically modulating molecular interactions, were involed in multiple 
cellular mechanisms that contribute to health and disease. Because of the poor sensitivity of 
existing glycomics approaches and the lack of efficient and unbiased strategies for releasing 
glycans from complex samples, current technologies for evaluating glycans require relatively large 
amounts of biological samples for detailed structural analyses, which limits many potential 
applications. Hence, there is an urgent need to develop a simple and sensitive method for the 
analyzis of all the glycans synthesized by cells (the cellular glycome). [45] 
GalNAc is linked to Ser or Thr residues with an α-linkage by a large family of over 20 
different polypeptide N-acetylgalactosamine transferases (ppGalNAcTs). Unlike most 
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glycosylation, which happens in the ER, GalNAc O-glycosylation occurs in the Golgi after protein 
folding.[46] Each ppGalNAcT has two domains: a catalytic glycosyltransferase domain and ricin-
homology lectin domain. This lectin domain has been implicated in governing the selectivity and 
activity of several members of the family.[47] Unlike N-glycosylation and several other types of O-
glycosylation, to date no consensus sequence has been identified for the addition of O-GalNAc; it 
has even been suggested that no such sequence exists and that ppGalNAcTs recognize and modify 
protein secondary structures, like the β-turn, instead of specific primary sequences.[48] What is 
known, as demonstrated by several studies discussed in greater detail later on, is that each 
ppGalNAcT homolog has a slightly different activity profile for peptide and/or glycopeptide 
substrates. Additionally, the expression of each homolog varies spatially across tissues and 
temporally during development.[46, 49] Such a high-level regulation during cell differentiation and 
organismal development is indicative of critical roles for these enzymes and the O-GalNAc 
modifications they impart. Interestingly, the deletion of the ppGalNAcT-1, T-4, T-5, or T-13 genes 
in mice fails to result in any observable phenotype.[50] This might indicate a high level of 
redundancy and overlap between the functions of each family member. However this situation 
does not hold for all systems studied, as the deletion of any one of five different Drosophila 
melanogaster O-GalNAc transferases is lethal[49] and inactivating mutations of ppGalNAcT-3 in 
humans cause the rare autosomal recessive metabolic disorder familial tumoral calcinosis.[51] 
Clearly, in certain cellular contexts, a single O-GalNAc transferase can have unique and critical 
functions. After the initial O-GalNAc transfer, further elaboration is accomplished in the Golgi 
apparatus by a suite of up to 30 glycosyltransferases to yield a huge variety of mature “mucin-
type” O-GalNAc glycans (Fig 2.1). 
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Figure 2.1 Biosynthesis of representive O-GalNAc protein in the ER and Golgi apparatus. 
2.1.2 Functional effects of O-GalNAc glycosylation 
O-GalNAc glycosylation is the most common form of O-glycosylation in mammals, 
occurring in an estimated 10% of all mammalian proteins and half of all proteins passing through 
the secretory system.[52] The most well-known examples of proteins carrying this type of 
glycosylation are the mucins, and in fact O-GalNAc glycosylation is referred to as “mucin-type” 
glycosylation in the literature due to the strength of this association.[48, 53] Mucins can be divided 
into two categories: secreted mucins that form extensive oligomers and result in a viscous, mucosal 
layer around tissues; and membrane-bound mucins that are monomeric and form a significant 
amount of the glycocalyx that surrounds and protects many cells.[54] The most relevant feature of 
mucin proteins is the so-called “mucin-domain” which consists of a large number of repeats of a 
mucin-subtype-specific sequence.[55] These repeated sequences, often referred to as “tandem 
repeats”, are heavily glycosylated with densely clustered O-GalNAc glycans.[48] Additionally, 
there are a number of non-mucin proteins contain domains that are structurally very similar to the 
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heavily glycosylated, tandem-repeat regions of mucins, and these are also referred to as “mucin 
domains”.[55a, 56] 
O-GalNAc glycans in these mucin domains are frequently acknowledged for their ability 
to prevent proteolytic degradation.[57] Early light microscopy data indicated that mucin domains 
adopt a rigid, extended conformation in solution. A multitude of studies since then have established 
that this structure is a general feature of mucin domains and that this rod-like structure is dependent 
on the presence of O-GalNAc glycan clusters throughout the sequence.[58] Therefore, the function 
of O-GalNAc glycosylation in these domains has traditionally been thought of as mainly structural: 
producing a stable, extended structure on the cell surface for display of other, more functionally 
important, protein domains, with little importance placed on the actual glycosylation pattern(s) 
present.[47a] For example, glycans on extracellular proteins are known to inhibit oligomerization 
through what is probably the nonspecific charge–charge repulsion of negatively charged end 
groups.[59] The fact that the sequence of mucins and mucin domains has been only lightly 
conserved during evolution has also been used as evidence for this assumption.[60] 
While there is undeniably an important structural aspect to mucin glycosylation, numerous 
examples have emerged of glycans acting in a much more specific manner, for example, it has 
been suggested that they are integral to the molecular code used in everyday cellular 
communication and recognition.[61] As evidence of these more specific roles, the glycosylation 
patterns of many proteins appears to be tightly regulated during cellular maturation,[62] and both 
temporally and spatially during development.[63] Glycan patterns on mucins have also been shown 
to vary in a region-specific way in several different body systems.[56, 64] The intestinal tract is a 
prime example, where different core structures are specific to each region and sialic acids appear 
in a well-defined gradient increasing from the ileum to the colon.[65] Mucin-type glycosylation is 
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also known to be important in governing selectivity in cell–cell communication and signaling in 
several different systems including T cell maturation,[66] Notch signaling,[67] leukocyte 
migration[68] and mucin signaling.[69] This type of glycosylation is critical to proper processing of 
many proteins from the proprotein form to maturity[70] and important in regulating cleavage by a 
disintegrin and metalloprotease (ADAM) proteases and subsequent shedding of the extracellular 
domains of many diverse membrane proteins including Notch[67] and TNF-α.[71] Interestingly, this 
regulation has been observed to be both positive and negative, so it is not a simple steric-
interference mechanism and may involve specific binding interactions.[71] Cytokines, secreted 
soluble proteins that are involved in cell communication, are also known to be regulated through 
several types of glycosylation, including O-glycosylation with mucin-type glycans.[72] Chemical 
biology has clearly aided in the studies of O-GalNAc glycosylation. As discussed below, much of 
the early work on structural and functional effects of O-GalNAc glycosylation focused on small 
glycopeptides. The readily available and pure homogenous glycoforms made it possible to draw 
strong conclusions about the different substrate specificities of ppGalNAcTs and the ability of O-
GalNAc glycans to affect the structural and functional properties of proteins. 
Chemical biology has also contributed to the study of functional aspects of mucin-type 
glycans in biological systems. As mentioned earlier, glycosylation patterns on extracellular 
membrane proteins are very important for cellular communication and adhesion. For example, 
during inflammation, leukocytes adhere to endothelial cells near the site of injury before migration 
towards the injury site.[73] This adherence is the result of P-selectin on the endothelial cells binding 
specific ligands on leukocytes, the most important of which is known as P-selectin glycoprotein 
ligand-1 (PSGL-1). P-Selectin binds to the extreme terminus of PSGL-1, and both tyrosine 
sulfation and O-glycosylation of PSGL-1 in this region have been shown to be critical for high-
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affinity binding in studies of genetic knockout models.[73] To identify the particular modifications 
required for binding in this context, the Cummings group chemo-enzymatically synthesized a 23-
mer glycosulfopeptide based on the N-terminal sequence of PSGL-1 that contain three 
sulfotyrosines and a sialyl Lewis x (sLex) hexasaccharide.[74] To avoid problems with site-
specificity of ppGalNAcTs, the peptide was synthesized on solid phase with the first GalNAc at 
position Thr 57 in place. Enzymatic transformations by a series of five glycosyltransferases 
constructed the full hexasaccharide, and lastly, addition of the sulfate groups was also 
accomplished enzymatically. It was found that the sulfotransferase was able to add sulfates to all 
three tyrosines in the glycopeptide simultaneously.[74a] What’s more[74b], the authors synthesized 
aglycosulfopeptide with a core-1 sLeX-containing hexasaccharide and the same three 
sulfotyrosines through a very similar chemoenzymatic approach. The authors then tested the two 
final glycosulfopeptides for binding affinity to P-selectin and found that only one which construct 
with the core-2 glycan structure was bound to a measurable degree.[74] In addition, when the 
terminal sialic acid was removed from the glycan, binding was abolished. Moreover, they found 
that the synthetic intermediate carrying the full-length glycan, but not the sulfates, did not bind, 
nor did the isolated hexasaccharide bind. The results of this study indicate that both modifications, 
sulfation and glycosylation, are critical to high-affinity binding between PSGL-1 and P-selectin. 
However, the authors were unable to chemo-enzymatically prepare any partially-sulfated 
glycopeptide products, and they could not address the question of whether or not specific sulfo-
tyrosines were more important to binding than others. This question was solved in a follow-up 
study by the same group that used chemical synthesis to introduce the sulfo-tyrosine residues in a 
completely controlled manner.[75] In this study they synthesized a large library of 
glycosulfopeptides containing each possible combination of 0–3 sulfate groups and several 
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different glycan structures. Characterization of each construction and comparison of the results 
revealed that the most important determinant of binding was the presence of a fucose in the sLeX 
epitope on the peptide, although the number and pattern of sulfate groups as well as the terminal 
sialic acid had strong effects on binding. Also noteworthy is the site-specific nature of this glycan 
dependence, moving the full-length glycan from the natural glycosylation site to a nearby site (both 
threonines) resulted in complete loss of binding.[75] 
2.1.3 CORA technology 
Present on over 80% of proteins[76] that traverse the secretory apparatus, mucin type O-
glycan with O-GalNAc-linkage to Ser/Thr/Tyr residues is one of the most common types of protein 
glycosylation and is important in many normal and pathologic settings[77]. In contrast to N-glycans, 
which can be released enzymatically, O-glycans require chemical strategies for their release—
primarily alkaline β-elimination, which is inefficient and may result in O-glycan degradation. To 
address these problems, we recently developed a technology termed Cellular O-glycome 
Reporter/Amplification (CORA)[78], which used Ac3GalNAc-α-Bn as precursor to amplify and 
profile the mucin-type O-glycome in living cell, resulting 100-1000x increased sensitivity over 
traditional methods (Fig 2.2). Isotope-Cellular O-glycome Reporter Amplification (ICORA) was 
developed later to analyze the O-glycome from cells by isotope labeling[79]. We noticed that CORA 
was showed effective at concentrations <250 μM and short incubation times with no observed side 
effect on cellular properties or glycosylation. Prior studies showed that treating cells with high 
concentrations of Bn-α-GalNAc for O-glycan inhibition produced mainly short Gal-β3-GalNAc-
α1-O-Bn and sialyl-Gal-β3-GalNAc-α1-O-Bn derivatives.[80] However, our success with CORA 
using low concentrations of this Ac3GalNAc-α-Bn derivative as a precursor indicates that it is well 
taken up by live cells, converted to Bn-α-GalNAc, efficiently by T-synthase and further accessed 
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by a wide range of enzymes in the secretory pathway, including the most terminal types of glycan 
modifications and extensions. But in the former work the precursor is limited to Ac3GalNAc-α-
Bn, which hindered many potential applications of CORA. 
 
Figure 2.2 Principle of CORA technology 
Herein, we described a rapid parallel synthesis of cellular O-glycome precursors via 
microwave assisted reaction. By this synthesis method, a library of Ac3GalNAc-α-Bn derivatives 
was successfully synthesized, including fluorescent and other well-known functional groups. 
Subsequent screening of CORA activity on living cell and enzymatic activity on T-synthase were 
carried out to evaluate of these derivatives. With these new precursors with functional groups in 
hand, the application of CORA is widespread, such as analysis and isolation of glycan on HPLC, 
interrogation by glycan-binding proteins on microarray, secretory biological pathway study by 
fluorescent labeling, identify structure by IsoTaG and so on. 
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2.2 Result and discussion 
2.2.1 Design and Synthesis of CORA precursor candidates. 
In former work, the application of CORA was limited by the only precursor Ac3GalNAc-
α-Bn with weak UV and no active functional group. In this work, we structure-based designed 26 
Ac3GalNAc-α-Bn derivatives with active functional groups (Figure 2.3). The template of 
Ac3GalNAc-α-Bn was reserved to keep the CORA activity to the greatest extent. These functional 
groups on the derivatives is designed to be used by well-established methods such as fluorescent 
labeling strategy (fluorescent group; 20 and 21), copper-catalyzed azide−alkyne cycloaddition 
(azide and alkyne groups; 18, 23, 24, 25, 26 and 27), Raman reporter strategy (nitrile group; 12), 
IsoTaG strategy (bromide group; 2, 3, 4, 5, 7, 8, 10 and 22), and Diels−Alder reaction (alkene 
group; 18). 
 
Figure 2.3 Structure of designed Ac3GalNAc-α-Bn derivatives. 
 
As shown in scheme 1, compound 2-22 were synthesized by microwave reaction described 
by Beau and co-workers to achieve α-glycosidation from glycosamine pentaacetates[81]. This one 
73 
step reaction avoids the use of 2-azido-2-deoxy or other nonparticipating temporary groups at C-
2. By controlling the temperature and reaction time, we got desired product in acceptable yield. 
We also tried the reflux method developed by Du and co-workers[82], but we got complex mixture 
of decomposition products for some compounds. Microwave assisted reaction also showed shorter 
reaction time and better α:β ratio due to high reaction temperature. Compounds with azido 
group cannot be achieved by Fig 2.4 directly, due to reaction between azido group and Cu(OTf)2. 
Compound 23-27 were prepared as outline in Fig 2.5. Compound 11 was treated with NaN3 in 
MeCN to give compound 23. The nitro group on compound 13-16 were modified to azido group 
to produce Compound 24-27. 
 
 
Figure 2.4 Microwave assisted synthesis of Ac3GalNAc-α-Bn derivatives. 
 
 
Figure 2.5 Synthesis of Ac3GalNAc-α-Bn derivatives with azido group. 
 
2.2.2 CORA activity and T-synthase activity assays. 
Having these Ac3GalNAc-α-Bn derivatives in hand, we first would like to determine if 
they are the substrate for T-synthase, since T-synthase activity is necessary for producing Bn-O-  
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Table 2.1 Acceptor activity and CORA precursor activity of compounds. 
Compounds 
Relative acceptor  
activity (RAA)  
Relative CORA precursor  
activity (RCPA) 
1 1 1 
2 1.81 2.17 
3 1.93 2.19 
4 1.99 2.85 
5 1.55 2.34 
6 1.19 2.53 
7 1.67 2.89 
8 1.96 2.09 
9 1.92 2.65 
10 2.17 0.05 
11 0.59 0.05 
12 1.63 0.05 
13 4.69 1.30 
14 2.26 0.23 
15 3.01 0.45 
16 3.01 0.21 
17 0 0 
18 1.64 1.86 
19 11.00 0.05 
20 13.38 0.05 
21 1.91 1.41 
22 3.85 4.29 
23 1.34 0.97 
24 1.59 0.79 
25 1.29 1.58 
26 1.28 1.68 
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27 2.15 2.45 
 
glycans in CORA procedure, and cell lines without functional Cosmc cannot secret Bn-O-glycans. 
Therefore, we assayed the acceptor activity of all compounds for T-synthase by using HPLC. The 
procedure was as follows: 0.1 mM compound and 0.5 mM UDP-Galactose were catalyzed by 0.4 
ng/mL T-synthase (provided by Dr. cummings’ lab) in 20 mM MES buffer pH 6.8 (containing 20 
mM MnCl, 0.5% Triton X-100) at 37 ℃ for 18 h, then the reaction was quenched by equal volume 
of methanol, and stored in -80 ℃ for overnight. The freezed samples were unfroze and centri-
fuged at 14,000 rpm for 5 min, then the supernatants were loaded onto C18 (XBridge TM, 35 mm, 
30×150 mm) column. SHIMADZU HPLC system was used, and mobile phase A consisted of 0.1% 
TFA in Acetonitrile and mobile phase B was 0.1% TFA in water. A linear gradient from 5 % to 
60% A over 30 minutes at a flow rate of 0.4 mL/min was applied. Soft-ware EZStart 7.4 was used 
for data analysis. The acceptor activity of Bn-α-GalNAc was set as 1, the RAA (relative accep-tor 
activity) of compound 2-27 was calculated and listed in Table 2.1. The data showed that most of 
the compounds were better accepter than Bn-α-GalNAc for T-synthase, especially compounds 19 
and 20, which represented more than 10-fold accepter activity than compound 1. However, 
compound 11 of which RAA value was 0.59 was not as good as Bn-α-GalNAc, and compound 17 
whose RAA value was zero was not an ac-ceptor for T-synthase.  
Due to the promising RAA of most compounds, we had high expectations for their CORA 
precursor activity. Therefore, we further tested their CORA precursor activity in living cell. Firstly, 
we treated A549 Cell with 50 µM compound 2-27 to see if they can produce corresponding O-
glycans like the known CORA precursor Bn-α-GalNAc. The result showed that compound 2-9, 
13-16, 18, 21-27 can produce the corre-sponding O-glycan peaks like compound 1.Taken 
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compound 22 as an example, it produced a similar MS profile to Bn-α-GalNAc. As expected, 
compound 17 which is not the acceptor for T-synthase cannot work as CORA pre-cursor, and 
compound 11 whose RAA is less than 1 can only produce a few O-glycans in low MS intensity. 
Interestingly, compound 10, 12, 19 and 20 of which RAA are more efficient than Bn-α-GalNAc 
can only make little and weak O-glycan peaks in MS profile, particularly compound 19 and 20, 
which are the best two acceptors for T-synthase, can only produce core 1 and sialyl core 1 O-
glycans. These data indicate that these compounds cannot be processed further in biological 
system. In order to evaluate the exact CORA precursor activity, we developed the following exper-
iment. A549 cells were incubated with compound & Bn-α-GalNAc mixture at the ratio of 1:1 (50 
mM: 50 mM) for 3 days, then the media was collected and went through the Amicon OR 10K 
centrifugal filter (Millipore), then purified by 50 mg Sep-PakOR C18 cartridge (Waters), and 
analyzed by MALDI-MS-TOF. The CORA precursor activity of Bn-α-GalNAc was set as 1, the 
relative CORA precursor activity (RCPA) was calculated by formulation: RCPA of compound = 
the total MS intensity of all derivatized-O-Glycan peaks/ the total MS intensity of all Bn-O-Glycan 
peaks. The MS intensity ratio of the pure compound to Bn-α-GalNAc was used for normaliza-tion. 
Every experiment was repeated for 3 times. The RCAP data in table 1 showed that compound 2-
9, 13, 18, 21, 22, 25-27 performed stronger CORA precursor activity than standard compound 1, 
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while compound 14-16, 24 were less efficient than Bn-α-GalNAc, compound 10-12, 19, 20 barely 
had the CORA precursor activity.  
 
Figure 2.6 CORA activity and T-synthase activity of designed precurors. 
 
2.2.3 SAR study and evaluation of the precursor activity. 
The results showed that compound 2-9 with halogen substitution on aromatic ring 
performed stronger CORA activity than standard compound 1, which suggested that halogen on 
the aromatic ring contributes to improve the binding with glycosyltransferase. The compound with 
Br may be used for IsoTaG glycoproteomics platform probe. Derivatives 10, 11 and 12 don’t have 
CORA activity but showed substrate activity for T-synthase, which might result from metabolism 
during the secretory pathway in the cell. Precursor 13, 14, 15 and 16 bearing nitro group on phenyl 
ring showed better results from enzymatic substrate activity than CORA activity, which due to 
kind of prevention of nitro group during the secretory pathway. Compound 17 was not recognized 
by T-synthase which certainly led to no CORA activity. Most interestingly, Candidates 18, 23, 24, 
25, 26 and 27 bearing with alkyne or azido group showed CORA activity and some of them even 
better than standard precursor compound 1, with which we can add a fluorescent tag by click 
reaction in the future. Compound 19 and 20 showed no CORA activity but very good substrate 
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activity, which suggested that phenol group got blocked during the secretory process. However, 
compound 19 and 20 with strong substrate activity may act as potent and competitive inhibitor of 
T-synthase, which is never reported before. Precursor 21 with fluorescence itself also showed 
CORA activity, which could be an ideal fluorescent label precursor without any additional 
reaction. Candidates 22 and 27 showed better CORA activity and substrate activity than candidates 
4 and 26, which suggested longer linker between GalNAc and aromatic ring is good for enzyme 
to take up substrate. For the compounds with T-synthase activity but no or less CORA activity, we 
assumed they were metabolized in the cell since they should get through the cell membrane and 
go into Golgi easily. 
2.3 Conclusion 
In summary, we designed a rapid parallel synthesis of a library of cellular O-glycome 
precursor via microwave assisted reaction. A total number of 26 Ac3GalNAc-α-Bn derivatives, 
containing fluorescent and other popular functional groups, were successfully synthesized by this 
microwave assisted method. In addition, subsequent assays of CORA activity on living cell and 
enzymatic activity on T-synthase were tested to evaluate of these derivatives. With these new 
functional precursors in hand, the widespread application of CORA on many of areas is predicted, 
such as analysis and isolation of glycan on HPLC, interrogation by glycan-binding proteins on 
microarray, secretory biological pathway study by fluorescent labeling, identify structure by 
IsoTaG and so on. 
2.4 Experiment section 
2.4.1 Chemical synthesis 
Materials: 
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All chemicals were purchased as reagent grade and used without further purification. 
Anhydrous dichloromethane (CH2Cl2), acetonitrile (CH3CN), tetrahydrofuran (THF), N,N-
dimethyl formamide (DMF), diethyl ether (Et2O), toluene, and methanol (MeOH) were purchased 
from a commercial source without further distillation. Pulverized Molecular Sieves MS-4 Å 
(Aldrich) for glycosylation was activated by heating at 350 oC for 3 h. Reactions were monitored 
by analytical thin-layer chromatography (TLC) in EM silica gel 60 F254 plates and visualized 
under UV (254 nm) and/or by staining with acidic ceric ammonium molybdate or p-anisadehyde. 
Flash chromatography was performed on silica gel (Merck) of 40-63μm particle size and P2 gel 
(Biorad). 1H and 13C NMR spectra were recorded on a Bruker AVANCE 400 (400 MHz), and 
Bruker AVANCE 600 (600 MHz) spectrometer at 25 oC. All 1H Chemical shifts (in ppm) were 
assigned according to CDCl3 (δ= 7.24 ppm) and D2O (δ = 4.79 ppm) and all 
13C NMR was 
calibrated with CDCl3 (δ = 77.00 ppm). Coupling constants (J) are reported in hertz (Hz). Splitting 
patterns are described using the following abbreviations: s, singlet; brs, broad singlet; d, doublet; 
t, triplet; q, quartet; dd, doublet of doublet; m, multiplet. 1H NMR spectra are reported in the 
following order: chemical shift, multiplicity, coupling constant(s), and number(s) of protons. All 
NMR signals were assigned on the basis of 1H NMR, COSY, HSQC, HMQC, and 13C NMR 
experiments. HPLC-MS experiments were performed on an LTQ-Orbitrap Elite mass 
spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 
high-performance liquid chromatography system (Thermo Fisher). Samples were transmitted into 
MS with a silica column. LTQ-Orbitrap Elite mass spectrometer was operated in the data-
dependent mode. A full-scan survey MS experiment (m/z range was set according to the molecular 
weight of O-mannose glycan; automatic gain control target, 1,000,000 ions; resolution at 400 m/z, 
240,000; maximum ion accumulation time, 200 ms) was acquired by the Orbitrap mass 
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spectrometer. MALDI-TOF MS analyses were performed on UltrafleXtreme MALDI TOF/TOF 
Mass Spectrometer (Bruker). Scan range of MS was set according to the molecular weight of O-
mannose glycans, and reflector mode was used for O-mannose glycan analysis. Mass spectra were 
obtained in both positive and negative extraction mode with the following voltage settings: ion 
source 1 (19.0 kV), ion source 2 (15.9 kV), and lens (9.3 kV). The reflector voltage was set to 20 
kV. The laser was pulsed at 7 Hz and the pulsed ion extraction time was set at 400 ns. The laser 
power was kept in the range of 40–90%. 
General Procedures 
A) Microwave assisted synthesis of Ac3GalNAc-α-Bn derivatives 
A mixture of peracetylated galactosamine (1 mmol), acceptor (4 mmol) and copper(II) 
trifluoromethanesulfonate (0.15 mmol) in dry 1,2-Dichloroethane was stirred at 130 °C in 
microwave reactor for 25 min. The resulting solution was washed with saturated aqueous NaHCO3 
and brine solution, dried over Na2SO4, filtered, and concentrated in vacuo. The resulting residue 
purified on a silica gel column to get the final product. The alcohol acceptors and corresponding 
yield were shown in Table S1. 
B) Synthesis of precursor with azidobenzene group 
The precursor with nitrobenzene group (1 mmol) was dissolved in THF at room 
temperature, followed by addition of ammonium chloride (3 mmol) and Zn dust (<10 micron, 10 
mmol). After being stirred overnight, the mixture was concentrated in vacuo to give a residue for 
the next step without further purification. 
C) Deacetylation reaction 
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The peracetylated compound was dissolved in MeOH, and NaOMe in MeOH was added 
until pH was 10. After stirring at room temperature for 3 h, the solution was neutralized with ion-
exchange resin (H+), then filtered and concentrated in vacuo to produce the product. 
 
2-Bromobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (2) 
1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 7.8 Hz, 1H), 7.42 – 7.31 (m, 2H), 7.31 – 7.20 
(m, 1H), 5.70 (d, J = 9.7 Hz, 1H), 5.39 (d, J = 2.5 Hz, 1H), 5.18 (dd, J = 11.3, 3.3 Hz, 1H), 4.99 
(d, J = 3.7 Hz, 1H), 4.78 (d, J = 11.7 Hz, 1H), 4.66 – 4.53 (m, 2H), 4.27 (t, J = 6.7 Hz, 1H), 4.12 
(dd, J = 6.5, 2.4 Hz, 2H), 2.17 (s, 3H), 2.07 (s, 3H), 1.99 (s, 3H), 1.94 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 171.05, 170.57, 170.48, 170.17, 135.76, 133.28, 130.98, 130.34, 127.83, 124.26, 
97.12, 69.92, 68.64, 67.46, 67.23, 62.07, 47.73, 23.44, 20.89. 
 
 
3-Bromobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (3) 
1H NMR (400 MHz, CDCl3) δ 7.55 – 7.41 (m, 2H), 7.25 (dd, J = 4.7, 2.4 Hz, 2H), 5.80 (d, 
J = 9.5 Hz, 1H), 5.39 (d, J = 2.3 Hz, 1H), 5.18 (dd, J = 11.4, 3.2 Hz, 1H), 4.98 (d, J = 3.7 Hz, 1H), 
4.69 (d, J = 12.1 Hz, 1H), 4.60 (ddd, J = 11.4, 9.6, 3.7 Hz, 1H), 4.49 (d, J = 12.1 Hz, 1H), 4.20 (t, 
J = 6.5 Hz, 1H), 4.16 – 4.02 (m, 3H), 2.16 (s, 3H), 2.06 (s, 4H), 1.99 (s, 3H), 1.96 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 170.92, 170.45, 170.35, 170.13, 138.98, 131.41, 131.06, 130.29, 
126.68, 122.75, 97.06, 69.07, 68.25, 67.34, 67.04, 61.95, 47.74, 23.27, 20.77, 20.75. 
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4-Bromobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (4) 
1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.3 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 5.55 (d, J 
= 9.7 Hz, 1H), 5.38 (d, J = 2.5 Hz, 1H), 5.17 (dd, J = 11.4, 3.2 Hz, 1H), 4.97 (d, J = 3.7 Hz, 1H), 
4.66 (d, J = 11.9 Hz, 1H), 4.60 (ddd, J = 11.3, 9.8, 3.7 Hz, 1H), 4.46 (d, J = 11.9 Hz, 1H), 4.18 (t, 
J = 6.5 Hz, 1H), 4.16 – 4.03 (m, 2H), 2.17 (s, 3H), 2.06 (s, 3H), 2.00 (s, 3H), 1.93 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 171.08, 170.52, 170.43, 170.07, 135.68, 131.97, 129.93, 122.49, 97.20, 
69.44, 68.40, 67.41, 67.13, 61.99, 47.87, 23.39, 20.87, 20.83.  
 
4-Fluorobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (5) 
1H NMR (400 MHz, CDCl3) δ 7.30 (dd, J = 8.6, 5.5 Hz, 2H), 7.07 (t, J = 8.6 Hz, 2H), 5.62 
(d, J = 9.6 Hz, 1H), 5.38 (d, J = 2.8 Hz, 1H), 5.17 (dd, J = 11.4, 3.2 Hz, 1H), 4.98 (d, J = 3.7 Hz, 
1H), 4.68 (d, J = 11.6 Hz, 1H), 4.59 (ddd, J = 11.3, 9.8, 3.7 Hz, 1H), 4.48 (d, J = 11.6 Hz, 1H), 
4.20 (t, J = 6.5 Hz, 1H), 4.17 – 4.03 (m, 2H), 2.16 (s, 3H), 2.06 (s, 4H), 1.99 (s, 3H), 1.92 (s, 3H); 
13C NMR (101 MHz, CDCl3) δ 171.06, 170.52, 170.44, 170.08, 132.49, 130.24, 130.15, 115.85, 
115.63, 97.05, 69.47, 68.44, 67.43, 67.06, 61.99, 47.85, 23.34, 20.83, 20.80. 
 
 
4-Chlorobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (6) 
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1H NMR (400 MHz, CDCl3) δ 7.47 – 7.32 (m, 2H), 7.32 – 7.21 (m, 2H), 5.58 (d, J = 9.6 
Hz, 1H), 5.38 (d, J = 2.4 Hz, 1H), 5.18 (dd, J = 11.4, 3.3 Hz, 1H), 4.98 (d, J = 3.7 Hz, 1H), 4.68 
(d, J = 11.8 Hz, 1H), 4.60 (ddd, J = 11.3, 9.7, 3.7 Hz, 1H), 4.48 (d, J = 11.8 Hz, 1H), 4.19 (t, J = 
6.5 Hz, 1H), 4.16 – 4.02 (m, 2H), 2.17 (s, 3H), 2.06 (s, 3H), 1.99 (s, 3H), 1.93 (s, 3H); 13C NMR 
(101 MHz, CDCl3) δ 171.10, 170.53, 170.45, 170.08, 135.18, 134.40, 129.65, 129.02, 97.19, 
69.42, 68.42, 67.43, 67.14, 62.00, 47.89, 23.40, 20.87, 20.83. 
 
 
3-Bromo-4-fluorobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-
galactopyranoside (7) 
1H NMR (400 MHz, CDCl3 δ 7.54 (dd, J = 6.5, 2.1 Hz, 1H), 7.24 (ddd, J = 8.3, 4.6, 2.1 Hz, 
1H), 7.13 (t, J = 8.3 Hz, 1H), 5.79 (d, J = 9.5 Hz, 1H), 5.39 (d, J = 2.5 Hz, 1H), 5.18 (dd, J = 11.4, 
3.3 Hz, 1H), 4.98 (d, J = 3.7 Hz, 1H), 4.66 (d, J = 12.0 Hz, 1H), 4.59 (ddd, J = 11.4, 9.5, 3.7 Hz, 
1H), 4.47 (d, J = 12.0 Hz, 1H), 4.19 (t, J = 6.6 Hz, 1H), 4.16 – 4.03 (m, 2H), 2.16 (s, 3H), 2.06 (s, 
4H), 2.00 (s, 3H), 1.96 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 170.94, 170.43, 170.33, 170.11, 
160.16, 157.69, 134.23, 134.19, 133.28, 128.86, 128.78, 116.79, 116.57, 109.42, 109.21, 97.02, 
68.52, 68.20, 67.31, 67.07, 61.95, 47.79, 23.24, 20.76, 20.73. 
 
 
4-Bromo-2-fluorobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-
galactopyranoside (8) 
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1H NMR (400 MHz, CDCl3) δ 7.40 – 7.27 (m, 2H), 7.22 (t, J = 7.9 Hz, 1H), 5.67 (d, J = 
9.6 Hz, 1H), 5.38 (d, J = 2.4 Hz, 1H), 5.14 (dd, J = 11.4, 3.3 Hz, 1H), 4.99 (d, J = 3.7 Hz, 1H), 
4.74 (d, J = 11.7 Hz, 1H), 4.59 (ddd, J = 11.3, 9.7, 3.7 Hz, 1H), 4.51 (d, J = 11.7 Hz, 1H), 4.21 (t, 
J = 6.4 Hz, 1H), 4.17 – 4.04 (m, 2H), 2.16 (s, 3H), 2.06 (s, 4H), 1.99 (s, 3H), 1.93 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 170.99, 170.51, 170.40, 170.14, 162.33, 159.82, 131.91, 131.86, 
127.79, 127.75, 123.02, 122.87, 119.64, 119.40, 97.34, 68.36, 67.38, 67.16, 63.98, 61.97, 47.75, 
23.29, 20.82, 20.77. 
 
 
3-(Trifluoromethyl)benzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-
galactopyranoside (9) 
1H NMR (400 MHz, CDCl3) δ 7.66 – 7.57 (m, 2H), 7.51 (dd, J = 4.8, 1.9 Hz, 2H), 5.68 (d, 
J = 9.5 Hz, 1H), 5.40 (d, J = 2.3 Hz, 1H), 5.19 (dd, J = 11.4, 3.3 Hz, 1H), 5.00 (d, J = 3.7 Hz, 1H), 
4.77 (d, J = 12.2 Hz, 1H), 4.68 – 4.54 (m, 2H), 4.21 (t, J = 6.8 Hz, 1H), 4.10 (qd, J = 11.2, 6.8 Hz, 
2H), 2.17 (s, 3H), 2.06 (s, 4H), 2.00 (s, 3H), 1.94 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.07, 
170.51, 170.41, 170.14, 137.75, 131.49, 129.34, 125.29, 125.25, 124.85, 124.81, 97.24, 69.27, 
68.32, 67.38, 67.18, 61.97, 47.89, 23.24, 20.83, 20.77. 
 
 
4-(Bromomethyl)benzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-
galactopyranoside (10) 
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1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.1 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H), 5.59 (d, J 
= 9.7 Hz, 1H), 5.38 (d, J = 2.4 Hz, 1H), 5.18 (dd, J = 11.4, 3.3 Hz, 1H), 4.98 (d, J = 3.7 Hz, 1H), 
4.71 (d, J = 11.9 Hz, 1H), 4.60 (ddd, J = 11.4, 9.8, 3.7 Hz, 1H), 4.53 – 4.44 (m, 3H), 4.20 (t, J = 
6.8 Hz, 1H), 4.14 – 4.01 (m, 2H), 2.16 (s, 3H), 2.05 (s, 3H), 1.99 (s, 3H), 1.92 (s, 3H); 13C NMR 
(151 MHz, CDCl3) δ 171.04, 170.51, 170.43, 170.08, 138.13, 136.99, 129.48, 128.69, 97.23, 
69.73, 68.46, 67.43, 67.09, 61.97, 47.86, 32.97, 23.40, 20.86, 20.83. 
 
 
4-(Chloromethyl)benzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-
galactopyranoside (11) 
1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 5.58 (d, J 
= 9.7 Hz, 1H), 5.39 (d, J = 2.5 Hz, 1H), 5.18 (dd, J = 11.4, 3.3 Hz, 1H), 4.98 (d, J = 3.7 Hz, 1H), 
4.72 (d, J = 11.8 Hz, 1H), 4.66 – 4.55 (m, 3H), 4.51 (d, J = 11.8 Hz, 1H), 4.20 (t, J = 6.8 Hz, 1H), 
4.17 – 4.01 (m, 2H), 2.17 (s, 3H), 2.06 (s, 3H), 1.99 (s, 3H), 1.92 (s, 3H). 13C NMR (101 MHz, 
CDCl3) δ 171.08, 170.54, 170.47, 170.11, 137.84, 136.98, 129.07, 128.67, 97.21, 69.77, 68.49, 
67.45, 67.11, 61.99, 47.88, 45.86, 23.42, 20.89, 20.85. 
 
 
4-Cyanobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (12) 
1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 8.2 Hz, 2H), 7.44 (d, J = 8.2 Hz, 2H), 5.67 (d, J 
= 9.4 Hz, 1H), 5.40 (d, J = 2.5 Hz, 1H), 5.21 (dd, J = 11.4, 3.2 Hz, 1H), 5.03 (d, J = 3.6 Hz, 1H), 
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4.77 (d, J = 12.6 Hz, 1H), 4.70 – 4.53 (m, 2H), 4.18 (t, J = 6.4 Hz, 1H), 4.15 – 4.03 (m, 2H), 2.17 
(s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.95 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.14, 170.48, 
170.38, 170.13, 142.05, 132.60, 128.37, 118.55, 112.23, 97.52, 69.11, 68.20, 67.27, 67.20, 61.87, 
47.97, 23.37, 20.86, 20.83, 20.80. 
 
 
2-Nitrobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (13) 
1H NMR (400 MHz, CDCl3) δ 7.99 (d, J = 8.2 Hz, 1H), 7.71 – 7.61 (m, 1H), 7.54 (dd, J = 
11.8, 4.4 Hz, 2H), 5.67 (d, J = 9.6 Hz, 1H), 5.38 (d, J = 2.6 Hz, 1H), 5.15 (dd, J = 11.4, 3.2 Hz, 
1H), 5.02 – 4.94 (m, 2H), 4.89 (d, J = 12.9 Hz, 1H), 4.63 (ddd, J = 11.4, 9.7, 3.6 Hz, 1H), 4.19 (t, 
J = 6.6 Hz, 1H), 4.12 (d, J = 5.9 Hz, 2H), 2.17 (s, 3H), 2.06 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 171.04, 170.56, 170.49, 170.43, 148.69, 133.43, 131.77, 130.10, 
129.45, 124.91, 97.65, 68.29, 67.33, 67.25, 67.06, 61.99, 47.76, 23.30, 20.84, 20.82, 20.78. 
 
 
3-Nitrobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (14) 
1H NMR (400 MHz, CDCl3) δ 8.21 (dd, J = 4.1, 2.1 Hz, 2H), 7.70 – 7.53 (m, 2H), 5.72 (d, 
J = 9.4 Hz, 1H), 5.41 (d, J = 2.5 Hz, 1H), 5.21 (dd, J = 11.4, 3.2 Hz, 1H), 5.03 (d, J = 3.6 Hz, 1H), 
4.82 (d, J = 12.5 Hz, 1H), 4.69 – 4.57 (m, 2H), 4.21 (t, J = 6.5 Hz, 1H), 4.11 (dd, J = 8.9, 2.9 Hz, 
2H), 2.17 (s, 3H), 2.07 (s, 3H), 2.01 (s, 3H), 1.98 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.14, 
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170.53, 170.39, 170.28, 148.59, 138.90, 133.91, 129.88, 123.40, 122.79, 97.36, 68.65, 68.20, 
67.32, 67.25, 61.95, 47.99, 23.36, 20.87, 20.85, 20.82. 
 
 
4-Nitrobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (15) 
1H NMR (400 MHz, CDCl3) δ 8.23 (d, J = 8.6 Hz, 2H), 7.50 (d, J = 8.6 Hz, 2H), 5.76 (d, J 
= 9.4 Hz, 1H), 5.41 (d, J = 2.6 Hz, 1H), 5.22 (dd, J = 11.4, 3.2 Hz, 1H), 5.05 (d, J = 3.5 Hz, 1H), 
4.82 (d, J = 12.8 Hz, 1H), 4.65 (dd, J = 14.9, 8.3 Hz, 2H), 4.20 (t, J = 6.5 Hz, 1H), 4.16 – 4.05 (m, 
3H), 2.18 (s, 3H), 2.05 (s, 4H), 2.02 (s, 3H), 1.97 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.12, 
170.48, 170.37, 170.17, 147.80, 144.05, 128.38, 123.98, 97.58, 68.78, 68.17, 67.25, 67.22, 61.88, 
47.97, 23.35, 20.85, 20.82, 20.79. 
 
 
4-Nitrophenethoxy 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside 
(16) 
1H NMR (400 MHz, CDCl3) δ 8.20 (d, J = 8.7 Hz, 2H), 7.43 (d, J = 8.7 Hz, 2H), 5.47 (d, J 
= 9.5 Hz, 1H), 5.30 (d, J = 2.2 Hz, 1H), 5.10 (dd, J = 11.4, 3.2 Hz, 1H), 4.89 (d, J = 3.6 Hz, 1H), 
4.53 (ddd, J = 11.4, 9.6, 3.6 Hz, 1H), 4.01 (tdd, J = 11.9, 10.6, 6.7 Hz, 3H), 3.87 (t, J = 6.9 Hz, 
1H), 3.74 (dt, J = 9.9, 6.5 Hz, 1H), 3.05 (t, J = 6.5 Hz, 2H), 2.15 (s, 3H), 2.03 (s, 3H), 2.00 (s, 3H), 
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1.85 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.09, 170.40, 170.32, 169.93, 146.91, 146.45, 
129.77, 123.79, 97.65, 68.23, 67.89, 67.19, 66.89, 61.72, 47.90, 35.68, 23.23, 20.81, 20.76, 20.68. 
 
 
3-Methoxy-4-nitrobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-
galactopyranoside (17) 
1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8.2 Hz, 1H), 7.07 – 6.95 (m, 2H), 5.66 (d, J = 
9.4 Hz, 1H), 5.41 (d, J = 2.3 Hz, 1H), 5.22 (dd, J = 11.4, 3.2 Hz, 1H), 5.04 (d, J = 3.6 Hz, 1H), 
4.75 (d, J = 12.6 Hz, 1H), 4.63 (ddd, J = 11.5, 9.5, 3.6 Hz, 1H), 4.56 (d, J = 12.6 Hz, 1H), 4.19 (t, 
J = 6.8 Hz, 1H), 4.13 – 4.07 (m, 2H), 3.99 (s, 3H), 2.18 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.95 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 171.20, 170.52, 170.39, 170.12, 153.36, 143.77, 126.31, 
119.37, 112.76, 97.56, 69.07, 68.22, 67.29, 61.88, 56.73, 48.06, 23.40, 20.88, 20.85. 
 
 
4-Ethynylbenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (18) 
1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.2 Hz, 2H), 7.28 (d, J = 8.1 Hz, 2H), 5.63 (d, J 
= 9.6 Hz, 1H), 5.39 (d, J = 2.5 Hz, 1H), 5.18 (dd, J = 11.4, 3.3 Hz, 1H), 4.98 (d, J = 3.7 Hz, 1H), 
4.71 (d, J = 12.0 Hz, 1H), 4.60 (ddd, J = 11.3, 9.7, 3.7 Hz, 1H), 4.51 (d, J = 12.0 Hz, 1H), 4.20 (t, 
J = 6.7 Hz, 1H), 4.16 – 4.03 (m, 2H), 3.12 (s, 1H), 2.17 (s, 3H), 2.05 (s, 4H), 1.99 (s, 3H), 1.93 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 171.06, 170.52, 170.44, 170.09, 137.39, 132.51, 128.07, 
122.29, 97.27, 83.19, 69.69, 68.41, 67.42, 67.13, 61.99, 47.86, 23.37, 20.85, 20.82. 
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4-Nitrophenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (19) 
1H NMR (400 MHz, CDCl3) δ 8.24 (d, J = 9.2 Hz, 2H), 7.19 (d, J = 9.2 Hz, 2H), 5.83 – 
5.72 (m, 2H), 5.46 (d, J = 2.5 Hz, 1H), 5.41 (dd, J = 11.4, 3.3 Hz, 1H), 4.80 (ddd, J = 11.6, 9.2, 3.5 
Hz, 1H), 4.20 (t, J = 6.5 Hz, 1H), 4.17 – 4.09 (m, 1H), 4.09 – 3.99 (m, 1H), 2.20 (s, 3H), 2.07 (s, 
4H), 1.99 (s, 3H), 1.92 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.27, 170.41, 170.33, 170.28, 
160.80, 143.22, 126.00, 116.61, 96.41, 68.31, 67.79, 66.99, 61.60, 48.04, 23.37, 20.89, 20.81, 
20.66. 
 
 
4-Methylumbelliferyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside 
(20) 
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.8 Hz, 1H), 7.09 (d, J = 2.4 Hz, 1H), 7.03 (dd, 
J = 8.8, 2.4 Hz, 1H), 6.20 (d, J = 1.1 Hz, 1H), 5.92 (d, J = 9.3 Hz, 1H), 5.70 (d, J = 3.5 Hz, 1H), 
5.46 (d, J = 2.5 Hz, 1H), 5.41 (dd, J = 11.4, 3.3 Hz, 1H), 4.79 (ddd, J = 11.5, 9.3, 3.5 Hz, 1H), 4.24 
(t, J = 6.6 Hz, 1H), 4.17 – 4.09 (m, 1H), 4.05 (dd, J = 11.3, 7.1 Hz, 1H), 2.42 (d, J = 1.0 Hz, 3H), 
2.20 (s, 3H), 2.06 (s, 4H), 2.00 (s, 3H), 1.94 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.20, 170.43, 
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170.35, 160.89, 158.86, 154.98, 152.25, 125.97, 115.63, 113.38, 113.20, 104.90, 96.74, 68.02, 
67.97, 67.05, 61.59, 47.99, 23.38, 20.90, 20.84, 20.67, 18.81. 
 
 
2-Methylnaphthyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside 
(21) 
1H NMR (400 MHz, CDCl3) δ 7.92 – 7.83 (m, 3H), 7.78 (s, 1H), 7.58 – 7.48 (m, 2H), 7.44 
(dd, J = 8.4, 1.6 Hz, 1H), 5.70 (d, J = 9.7 Hz, 1H), 5.41 (d, J = 2.4 Hz, 1H), 5.23 (dd, J = 11.4, 3.3 
Hz, 1H), 5.05 (d, J = 3.7 Hz, 1H), 4.90 (d, J = 11.8 Hz, 1H), 4.68 (d, J = 11.8 Hz, 1H), 4.62 (ddd, 
J = 11.3, 9.8, 3.6 Hz, 1H), 2.17 (s, 3H), 2.06 (s, 4H), 2.00 (s, 4H), 1.90 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 170.92, 170.45, 170.38, 170.01, 133.94, 133.17, 133.14, 128.60, 127.88, 127.78, 
127.36, 126.55, 126.43, 125.81, 97.02, 77.42, 77.10, 76.78, 70.25, 68.45, 67.41, 67.02, 61.98, 
47.74, 23.24, 20.77, 20.72. 
 
 
4-Bromophenethoxy 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside 
(22) 
1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 8.3 Hz, 2H), 7.12 (d, J = 8.3 Hz, 2H), 5.36 (d, J 
= 9.7 Hz, 1H), 5.31 (d, J = 2.1 Hz, 1H), 5.09 (dd, J = 11.3, 3.2 Hz, 1H), 4.81 (d, J = 3.6 Hz, 1H), 
4.51 (ddd, J = 11.3, 9.8, 3.6 Hz, 1H), 4.09 – 3.97 (m, 2H), 3.97 – 3.85 (m, 2H), 3.64 (dt, J = 9.7, 
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6.6 Hz, 1H), 2.88 (t, J = 6.1 Hz, 2H), 2.14 (s, 3H), 2.05 (s, 4H), 1.99 (s, 3H), 1.82 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 171.00, 170.43, 170.35, 169.97, 137.70, 131.64, 130.66, 120.48, 97.69, 
68.42, 67.29, 66.81, 61.78, 47.78, 35.20, 23.22, 20.82, 20.77. 
 
 
4-(Azidomethyl)benzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-
galactopyranoside (23) 
To a solution of compound 11 (100 mg, mmol) in acetonitrile was added sodium azide. 
After being stirred at 80 °C for 12 h, the solution was concentrated in vacuo, diluted with ethyl 
acetate and washed with water, and brine solution. The organic layer was dried over Na2SO4, 
filtered, and concentrated in vacuo to give a residue, which was purified by silica gel column 
chromatography to generate compound 23. 1H NMR (400 MHz, CDCl3 δ 7.34 (s, 4H), 5.73 (d, J 
= 9.6 Hz, 1H), 5.39 (d, J = 2.3 Hz, 1H), 5.18 (dd, J = 11.4, 3.3 Hz, 1H), 5.00 (d, J = 3.7 Hz, 1H), 
4.73 (d, J = 11.8 Hz, 1H), 4.60 (ddd, J = 11.3, 9.7, 3.7 Hz, 1H), 4.52 (d, J = 11.8 Hz, 1H), 4.36 (s, 
2H), 4.21 (t, J = 6.5 Hz, 1H), 4.16 – 4.02 (m, 2H), 2.16 (s, 3H), 2.05 (s, 4H), 1.99 (s, 3H), 1.92 (s, 
3H); 13C NMR (101 MHz, CDCl3) δ 170.92, 170.44, 170.37, 170.05, 136.80, 135.63, 128.68, 
128.55, 97.12, 69.66, 68.38, 67.36, 66.98, 61.91, 54.41, 47.76, 23.27, 20.77, 20.74. 
 
 
2-Azidobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (24) 
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1H NMR (400 MHz, CDCl3) δ 7.42 (td, J = 7.9, 1.5 Hz, 1H), 7.32 (dd, J = 7.5, 1.3 Hz, 1H), 
7.18 (ddd, J = 11.2, 8.4, 4.4 Hz, 2H), 5.65 (d, J = 9.7 Hz, 1H), 5.38 (d, J = 2.5 Hz, 1H), 5.16 (dd, 
J = 11.3, 3.3 Hz, 1H), 4.98 (d, J = 3.7 Hz, 1H), 4.69 (d, J = 11.4 Hz, 1H), 4.59 (ddd, J = 11.2, 9.8, 
3.7 Hz, 1H), 4.45 (d, J = 11.5 Hz, 1H), 4.29 (t, J = 6.7 Hz, 1H), 4.11 (qd, J = 11.2, 6.6 Hz, 2H), 
2.17 (s, 3H), 2.07 (s, 3H), 1.99 (s, 3H), 1.93 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.06, 170.56, 
170.50, 170.06, 138.95, 130.95, 130.19, 127.79, 125.07, 118.55, 97.39, 68.67, 67.49, 67.10, 66.12, 
62.02, 47.83, 23.42, 20.90, 20.84. 
 
 
3-Azidobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (25) 
1H NMR (400 MHz, CDCl3) δ 7.37 (t, J = 7.8 Hz, 1H), 7.09 (d, J = 7.7 Hz, 1H), 7.03 (dd, 
J = 8.0, 1.6 Hz, 1H), 6.97 (d, J = 1.7 Hz, 1H), 5.60 (d, J = 9.6 Hz, 1H), 5.39 (d, J = 2.4 Hz, 1H), 
5.19 (dd, J = 11.4, 3.3 Hz, 1H), 4.98 (d, J = 3.7 Hz, 1H), 4.70 (d, J = 12.0 Hz, 1H), 4.60 (ddd, J = 
11.4, 9.7, 3.7 Hz, 1H), 4.50 (d, J = 12.0 Hz, 1H), 4.20 (t, J = 6.8 Hz, 1H), 4.16 – 4.06 (m, 2H), 2.17 
(s, 3H), 2.07 (s, 3H), 2.00 (s, 3H), 1.95 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.10, 170.54, 
170.45, 170.12, 140.67, 138.73, 130.25, 124.65, 118.95, 118.74, 97.11, 69.45, 68.41, 67.43, 67.15, 
62.01, 47.90, 23.42, 20.89, 20.85. 
 
 
4-Azidobenzyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside (26) 
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1H NMR (400 MHz, CDCl3) δ 7.31 (d, J = 8.5 Hz, 2H), 7.04 (d, J = 8.5 Hz, 2H), 5.58 (d, J 
= 9.6 Hz, 1H), 5.38 (d, J = 2.3 Hz, 1H), 5.17 (dd, J = 11.4, 3.3 Hz, 1H), 4.97 (d, J = 3.7 Hz, 1H), 
4.68 (d, J = 11.7 Hz, 1H), 4.59 (ddd, J = 11.3, 9.7, 3.7 Hz, 1H), 4.48 (d, J = 11.7 Hz, 1H), 4.20 (t, 
J = 6.9 Hz, 1H), 4.16 – 4.03 (m, 2H), 2.17 (s, 3H), 2.06 (s, 4H), 1.99 (s, 3H), 1.92 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 171.09, 170.53, 170.45, 170.06, 140.37, 133.33, 129.97, 119.38, 97.03, 
69.54, 68.45, 67.43, 67.07, 61.99, 47.88, 23.41, 20.87, 20.84. 
 
 
4-Azidophenethoxy 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-galactopyranoside 
(27) 
1H NMR (400 MHz, CDCl3) δ 7.22 (d, J = 8.4 Hz, 2H), 6.99 (d, J = 8.4 Hz, 2H), 5.40 – 
5.28 (m, 2H), 5.10 (dd, J = 11.3, 3.3 Hz, 1H), 4.82 (d, J = 3.6 Hz, 1H), 4.52 (ddd, J = 11.2, 9.8, 3.6 
Hz, 1H), 4.11 – 3.97 (m, 2H), 3.97 – 3.84 (m, 2H), 3.65 (dt, J = 9.7, 6.6 Hz, 1H), 2.90 (t, J = 6.4 
Hz, 2H), 2.15 (s, 3H), 2.04 (s, 3H), 1.99 (s, 3H), 1.84 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
171.15, 135.45, 130.34, 119.27, 97.76, 68.73, 68.56, 67.42, 66.92, 61.89, 47.92, 35.27, 23.36, 
20.92, 20.88, 20.81. 
2.4.2 Assays 
A549 Cells were incubated with or without 50 uM Bn-α-GalNAc or compound& Bn-α-
GalNAc  mixture at the ration of 1:1 (50 M: 50 M) for 3 days, then collected the media, 
purified them by C18 SPE column (waters), and analyzed them by MALDI. Relative activity as 
CORA precursor was calculated by formulation as follow: the intensity of the peaks of all 
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derivatized-O-Glycans/ the in-tensity of the peaks of all Bn-O-Glycans/(the intensity or area of 
the peaks of compound/ the intensity or area of the peaks of Bn-a-GalNAc). Every experiment 
was repeated for 3 times. 
0.1 mM compounds and 0.5 mM UDP-Galactose were catalyzed by 0.4 ng/uL T-synthase 
(provided by Dr. Cummings’ lab) in 20 mM MES buffer pH 6.8 (containing 20 mM MnCl, 0.5% 
Triton X-100) at 37 ℃ for 18 h, then the reactions were quenched by equal volume of methanol, 
and stored in -80 ℃ for overnight. The frozen samples were un-froze and centrifuged at 14,000 
rpm for 5 min, then the supernatants were loaded on-to C18 (XBridge TM, 35 m, 30*150 mm) 
column. SHIMADZU HPLC system was used, and mobile phase A consisted of 0.1% TFA in 
Acetonitrile and mobile phase B was 0.1% TFA in water. A linear gradient from 5 % to 60% 
over 30 minutes at a flow rate of 0.4 mL/min was applied. Software EZStart 7.4 was used for 
data analysis. The disaccharide product peak   HPLC condition: The Yields was calculated by 
formulation as follow: The acceptor activity = Area of disaccharide peak / Area of 
(disaccharide+ the left com-pound)*100. The acceptor activity of Bn-a-GalNAc was set as 100. 
The relative acceptor activity = (The acceptor activity of com-pound/ The acceptor activity of 
Bn-a-GalNAc )*100. 
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3 STRUCTURE BASED DESIGN, SYNTHESIS AND ACTIVITY STUDIES OF 
SMALL HYBRID MOLECULES AS HDAC AND G9A DUAL INHIBITORSAberrant 
enzymatic activities or expression profiles of epigenetic regulations are therapeutic targets 
for cancers. Among these, histone 3 lysine 9 methylation (H3K9Me2) and global de-
acetylation on histone proteins are associated with multiple cancer phenotypes including 
leukemia, prostatic carcinoma, hepatocellular carcinoma and pulmonary carcinoma. In this 
study, we report the discovery of the first small molecule capable of acting as a dual 
inhibitor targeting both G9a and HDAC. Our structure based design, synthesis, and 
screening for the dual activity of the small molecules led to the discovery of compound 14 
which displays promising inhibition of both G9a and HDAC in low micro-molar range in 
cell based assays. 
3.1 Introduction 
Epigenetic modifications describe post-translational modifications that occur on the 
protein without lasting impact on the base genomic code. Likewise, epigenetic modifications are 
reversible due to the manner in which they occur, making restoration of the epigenome to its 
normal function a crucial target in many disease models.[83] In particular, dimethylation of histone 
3 at lysine 9 (H3K9Me2) and various acetylation marks on histones are directly correlated to the 
onset and advancement of multiple cancer phenotypes, including leukemia, prostatic carcinoma, 
hepatocellular carcinoma and pulmonary carcinoma.[84] Recently, there has been much success in 
the development of small molecules targeting these post-translational modifications. Epigenetics 
is still a field much in its infancy considering the number of epigenetic targets.[83e, 84a, 85] From this 
vast pool, epigenetic markers that related to leukemogenesis and tumorigenesis has shown to be a 
promising application of epigenetics. 
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Cancer is a disease with complicated treatment options due to the multifactorial basis of 
initiation and progression. Therefore a treatment targeting multiple components instead of a single 
component could be a particular interest in cancer therapeutics.[86] To meet this need, developing 
new lead molecules which target cancer from various stages of disease development from either 
known inhibitors or de novo is essential for improving effectiveness and side effects/toxicity 
profile.[87] Herein we report the design, synthesis and extensive biological evaluation of a class of 
small molecules targeting the enzymes histone deacetylases (HDACs) and histone 
methyltransferases (G9a), both are key posttranslational enzymes in cancer development. 
 
Figure 3.1 Examples for known HDAC inhibitors and G9a Inhibitors. 
  
Histone deacetylases (HDACs) fall into the category of eraser enzymes, so termed due to 
their ability to reverse the acetylation modification employed by another enzyme histone acetyl 
transferases (HATs).[88] However, despite the name, histone deacetylases have a wide range of 
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substrates included but not limited to strictly histones.[84c] Aberrant activity of HDACs have been 
well documented in several cancer phenotypes, with HDAC inhibitors (HDACIs, Fig 1) proven as 
antineoplastic agents. HDACIs have multiple cell type-specific effects in vitro and in vivo, such as 
growth arrest, cell differentiation and apoptosis in malignant cells.[84a, 89] HDACIs have been 
shown to induce apoptosis in both solid and hematopoietic malignancies using both transcription 
dependent and transcription independent mechanisms.[90] While histone acetylation regulated by 
HDAC and their corresponding writer enzymes HATs, protein methylation is similarly regulated 
by protein lysine methyltransferases enzymes (PKMT), protein arginine methyltransferases 
(PRMT) and their corresponding demethylase enzymes.[83a, 91] Our particular interest is the PKMT 
G9a (also known as KMT1C, EHMT2), which is a histone 3 lysine 9 (H3K9) specific 
methyltransferase that is overexpressed in many cancers including leukemia, hepatocellular 
carcinoma and pulmonary carcinoma. G9a is notable for its roles in cancer cell proliferation, 
whereas knockdown of G9a in prostate, lung, and leukemia cancer cells resulted in the inhibition 
of cell growth.[83e, 92] Presently, there are number of small molecules with different structural cores 
that have been found to inhibit G9a, which are also under consideration in clinical trials.[83e, 93] In 
addition to catalyzing mono- and dimethylation of H3K9, G9a and its closely related protein GLP, 
also dimethylate lysine 373 of the tumor suppressor p53 to repress the transcriptional activity of 
p53.[94] 
Different modifications of chromatin associated with variable functions, with the extent of 
modifications and specific residue selected imparting different overall result. For example， 
hyper-acetylation of histone H3 and H4 both known to be activators associated with ongoing 
transcription.[95] However, methylation of H3K9 and H3K27 are associated with gene silencing 
and repressive marks.[96] Following these pathways of distinct and uncorrelated functionalities, we 
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proposed that concurrent inhibition of G9a and HDAC may help histone protein to retain the 
transcriptional activity via targeting two pathways. First affecting the reduced formation of 
corepressor marks (H3K9Me2 and p53K373Me2) as a downstream effect of G9a inhibition, and 
secondly with a relaxed and acetylated chromatin promoted by the HDAC inhibition. We also 
hypothesize a potential competition between the HDAC and G9a enzyme because they share 
common substrate (H3K9 and p53K373), a substrate in its acetylated state cannot be further 
methylated, thereby causing an indirect inhibition of G9a. It should also be noted that HDACIs 
show only a moderate and limited biological response when applied as a mono treatment, with 
therapeutic effect significantly improved in combination with other anticancer agents.[87a, 87c, 97] 
Hence, the optimal deployment of these molecules may be a combination with other epigenetic 
drugs, acting against the set of enzymes responsible for the setup and maintenance of epigenetic 
information.[98] 
 
3.2 Result and discussion 
Initial tests designed around assessing whether a synergistic effect would be observed in 
real when a combination of G9a inhibitor and HDAC inhibitor used in conjunction. Towards this, 
the MDA-MB-231 and MCF-7 cell lines treated with either SAHA (1-100 µM), BIX-01294 (1-
100 µM), or a mixture of SAHA and BIX-01294 (1:1; 1-100 µM). As indicated in Table 1 (EC50 
graphs available in Supplemental Information, Figure S1), when applied in combination 
performance was enhanced towards MDA-MB-231 and comparable in MCF-7. Despite being two 
distinct molecules with different physiochemical properties, application of both displayed a 
significant improvement (approximately 34% lower EC50 to SAHA, and 13% lower EC50 to BIX-
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01294 in MDA-MB 231). Effectively, this provided the basis for incorporating both SAHA and 
BIX-01294 into a single moiety capable of preserving inhibitory activity against both targets. 
Table 3.1 Combination study of BIX-01294 and SAHA 
Inhibitor (10 µM) MDA-MB-231 MCF-7 
SAHA 2.874±0.84 8.124±4.98 
BIX-01294  2.155±0.88 8.103±1.99 
SAHA+ BIX-01294  1.891±0.56 8.564±2.17 
 
Multi-target treatments are typically utilized two approaches, formulating two active 
moieties as a cocktail, or hybridizing properly selected active moieties into a single molecule. The 
first method heavily relies on both compounds having comparable solubility, or else fine-tuning 
the formulation to ensure the desired bioavailability.[86a, 86d, 87d, 99] In contrast, a dual-target drug 
doesn't have such issue with different solubility or bioavailability. However, hybrid compounds 
are challenging to design due to the difficulties in optimizing a pharmacophore from two dissimilar 
compounds that can retain multiple functionalities inside the body. There have been some notable 
successes in the latter regard, with few drugs already on the market with superior performance to 
their cocktail counterparts.[87e] Currently available hybrid drugs target different stages of disease 
development despite their precursors targeting the same diseases.[87a, 87d, 99b, 100] In light of these 
studies, we propose that a hybrid drug that instead targets components belonging to the same 
scheme in disease progression or has otherwise interdependent functionality would yield an 
improved synergistic effect. Herein we report the design, synthesis, screening and biological study 
of a lead molecule for further development as a drug candidate utilizing this principle. 
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3.2.1 Compound design 
From the available data on G9a and HDAC in the forms of known inhibitors and their 
respective X–ray crystal structures, we observed several details regarding their prospective 
ligands. For instance, all HDAC inhibitors are comprised of three parts- a lipophilic cap connected 
to a hydrophilic Zn2+ binding group by an alkyl, or arylene linker, with the cap portion being 
different bulky groups. Likewise, current G9a inhibitors, except for the fungal metabolite 
chaetocin, are primarily derived from the parent compound BIX-01294. Since the discovery of 
BIX-01294, a clear majority of the G9a inhibitors to emerge based on the quinazoline core of BIX-
01294. As the lipophilic quinazoline core resemble the lipophilic bulky cap for HDAC inhibitors, 
we reasoned that the G9a core could feasibly function as the core scaffold of a HDAC and G9a 
dual inhibitor. There have been notable success stories in regard of varying the cap or linker portion 
of the HDAC inhibitor, while the metal binding portion kept as a hydroxamic acid or an ortho-
amino benzamide.[86a, 87c, 87e, 101] Following this line of thinking, we added the linker and the 
hydroxamic acid at the C2, and C4 of quinazoline ring to obtain the desired hybrid molecules (Fig 
2A). This design was inspired by the fact G9a have many inhibitors with bulky side chains as in 
the case of E72, HDACIs can also afford a reasonable variety of lipophilic cores (Fig 1). Various 
analogs with different linker lengths and diverse groups at C6 and C4 cyclohexylamine positions 
were also designed. All these compounds classified into three for ease of reference. 
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Figure 3.2 A) Design for Hybrid Molecules, B) Structural representation of designed 
compounds. 
 
3.2.2 Synthesis 
The designed analogs were synthesized from two building blocks; commercially available 
2,4-dichloro-6,7-dimethoxyquinazoline (1) was used for the dimethoxy analogs (Fig 3) and, 2-
amino-4-methoxybenzoic acid (8) used for monomethoxy analogs (Fig 4). Initially, we synthesized 
only a few analogs of class III to assess the effectiveness of the HDAC substitution while opening 
the piperazine ring originally present at the prototype BIX-01294, this class was particularly 
intended to explore the SAR of R1. The bulky seven-member ring was then replaced with an 
ethylene diamine and coupled with various esters of different chain lengths (three to seven carbons 
for investigating the optimal length for the HDAC inhibition) to produce compounds 4, 5, 6 and 
7. To check the effect of bulky groups at the C4 position of the heterocyclic ring, an isopropyl 
group then introduced to the tertiary amine instead of the methyl group to produce the set of 
compounds 4a, 5a, 6a and 7a (Series IIIA, Fig 3). While investigating the binding characteristics 
of known G9a/GLP inhibitors, the C6 methoxy group of quinazoline ring was hypothesized not to 
contribute significantly to ligand-receptor interactions. Therefore, the methoxy at C6 was 
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eliminated to find a balance for HDAC activity. Compounds in class II designed from this 
rationale. Compounds 13-17 have a 4-aminobenzyl piperidine at C4, while 13a-17a possess an 
isopropylpiperidin-4-amine. Recent studies of UNC0965 wherein a biotin tag was applied to 
UNC0638 found that UNC0965 retained biological activity,[102] following this lead, C4 of 
quinazoline ring was explored. Compounds with the HDAC pharmacophore on the C4 carbon of 
quinazoline core termed as class I, with analogs 19 and 20 retaining the C6 methoxy group, and 
21 and 22 lacking the methoxy group. 
 
Figure 3.3 Synthesis cheme of dimethoxy analogs. 
Reagents and conditions: (i) 1-methylpiperidin-4-amine/1-isopropylpiperidin-4-amine, DIPEA, DMF, rt, 3 h, 80-86%, 
(ii) tert-butyl (2-aminoethyl)carbamate, DIPEA, 160 °C Microwave, 10 min, 60-66%, (iii) TFA/DCM, 3 h, (iv) 
MonomethylSuberate, EDCl, HOBt, 8 h, (v) 50% NH2OH in water, MeOH, 60°C, 8 h , 30-38% over two steps. 
Fig 3.3 compounds were synthesized from the commercially available starting material 1. An 
initial displacement reaction using a primary amine was used to introduce the C4 selective 
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substitution, with the second displacement to introduce the linker at the C2 position following the 
microwave assisted reaction previously reported.[103] Boc-protected ethylene diamine was treated 
with compound 2 at 160 oC in a microwave for 10 min to yield product 3 with excellent yield. 
Afterward, the amine 3 was deprotected with TFA/DCM, and the free amine was treated with 
corresponding monomethyl esters (carbon chain 2-6) in the presence of coupling reagent EDCl 
and HOBt for about 8 hours to produce mono methyl ester substituted at the C2 position. The ester 
compounds further treated with hydroxylamine in water to get the corresponding hydroxamic acid 
derivatives, which were purified using reverse phase flash chromatography to obtain compounds 
4-7 and 4a-7a in good yield. Synthesis of compounds in Fig 4 requires the C6 demethoxy core, 
and this was synthesized according to the reported procedure to yield 10.[104] Appropriate 
displacement and coupling reactions in this core as demonstrated in Fig 4 afforded compounds 13-
17 and 13a-17a. Compounds with the HDAC pharmacophore at the C4 position (Fig 2B) were 
synthesized from the starting material 1. As Figure 5 showed, Pd/C hydragenolysis was used to 
eliminate the benzyl group and produce the free amine of 18 for the coupling of monomethyl esters 
to result in compounds 19-22. A parallel synthesis and testing strategy were used in establishing 
the primary SAR, with the clear rationalization of the structure and activity at each stage we could 
reduce the synthetic targets. Initially, we evaluated the G9a potential after the introduction of 
HDAC pharmacophore. A biochemical assay using MALDI-TOF was used to visualize the effects 
of the synthesized compounds on G9a enzymatic activity, we carried out a biochemical reaction 
involving target enzyme G9a, methyl donor SAM and substrate H3 peptide at a concentration of 
400 nM, 10 µM and 5 µM respectively.[105] After successfully optimizing the reaction conditions 
and reaction time to see at least 80% of the substrate converted to the methylated form (H3K9Me1 
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or H3K9Me2) with no tri-methylation, we tested BIX-01294 for an optimum level of inhibition 
and fixed the concentration as 5 µM for each inhibitor. 
 
Figure 3.4 Synthesis scheme for monomethoxy analogs. 
Reagents and condition: (i) Urea, 200°C, 2 h, (ii) POCl3, reflux 16 h, 40% in two steps, (iii) 4-aminobenzylpiperidin/1-
isopropylpiperidin-4-amine, DIPEA, DMF, rt, 3 h, 74% and 86%, (iv) tert-butyl (2-aminoethyl)carbamate, DIPEA, 
160 °C Microwave, 10 min, 64% and 68%, (v) TFA/DCM, 3 h, (vi) MonomethylSuberate, EDCl, HOBt, 8 h, 70% in 
two steps, (vii) 50% NH2OH in water, MeOH, 60 °C, 8 h , 30-40%. 
Most of the compounds retained G9a inhibition capabilities, indicated by the reduction in 
the ratio of the H3K9Me1 and H3K9Me2 peaks compared to the control reaction (Fig 3.6). While 
fractionally less potent than parent BIX-01294, retention of inhibitory capabilities was nonetheless 
verification of the initial hypothesis. These result corresponded to the MALDI-TOF study done by 
a previously reported procedure.[105] With the knowledge that G9a activity preserved in the 
biochemical assay, next, we investigated the effect in the cell. H3K9Me2 cell immunofluorescence 
In-Cell Western (ICW) assay was used to assess G9a inhibition potential, and homogeneous 
cellular histone deacetylase assay used for measuring HDAC inhibition. 
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Figure 3.5 Synthesis scheme of compound 19-22. 
Reagents and condision: (i) 4-aminobenzylpiperidin, DIPEA, DMF, rt, 3 h, 90%, (ii) 1-methyl-1,4-diazepane, DIPEA, 
160 °C Microwave, 10 min, 74%, (iii) EtOH, Pd/C, H2, 8 h, (iv) Monomethylsuberate/monomethylpimelate, EDCl, 
HOBt, 8 h, (v) 50% NH2OH in Water, MeOH, 60 °C, 8 h, 44% and 45%, (vi) NHBoc-ethylinediamine, DIPEA, DMF, 
rt, 3 h, 78%, (vii) 1-methyl-1,4-diazepane, DIPEA, 160 °C Microwave, 10 min, 69%, (viii) TFA/DCM, 8 h, (ix) 
Monomethylsuberate/ monomethylpimelate, EDCl, HOBt, 8 h, (x) 50% NH2OH in water, MeOH, 60 °C, 8 h , 29%-
36%. 
3.2.3 Functional potency evaluation for G9a inhibition 
For assessing the functional potency of the dual inhibitors, we evaluated all the compounds 
by H3K9Me2 cell immunofluorescence In-Cell Western (ICW) assays and the results shown in 
Table 2. The MDA-MB-231 cell line was used in this study as this cell line possesses robust 
H3K9Me2 levels.[5] Our results suggested that compounds belonging to the class IV (southwest 
directing HDAC) exert a G9a activity comparable to the parent compound BIX-01294, but all 
other classes were significantly less potent. 
Table 3.2 H3K9Me2 cell immunofluorescence In-Cell Western (ICW) assay results. 
Compound G9a IC50 (µM) Compound G9a IC50 (µM) 
4 96.69±1.68 4a 74.21±1.94 
5 >100 5a 66.63±3.98 
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6 >100 6a >100 
7 76.74±0.89 7a 54.55±3.05 
13 37.79±2.80 13a >100 
14 7.136±1.62 14a 46.83±1.97 
15 72.10±1.37 15a 46.97±3.33 
16 90.26±3.75 16a 45.71±1.76 
19 99.63±3.13 21 ND 
20 97.51±2.78 22 60.65±3.66 
BIX-01294 4.563±1.2 5b 87.39±5.44 
 
3.2.4 Functional potency evaluation for HDAC inhibition 
The enzymatic activity of HDAC was measured in intact cells using the homogeneous 
cellular assay method.[89] A cell-permeable peptide Boc-K(Ac)-AMC used as the HDAC substrate, 
after deacetylation it is cleaved by trypsin to release the fluorescent 7-amino-4-methylcoumarin 
(AMC) and further quantified. Each compound candidate tested in both Hela and K562 cell lines, 
two compounds (13 and 14) showed significant HDAC inhibition (Table 3, see Supplemental 
Information Table 2 for full results). An evaluation of these structures indicated that only class III 
compounds displayed the desired activity, it was inconclusive if the R1 and R2 substitutions were 
responsible. Compound 5b, synthesized from 3b with a benzyl group at R1 and a methoxy at R2, 
did not show decent inhibition of HDAC compared with Compound 14. Which indicated two 
important strategies for designing HDAC inhibitors with quinazoline core; an aromatic ring at R2 
is essential for HDAC activity while the methoxy group at C6 of quinazoline core almost destroys 
HDAC inhibition. Linker lengths vary from Compound 11 to 14, in which, compounds with 5 or 
6 methylene groups between the lipophilic core and Zn binding domain found to be the best choice. 
Similarly, compounds 19-22 with the R1 substituted with the HDAC chain did not show promising 
activity, leaving 13 and 14 as the candidates for further study. Closer examination of the tested 
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compounds indicated that HDAC activity is limited to compounds with a benzyl group at the 4-
aminopiperidin ring (R1) along with no substitution at C6. 
Table 3.3 Results of homogeneous cellular histone deacetylase assay 
Compound  Hela IC50 (µM) K562 IC50 (µM) 
13  15.33±0.79 27.75±0.59 
14  13.80±1.22 5.735±1.23 
SAHA  5.044±0.53 2.056±0.59 
 
3.2.5 Molecular Docking Analysis 
Molecular Docking analysis and molecular dynamics simulations were widely used to 
estimate the interactions between protein and small molecular compounds theoretically [106]. Our 
assays found that 14 had good cellular potency for inhibition of both G9a and HDAC, so docking 
studies were used to examine the interactions of 14 with the target proteins compared to known 
ligands using Schrödinger Suite 2014-3.[107] The crystal structure of human HDAC8 with MS-344 
(PDB ID: 1T67) and human G9a with BIX-01294 (PDB ID: 3FPD) were employed as the 
templates for molecular docking studies.[105, 108] SP Glide algorithm was first validated by docking 
MS-344 and BIX-01294 from the complex back to the protein, ligand preparation was done using 
LigPrep with OPLS_2005. The search space was defined using Receptor Grid Generation in Glide, 
with the centroid of the ligand chosen to define the grid box. Standard precision mode was selected 
for validation docking, and default settings for scaling van der Waals radii were used. No 
constraints were defined for the docking runs. The docking pose with the highest score returned 
for MS-344 and BIX-01294 were compared with the starting protein complex. For subsequent 
molecular docking of compound 14 in the binding site of HDAC8 and G9a, LigPrep was used for 
energy minimizations of the molecule with the OPLS_2005 force field. Using the initial grids 
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generated for HDAC8 and G9a, the standard precision docking was repeated for compound 14 as 
described above. 
Table 3.4 GLIDE docking results for MS-344 and compound 14 at the catalytic site of HDAC8 
(PDB ID:1T67) 
S. No. Ligand ID 
Docking 
Score 
GLIDE 
score 
Interactions 
Hydrogen Bonds Interaction 
with Zn2+ 
Backbone Side Chain 
1 MS-344 -7.931 -7.931 
His142,  
His143,  
Gly151,  
Gly304; 
Asp101, 
Tyr306; 
Ionic 
interaction 
2 14 -7.934 -8.369 
Gly140, 
His142,  
Gly151, 
Gly304; 
Asp101, 
Tyr306; 
Ionic 
interaction 
Table 4 and 5 showed the results of docking along with the prominent interactions for 
compound 14 with HDAC8 and G9a. Fig 7 illustrated the predicted binding modes and the detailed 
protein−inhibitor interactions of HDAC8 and G9a with compound 14, respectively. Fig 7A showed 
that the catalytic tunnel of HDAC8 was occupied by the aliphatic side chain of the inhibitor, while 
the hydroxamate group chelated the zinc ion and hydrogen bonds with residues in the catalytic 
Table 3.5 GLIDE docking results for BIX-01294 and compound 14 at the catalytic site of G9a 
(PDB ID: 3FPD) 
S.No. 
Ligand 
ID 
Docking 
Score 
GLIDE 
Score 
Interactions 
Hydrogen Bonds 
Interaction 
with Zn2+ 
Backbone Side Chain 
1 
BIX-
01294 
-7.664 -8.134 Ala1134 
Asp1131,  
Asp1135, 
Asp1140; 
NA 
2 14 -7.321 -7.52 
Arg1137, 
Glu1138 
Asp1131, 
Asp1135,  
Asp1140, 
Arg1214; 
NA 
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tunnel. The zinc ion displayed a trigonal bipyramidal geometry and two points contacted with the 
ligand (Fig 7A and 7C). Docking studies suggested important structural/catalytic roles for Gly140, 
His142, Gly151 and Gly304 in the active site and extending to Tyr306, Asp101. Moreover, 
compound 14 occupies the binding pocket in a similar posture as MS-344 in the catalytic site of 
HDAC8 (Supplemental Information Fig S3). 
A similar study was performed to establish the binding characteristics of compound 14 
with G9a. The binding model of compound 14 showed that it shares common hydrogen bonding 
interactions with key residues of the catalytic domain in a mode comparable to BIX-01294 
(Supplemental Information Fig S4). Most notably, the piperidine ring substituted at quinazolin-4-
amine in compound 14 has hydrogen bonding interactions with Arg1137, Glu1138 residues, and 
the aliphatic chain was involved in some more hydrogen bonding interaction with the side chains 
of residues Asp1131, Asp1135, Asp1140 and Arg1214 (Fig 7B and 7D). 
3.2.6 Cell Anti-proliferation Assay 
Cell anti-proliferation assays were performed to determine the toxicity of these inhibitors. 
Several cell lines (MDA-MB-231, MCF-7 and A549) were incubated and then treated with varying 
concentrations of the inhibitors for 72 h, respectively. After the first cell culture screening, it was 
determined that the inhibitors were more effective with breast cell lines (MDA-MB 231 and MCF-
7) compared to other cell lines, particularly compound 13 and 14 (Table 6, and Supplemental 
Information Table 4). These compounds were further evaluated against the control cell line 
HEK293 to test their toxicity with a non-cancerous cell line. As seen in Table 6, both SAHA and 
BIX-01294 appear to be toxic to cancer and normal cells, but compounds 13 and 14 displayed 
lower toxicity, particularly compound 14. 14 also showed improved anti-proliferation abilities in 
all cancer cell lines and reduced toxicity in normal cell line compared to 13. 
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Figure 3.6 Molecular docking study results. 
A) Predicted binding mode of compound 14 on HDAC8 (PDB ID: 1T67), B) Predicted binding mode of compound 
14 on G9a (PDB ID: 3FPD), C) Binding model of active compound 14 (orange) as revealed from GLIDE docking in 
the HDAC8 catalytic site (PDB ID: 1T67). The green dashed lines represent hydrogen bonds. The turquoise sphere 
represents Zn cation and with a trigonal bipyramidal coordination geometry. The pink dashed lines indicates the two 
contacts between the ligand and Zn cation, with the mixed dashed lines representing interaction between Zn cation 
and amino acid residues. H-bond distances (Å) between heteroatoms of ligand and amino acid residues are as follows: 
Asp101 (1.90), His142 (2.02), His143 (3.64), Gly151 (3.68), Gly304 (3.00), Tyr306 (2.17), D) Binding model of 
active compound 14 (orange) as revealed from GLIDE docking in the G9a catalytic site (PDB ID: 3FPD). The green 
dashed lines represent hydrogen bonds. H-bond distances (Å) between heteroatoms of ligand and amino acid residues 
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are as follows: Asp1131 (1.66), Asp1135 (1.75, 1.81), Arg1137 (3.33), Glu1138 (3.98), Asp1140 (1.77), Arg1214 
(2.68, 2.90) 
Table 3.6 Inhibition of compounds 13 and 14 on the growth of cancer cells and normal cells. 
compound EC50 (µM) 
 MDA-MB 
231b 
MCF-7c A549d HEK293e 
13 89.33±1.23 79.43±2.72 >100a 56.96±1.12 
14 10.02±1.66 37.36±2.20 36.24±1.76 19.95±0.19 
SAHA 2.874±0.84 8.124±4.98 19.31±1.26 2.482±1.13 
BIX-
01294 
2.155±0.88 8.103±1.99 21.74±2.73 2.048±0.98 
a>100 in the cases where the IC50 did not reach at the highest tested concentration (100 µM). bMDA-MB-231: breast 
cancer cell line; cMCF-7: breast cancer cell line; dA549: human lung cancer cell line; eHEK293 normal cell line; 
SAHA and BIX-01294 were used as the positive controls; Cells were exposed to the different inhibitors with various 
concentrations for 72h. Inhibition of cell growth by the listed compounds was determined by using CCK-8 kit. Data 
shown as mean ± SD of triplicates. 
3.2.7 ADME Prediction Studies 
The same procedures and principals from the earlier in silico physico-chemical evaluations 
of known HDACIs were applied here to evaluate these novel dual inhibitors.[109] ADMET module 
of Discovery Studio 3.1 was used to predict physical properties. Using Lipinski’s rule of five,[110] 
the octanol–water partition coefficient (AlogP98) should be less than 5. As seen in Table 7, the 
candidate compound 14 is well within accordance of the rule. In addition, other values also fell 
into the acceptable ranges of PSA-2D (7–200) and QplogS (−6.5 to 0.5), indicating 14 may possess 
good bioavailability. These parameters were also taken into consideration in identifying better 
inhibitors, suggesting that 14 has the characteristics desirable for a drug candidate. 
Table 3.7 ADME prediction results 
Entry M.W QPlogSc PSA PSA-2Db AlogP98a 
14 515.654 -3.702 161.25 141.462 2.511 
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 SAHA 264.324 -2.139 102.256 81.037 1.838 
BIX-01294 476.62 -6.792 50.675 63.249 4.189 
aAlogP98 means atom-based LogP (octanol/water), bPSA-2D means 2D fast polar surface area. cQplogS means 
predicted aqueous solubility. 
3.3 Conclusions 
Considering the inherent deficiency of HDACIs as a monotherapy, in conjunction with the 
past success of incorporating the HDAC pharmacophore into many dual inhibitors, we 
hypothesized that the core metal ion binding hydrophilic segment could be coupled with the 
lipophilic core of G9a inhibitors to increase the effectiveness. Both G9a and HDACs are 
therapeutic targets for cancer therapy and are both capable of targeting identical substrates (H3K9 
and lysine 373 of p53). In search of a lead molecule featuring both HDAC and G9a inhibition, the 
H3 mimicking quinazoline core of G9a inhibitors used as a base scaffold. Next, several 
modifications at different sites introduced to cover most of the possible chemical space related to 
the position and chain length (linker gap between the metal binding portion and G9a core). From 
this design, we synthesized more than 20 compounds and tested biochemically and in vitro to see 
if they displayed the desired dual activity. Our primary assessment of success was from MALDI-
TOF evaluation of the H3K9 methylation profile, many of the compounds retained G9a inhibition 
potential. Cell-based assays for all the compounds against several cell lines were used to determine 
their inhibition potential, and we found that 13 and 14 displays the desired dual activities 
comparable to the controls SAHA and BIX-01294. Cell toxicity of these compounds was 
determined using CCK-8, showing that compound 14 was both more effective and less toxic 
compared to 13. The ADMET module of Discovery Studio 3.1 also predicted that the compound 
14 has excellent physico-chemical properties, making it a viable drug candidate. Discovery of 
these small molecules with dual activity towards two epigenetic targets, HDACs and G9a, will 
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provide the route for developing similar compounds with high potency soon. It is also worth 
mentioning that compound 14 may also act as a valuable tool in investigating the multi-targeting 
strategy, and its possible impacts on epigenetic targets. As this is the first time this sort of work 
has been done in respect to these two targets, it may also provide the basis for understanding 
histone cross-talk among distinct epigenetic targets. With this broad prospective, we further plan 
for a detailed SAR study specifically to compound 14 to provide a more potent dual inhibitor in 
conjunction with a mechanistic reasoning to understand the synergistic effect of inhibiting both 
HDACs and G9a methyltransferases. 
3.4 Experiment Sections 
Reagents were purchased from commercial suppliers Sigma-Aldrich, Alfa Aesar, TCI and 
Acros, and were used without further purification unless otherwise indicated. Anhydrous solvents 
(e.g., DMF, DIPEA, MeOH, DCM) were purchased from Sigma-Aldrich. The synthetic progress 
was monitored using silica gel 60 F254 thin layer chromatography plates (Merck EMD Millipore). 
Microwave reactions were performed using Initiator for organic synthesis. Column 
chromatography purifications were performed on an Isolera one system using SNAP columns with 
KP-Sil silica or Zip Si columns with KP-Sil normal phase silica cartridges (unless otherwise 
stated). The nuclear magnetic resonance spectra were recorded on a 400 MHz spectrometer by 
Topspin 3.1 with solvents of CDCl3 and CD3OD. Chemical shifts described in ppm. Coupling 
constants, when reported, are described in hertz (Hz). High-resolution mass spectra (HRMS) data 
were acquired using orbitrap elite mass spectrometer with an electrospray ionization (ESI) source. 
All the samples were run under FT control at 600000 resolution. All temperatures are described in 
°C. The purity of all final compounds was confirmed by RP-HPLC analysis, was >95% or 
mentioned in the synthetic procedure. Analytical high performance liquid chromatography 
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(HPLC) was performed using a Waters Agilent 1260 infinity, column used was Agilent eclipse 
plus C18 3.5 µM reverse phase 150 mm×4.6 mm chromatography column. Samples were detected 
using a wavelength of 254 nm. All samples were analyzed using acetonitrile (0.1% TFA):water 
(0.1% TFA) 5-60% over 30 min and a flow rate of 0.4 ml/min. Preparative HPLC was performed 
using the XBridge prep C18, 5 µM, 10×150 mm column and a flow rate of 1 ml/min.  
3.4.1 Synthesis 
H3 (1-20, ARTKQTARKSTGGKAPRKQL): Peptide was synthesized through Fmoc-
Strategy. Automated peptide synthesis was performed on Liberty Blue Peptide Synthesizer. 
Peptide were synthesized under microwave-assisted protocols on Wang resins. The deblock 
mixture was 20% piperidine in DMF. The following Fmoc-Lys(Boc)-Wang resin from Nova 
biochem were employed. The Fmoc-protected amino acids were purchased from Chempep. 
Cocktail of TFA/TIS/Dodt/H2O (92.5:2.5:2.5:2.5) was used to cleave peptides off the resin. After 
cleavage, crude peptide was purified through a reverse phase C18 column (purchased from 
Agilent, Eclipse XDB-C18, 5 µm, 9.4*250mm). 
Procedure A: General procedure for compounds 2, 2a and 2b. 4-amino-piperidines (18.01 
mmol) were added to a solution of 2,4-dichloro-6,7-dimethoxyquinazoline (2.11 g, 8.14 mmol in 
DMF 20 ml), followed by the addition of N,N-diisopropylethylamine (1.5 ml, 8.62 mmol) and the 
resulting mixture was stirred at room temperature for 2 h until TLC showed that the starting 
material had disappeared. Water was added to the reaction mixture, and the resulting solution was 
extracted with ethyl acetate. The organic layer was washed with 0.5% acetic acid aqueous solution 
and brine, dried and concentrated to give the crude product, which was purified on flash column 
via eluting with hexane-ethyl acetate (20%) to get 3.0g of the desired compound, yield 80-86%. 
Spectral properties of the product was matched with the reported compounds. 
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Procedure B: General procedure for compounds3, 3a and 3b. Compound 2 (6.0 mmol) 
was dissolved in 8 ml of isopropanol. To this solution was added tert-butyl (2-aminoethyl) 
carbamate (1.92 g, 12 mmol) and DIPEA (1.5 ml, 7.2 mmol). The resulting solution was placed 
inside a microwave at 160 oC for 10 min. After cooling, TLC indicated the reaction was completed. 
Solvent was removed under reduced pressure, the residue was dissolved in DCM, washed with the 
saturated NaHCO3 solution. The combined organic phase was dried over Na2SO4 and concentrated 
under reduced pressure. The residue was purified on silica gel column, eluting with 5% MeOH in 
DCM (containing 0.5% Et3N) to give 1.8 g of the Boc–protected amino compound as pale yellow 
solid, yield 60-66%.  
N2-(2-aminoethyl)-6,7-dimethoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-
diamine (3): Brown solid, 1.8 g, 66% yield. M.P. 109-107 oC, 1H NMR (400 MHz, CDCl3) δ 7.10 
(s, 1H), 7.06 (s, 1H), 6.19 (s, 1H), 4.33 – 4.20 (m, 1H), 3.91 (s, 6H), 3.17 (d, J = 5.4 Hz, 2H), 2.93 
– 2.75 (m, 4H), 2.50 (s, 2H), 2.30 (s, 3H), 2.14 (m, 4H), 1.78 – 1.60 (m, 2H), 1.42 (s, 9H). 13C 
NMR (100 MHz, CDCl3) δ 159.5, 155.9, 154.8, 153.2, 148.9, 147.9, 107.1, 106.7, 101.3, 80.2, 
56.6, 56.1, 54.5, 46.8, 45.0, 39.2, 30.4, 27.8. HRMS (ESI): m/zcalcd for C23H36N6O4 [M + H]
+, 
461.2876; found, 461.2862. 
N2-(2-aminoethyl)-6,7-dimethoxy-N4-(1-isopropylpiperidin-4-yl)quinazoline-2,4-
diamine (3a): Brown solid, 1.7 g, 60% yield. M.P. 114-116 oC, 1H NMR (400 MHz, CDCl3) δ 
7.23 (s, 1H), 7.19 (s, 1H), 4.13 (s, 1H), 3.84 (s, 6H), 3.58 – 3.44 (m, 4H), 3.39 (d, J = 4.9 Hz, 2H), 
3.32 (d, J = 4.6 Hz, 2H), 2.96 – 2.83 (m, 2H), 2.11 (t, J = 11.3 Hz, 2H), 2.01 (d, J = 10.8 Hz, 2H), 
1.74 – 1.59 (m, 2H), 1.40 (s, 9H), 1.01 (s, 6H).13C NMR (100 MHz, CDCl3) δ 165.1, 158.8, 156.3, 
154.5, 145.6, 112.04, 108.9, 99.6, 80.8, 56.3, 55.9, 52.6, 49.9, 48.4, 41.4, 40.8, 31.7, 28.4. HRMS 
(ESI): m/zcalcd for C25H40N6O4 [M + H]
+, 489.3145; found, 489.3156. 
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N2-(2-aminoethyl)-6,7-dimethoxy-N4-(1-benzylylpiperidin-4-yl)quinazoline-2,4-
diamine (3b): Brown solid, 2.1 g, 64% yield. M.P. 130-132 oC 1H NMR (400 MHz, CDCl3) δ 7.36 
– 7.14 (m, 5H), 6.79 (s, 1H), 6.58 (s, 1H), 6.01 (s, 2H), 5.44 (s, 1H), 4.11 (d, J = 12.4 Hz, 1H), 
3.84 (m, 6H), 3.52 (s, 2H), 3.40 – 3.37 (m, 2H), 3.32 (d, J = 4.6 Hz, 2H), 2.93 – 2.84 (m, 2H), 2.11 
(t, J = 11.3 Hz, 2H), 2.01 (d, J = 10.8 Hz, 2H), 1.75 – 1.59 (m, 2H), 1.38 (s, 9H).13C NMR (100 
MHz, CDCl3) δ 165.1, 158.8, 156.3, 154.5, 145.6, 138.1, 129.2, 128.2, 127.1, 112.01, 108.9, 102.3, 
78.9, 63.0, 56.3, 55.9, 52.6, 49.9, 48.4, 41.4, 40.8, 31.7, 28.3. HRMS (ESI): m/zcalcd for 
C29H40N6O4 [M + H]
+, 537.3189; found, 537.3165. 
NH-Boc protection was removed to get the free amines of 3, 3a and 3b using TFA/DCM 
overnight, dried amine was used directly in next step without further purification. 
Procedure C: General procedure for compounds 4-7 and 4a-7a, to a stirred solution of 
corresponding monomethyl ester (0.25 mmol) in anhydrous CH2Cl2 (5 ml) was added EDCI (70 
mg, 0.35 mmol) followed by HOBt (50 mg, 0.35 mmol) at 0 °C. After 30 min, a solution of 
compound 3 (138 mg, 0.3 mmol) and DIEPA (0.1 ml, 0.5 mmol) in CH2Cl2 (2 ml) was added drop-
wise at 0 °C. The mixture was allowed to stir at rt and monitored by TLC. Upon completion, the 
organic layer was washed with saturated aqueous NaHCO3 solution followed by brine. The organic 
extracts were dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude 
product was purified by flash chromatography (MeOH/DCM up to 20%) to afford desired 
compounds as colorless oily liquid. HRMS (ESI): m/z calcd for C27H42N6O5 [M + H]
+, 531.3295; 
found, 531.3279. This intermediate in methanol (2.5 ml) was added a solution of hydroxylamine 
(1 ml, 50% in water). The resulting solution was stirred for 3 h at 60°C. Then solvent was removed 
under vacuum and the crude residue purified by flash chromatography using reverse phase silica 
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gel column using H2O (0.1% HCOOH)/CH3CN (0.1% HCOOH) as eluent (0-100 %). This 
afforded the expected derivatives as a yellow/brown sticky mass, 30-38% over 2 steps.  
N1-(2-((6,7-dimethoxy-4-((1-methylpiperidin-4-yl) amino) quinazolin-2-yl) amino) 
ethyl)-N8-hydroxyoctanediamide (4): 44 mg, 33% yield. 1H NMR (400 MHz, MeOD) δ 7.81 (s, 
1H), 7.59 (s, 1H), 6.91 (s, 1H), 4.68 (s, 1H), 3.93 (s, 6H), 3.64-3.47 (m, 5H), 3.23 (d, J = 1.4 Hz, 
4H), 3.14 (m, 1H), 2.90 (d, J = 16.0 Hz, 3H), 2.36-2.28 (m, 2H), 2.21-2.07 (m, 5H), 1.64 – 1.49 
(m, 4H), 1.30 (s, 4H). 13C NMR (100 MHz, MeOD) δ 183.7, 167.5, 148.4, 128.3, 124.8, 124.0, 
117.1, 110.9, 104.0, 55.4, 54.7, 53.3, 52.8, 46.1, 42.1, 41.8, 38.2, 35.9, 32.3, 28.2, 25.4. HRMS 
(ESI): m/zcalcd for C26H41N7O5 [M + H]
+, 532.3247; found, 532.3248. HPLC purity 95.45% ; tR= 
14.004 
N1-hydroxy-N8-(2-((4-((1-isopropylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-
2-yl)amino)ethyl)octanediamide (4a): 49 mg, 35% yield. 1H NMR (400 MHz, MeOD) δ 7.76 (s, 
1H), 7.70 (s, 1H), 6.90 (s, 1H), 4.72 (s, 1H), 3.92 (s, 6H), 3.60 (m, 5H), 3.48 - 3.38 (m, 4H), 3.33 
(dd, J = 3.2, 1.6 Hz, 1H), 2.39-2.19 (m, 5H), 2.07 (t, J = 7.1 Hz, 2H), 1.56 (d, J = 5.5 Hz, 4H), 
1.41-1.28 (m, 9H). 13C NMR (100 MHz, MeOD) δ 171.6, 166.3, 156.7, 153.1, 147.4, 147.2, 142.2, 
135.7, 125.2, 124.7, 120.0, 117.3, 110.5, 104.1, 103.7, 57.9, 55.5, 45.0, 34.1, 32.1, 28.3, 25.0, 15.8. 
HRMS (ESI): m/zcalcd for C28H45N7O5 [M + H]
+, 560.3560; found, 560.3554. HPLC purity 
95.12% ; tR= 14.820. 
N1-(2-((6,7-dimethoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-
yl)amino)ethyl)-N7-hydroxyheptanediamide (5): 38 mg, 30% yield. 1H NMR (400 MHz, 
MeOD) δ 7.70 (s, 1H), 6.97 (s, 1H), 4.69 (s, 2H), 3.96 (s, 6H), 3.85 (s, 1H), 3.67 – 3.49 (m, 4H), 
3.47 (d, J = 5.7 Hz, 2H), 3.25 (d, J = 13.5 Hz, 2H), 3.15 (d, J = 7.4 Hz, 1H), 3.05 – 2.83 (m, 4H), 
2.31 (d, J = 11.1 Hz, 2H), 2.23 – 2.06 (m, 5H), 1.64 – 1.52 (m, 3H), 1.35 (d, J = 6.9 Hz, 2H). 13C 
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NMR (100 MHz, MeOD) δ 174.8, 170.0, 163.8, 156.6, 156.0, 153.4, 147.3, 112.0, 108.9, 99.6, 
56.8, 53.6, 46.0, 40.5, 38.7, 37.4, 34.4, 30.4, 28.3, 25.2. HRMS (ESI): m/zcalcd for C25H39N7O5 
[M + H]+, 518.3091; found, 518.3080. HPLC purity 95.21% ; tR= 14.402 
N1-hydroxy-N7-(2-((4-((1-isopropylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-
2-yl)amino)ethyl)heptanediamide (5a): 51 mg, 38% yield. 1H NMR (400 MHz, MeOD) δ 7.75 
(s, 1H),  7.61 (s, 1H), 6.94 (s, 1H), 4.73 (s, 1H), 3.94 (s, 6H), 3.61 (m, 5H), 3.48 (s, 2H), 3.42 – 
3.23 (m, 3H), 2.39-2.21 (s, 5H), 2.09 (t, J = 6.9 Hz, 3H), 1.60 (s, 4H), 1.38 (m, 8H). 13C NMR 
(100 MHz, MeOD) δ 170.8, 167.7, 164.5, 155.5, 154.2, 152.0, 147.3, 110.8, 104.2, 98.1, 55.4, 
53.4, 52.6, 48.2, 47.1, 38.5, 37.1, 35.4, 31.9, 28.5, 25.6, 15.8. HRMS (ESI): m/zcalcd for 
C27H43N7O5 [M + H]
+, 546.3405; found, 546.3385. HPLC purity 93.80% ; tR= 14.991. 
N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-2-
yl)amino)ethyl)-N7-hydroxyheptanediamide (5b): 55 mg, 37% yield. 1H NMR (400 MHz, 
MeOD) δ 7.67 (d, J = 1.9 Hz, 1H), 7.44 (dt, J = 15.7, 7.9 Hz, 5H), 6.96 (s, 1H), 4.48 (s, 1H), 3.96 
(dd, J = 12.2, 3.3 Hz, 7H), 3.63 (s, 3H), 3.54 – 3.44 (m, 2H), 3.28 (d, J = 11.8 Hz, 2H), 2.72 (s, 
2H), 2.32 – 2.16 (m, 5H), 2.10 (t, J = 7.1 Hz, 1H), 1.94 (d, J= 13.8 Hz, 2H), 1.60 (ddd, J = 15.4, 
12.7, 7.5 Hz, 4H), 1.41 – 1.20 (m, 2H). 13C NMR (100 MHz, MeOD) δ 174.9, 171.4, 167.7, 159.4, 
156.3, 156.0, 153.3, 147.4, 136.1, 130.6, 130.4, 129.1, 128.7, 128.6, 103.6, 98.4, 97.9, 60.5, 55.5, 
51.1, 40.1, 38.3, 35.3, 28.5, 27.9, 25.0, 24.8. HRMS (ESI): m/zcalcd for C31H43N7O5 [M + H]
+, 
594.3440; found, 594.3460. HPLC purity 96.20% ; tR= 14.001. 
N1-(2-((6,7-dimethoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-
yl)amino)ethyl)-N6-hydroxyadipamide (6): 44 mg, 35% yield. 1H NMR (400 MHz, MeOD) δ 
7.65 (s, 1H), 6.93 (s, 1H), 4.69 (s, 1H), 3.95 (s, 6H), 3.60 (d, J = 14.8 Hz, 4H), 3.21 (m, 3H), 2.89 
(d, J = 9.2 Hz, 4H), 2.29 (m, 4H), 2.13 (s, 3H), 1.90 (dt, J = 13.6, 6.7 Hz, 1H), 1.64 (s, 4H), 1.39 
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(d, J = 6.6 Hz, 2H). 13C NMR (100 MHz, MeOD) δ 170.8, 168.2, 159.3, 156.5, 156.2, 153.3, 147.3, 
111.2, 108.6, 103.0, 55.5, 52.9, 46.0, 41.8, 40.56, 38.2, 37.4, 31.8, 28.2, 24.6. HRMS (ESI): 
m/zcalcd for C24H37N7O5 [M + H]
+, 504.2934; found, 504.2911. HPLC purity 96.81% ; tR= 13.374 
N1-hydroxy-N6-(2-((4-((1-isopropylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-
2-yl)amino)ethyl)adipamide (6a): 46 mg, 35% yield. 1H NMR (400 MHz, MeOD) δ 7.77 (s, 1H), 
7.64 (s, 1H), 7.32 (s, 1H), 6.96 (s, 1H), 4.73 (s, 1H), 3.96 (s, 6H), 3.72 – 3.52 (m, 5H), 3.47 (s, 
2H), 3.37 (d, J = 15.2 Hz, 2H), 2.39 (d, J = 12.1 Hz, 2H), 2.17 (m, 6H), 1.63 (s, 4H), 1.43 (d, J = 
6.3 Hz, 6H). 13C NMR (100 MHz, MeOD) δ 174.5, 170.5, 168.0, 157.1, 156.0, 153.5, 147.3, 113.4, 
108.4, 89.7, 57.2, 55.8, 49.2, 49.5, 40.8, 39.7, 38.0, 32.5, 28.2, 24.7, 15.5. HRMS (ESI): m/zcalcd 
for C26H41N7O5 [M + H]
+, 532.3247; found, 532.3245. HPLC purity 96.95% ; tR= 14.164 
N1-(2-((6,7-dimethoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-
yl)amino)ethyl)-N5-hydroxyglutaramide (7): 40 mg, 33% yield. 1H NMR (400 MHz, MeOD) δ 
7.68 (s, 1H), 7.63 (s, 1H), 7.30 (s, 1H), 6.84 (s, 1H), 4.66 (s, 1H), 3.92 (s, 6H), 3.61 (s, 4H), 3.46 
(s, 2H), 3.35 (d, J = 15.4 Hz, 3H), 2.90 (m, 3H), 2.29 (m, 4H), 2.14 (d, J = 6.6 Hz, 4H), 1.91 (s, 
2H). 13C NMR (100 MHz, MeOD) δ 170.8, 168.2, 159.4, 159.3, 156.5, 153.3, 147.3, 136.1, 122.1, 
111.2, 108.6, 103.7, 55.5, 52.9, 46.1, 41.8, 40.0, 38.4, 38.2, 35.2, 31.8, 28.2, 24.6. HRMS (ESI): 
m/zcalcd for C23H35N7O5 [M + H]
+, 490.2778; found, 490.2756. HPLC purity 95.61% ; tR= 12.751 
N1-hydroxy-N5-(2-((4-((1-isopropylpiperidin-4-yl)amino)-6,7-dimethoxyquinazolin-
2-yl)amino)ethyl)glutaramide (7a): 50 mg, 38% yield. 1H NMR (400 MHz, MeOD) δ 7.67 (s, 
1H), 6.93 (s, 1H), 4.72 (s, 2H), 3.94 (s, 6H), 3.59 (d, J = 12.4 Hz, 5H), 3.47 (s, 2H), 3.36 (d, J = 
13.9 Hz, 2H), 2.37 (s, 2H), 2.22-2.12 (m,  6H), 1.63 (m, 4H), 1.44 (s, 6H). 13C NMR (100 MHz, 
MeOD) δ 173.1, 168.0, 158.5, 156.5, 153.3, 134.9, 147.5, 110.6, 103.7, 98.5, 57.8, 55.2, 40.1, 
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38.4, 35.7, 32.4, 31.7, 28.5, 16.2, 15.8. HRMS (ESI): m/zcalcd for C25H39N7O5 [M + H]
+, 
518.3091; found, 518.3139. HPLC purity 93.38% ; tR= 13.670. 
Compounds 13-16 and 13a-16a 
2,4-dichloro-7-methoxyquinazoline: Compound 10 was prepared according to the 
previously reported procedure,[104] 3.4 g of anthranilic acid (20 mmol) and 3.5 equiv. of urea were 
finely powdered using mortar and pestle and heated to 200 °C in a round-bottom flask open to the 
atmosphere. After 2 h, the mixture was cooled, triturated with water, and filtered to give the 
product as crude. Product was dried and used in next step directly. Molecular ion peak for 
C9H8N2O3 was found at 192.0773. Crude quinazoline-2,4-dione and 2.4 g of N,N-diethyl aniline 
were mixed in 45 ml of phosphorus oxychloride, and the mixture was refluxed overnight under an 
argon atmosphere. The crude reaction mixture was concentrated, neutralized the excess of POCl3 
using NaHCO3 and extracted to EA, dried on Na2SO4 and evaporated, purified using flash column, 
eluting at 20% of EA/Hexane. White fluffy powder, 1.82 g, 40% overall yield. HRMS (ESI): m/z 
calcd for C9H6Cl2N2 [M + H]
+, 228.9935; found, 228.9934.  
N-(1-benzylpiperidin-4-yl)-2-chloro-7-methoxyquinazolin-4-amine (11) and  2-
chloro-N-(1-isopropylpiperidin-4-yl)-7-methoxyquinazolin-4-amine (11a). 
Compound 11 and 11a were prepared according to the procedure A, using 1-
methylpiperidin-4-amine or 1-benzylpiperidin-4-amine. 11: Yellow powder, 74%. M.P. 134-136 
oC, 1H NMR (CDCl3, 400 MHz) δ ppm 7.54 (d, J = 9.0 Hz, 1H), 7.27-7.34(m, 5H), 7.10 (d, J = 2.4 
Hz, 1H), 7.04 (dd, J1 = 9.0 Hz, J2 = 2.4 Hz, 1H), 5.61(d, J = 7.71 Hz, 1H), 4.23-4.33 (m, 1H), 3.88 
(s, 3H), 3.57 (s, 2H), 2.91 (d, J = 11.9 Hz, 2H), 2.24-2.30 (m, 2H), 2.08-2.13 (m, 2H), 1.59-1.69 
(m, 2H). 13C NMR (CDCl3, 100 MHz) δ ppm 163.7, 129.8, 158.3, 153.3, 137.7, 129.3, 128.3, 
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127.3, 122.0, 117.9, 107.2, 106.9, 62.9, 55.7, 52.0, 48.0, 31.9. HRMS (ESI): m/z calcd for 
C21H23ClN4O [M + H]
+, 383.1639; found, 383.1610. 
11a: Brownish yellow semi solid, 86%.1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 9.1 Hz, 
1H), 7.13 (s, 1H), 7.07 (d, J = 9.1 Hz, 1H), 4.28 (s, 1H), 3.92 (s, 3H), 2.88 (d, J = 11.0 Hz, 2H), 
2.35 (s, 3H), 2.26 (t, J = 11.6 Hz, 2H), 2.17 (d, J = 12.2 Hz, 2H), 1.86 (s, 1H), 1.66 (m, 2H). HRMS 
(ESI): m/z calcd for C15H19ClN4O [M + H]
+, 306.1247; found, 307.1323. 
N2-(2-aminoethyl)-N4-(1-benzylpiperidin-4-yl)-7-methoxyquinazoline-2,4-diamine 
(12) and N2-(2-aminoethyl)-7-methoxy-N4-(1-methylpiperidin-4-yl)quinazoline-2,4-diamine 
(12a) 
Compounds 12 and 12a were obtained via Procedure B: 
12: Brown solid, 1.94 g, 64%.1H NMR (400 MHz, CDCl3) δ 8.75 (s, 2H), 8.49 (d, J = 5.2 
Hz, 1H), 7.96 (s, 1H), 7.37 – 7.14 (m, 4H), 6.62 (d, J = 8.9 Hz, 2H), 5.56 (s, 1H), 4.22 (s, 1H), 
4.06 – 3.88 (m, 1H), 3.67 (d, J = 10.9 Hz, 3H), 3.51 (d, J = 19.7 Hz, 4H), 3.26 (s, 2H), 2.99 (dd, J 
= 14.9, 7.4 Hz, 1H), 2.90 (s, 2H), 2.09 (d, J = 35.0 Hz, 4H), 1.91 (d, J = 12.4 Hz, 3H), 1.28 (d, J = 
10.5 Hz, 10H). HRMS (ESI): m/z calcd for C28H38N6O3 [M + H]
+, 507.3084; found, 507.3047. 
12a: Brown solid, 1.75 g, 68%.1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.9 Hz, 1H), 
6.84 (s, 1H), 6.74 (d, J = 8.8 Hz, 1H), 5.55 (s, 2H), 4.18 (s, 1H), 3.88 (s, 3H), 3.61 (d, J = 3.9 Hz, 
2H), 3.39 (d, J = 4.8 Hz, 2H), 2.87 (d, J = 11.2 Hz, 2H), 2.34 (s, 3H), 2.21 (t, J = 11.3 Hz, 2H), 
2.12 (d, J = 11.8 Hz, 2H), 1.66 (dd, J = 21.0, 10.4 Hz, 2H), 1.44 (s, 9H). HRMS (ESI): m/z calcd 
for C22H34N6O3 [M + H]
+, 431.2771; found, 431.2767. 
Compounds 13-17 and 13a-17a were synthesized according to procedure C from the 
corresponding free amines, Yield varied from 30-40%, yellow/brown sticky solids were obtained 
after purification. 
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N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-7-methoxyquinazolin-2-yl)amino)ethyl)-
N8-hydroxyoctanediamide(13): 45 mg, 31% yield. 1H NMR (400 MHz, MeOD) δ 8.06 (s, 1H), 
7.52 (d, J = 33.6 Hz, 5H), 6.83 (d, J = 31.2 Hz, 2H), 4.62 (s, 1H), 4.34 (s, 2H), 3.89 (s, 3H), 3.70 
– 3.40 (m, 6H), 3.22 – 3.03 (m, 3H), 2.21 (m, 8H), 1.56 (s, 4H), 1.29 (s, 5H). 13C NMR (100 MHz, 
MeOD) δ 175.0, 171.5, 165.1, 159.8, 154.0, 151.3, 141.9, 130.9, 129.7, 129.6, 128.8, 125.4, 113.7, 
102.9, 98.0, 59.9, 55.3, 50.7, 40.0, 38.3, 35.7, 32.2, 28.4, 28.3, 27.9, 25.4, 25.1. HRMS (ESI): m/z 
calcd for C31H43N7O4 [M + H]
+, 578.3455; found, 578.3444. HPLC purity 95.41%; tR= 16.756. 
N1-hydroxy-N7-(2-((7-methoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-
yl)amino)ethyl)heptanediamide (13a): 44 mg, 33% yield. 1H NMR (400 MHz, CDCl3) δ 7.46 (s, 
1H), 6.85 – 6.49 (m, 2H), 4.20 (s, 1H), 3.87 (s, 3H), 3.70 – 3.46 (m, 4H), 2.95 (d, J = 10.6 Hz, 
2H), 2.36 (s, 3H), 2.23 (dd, J = 21.2, 12.2 Hz, 6H), 2.15 – 2.00 (m, 6H), 1.81 (d, J = 10.6 Hz, 3H), 
1.65 (s, 5H). 13C NMR (100 MHz, MeOD) δ 175.0, 168.6, 165.2, 153.8, 149.2, 134.8, 125.4, 113.7, 
108.7, 102.9, 98.0, 55.2, 52.8, 46.2, 42.2, 40.0, 38.2, 35.6, 32.2, 28.4, 28.3, 28.1, 25.3, 25.0. HRMS 
(ESI): m/z calcd for C25H39N7O4 [M + H]
+, 502.3142; found, 502.3143. HPLC purity 95.75%; tR= 
13.767. 
N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-7-methoxyquinazolin-2-yl)amino)ethyl)-
N7-hydroxyheptanediamide (14): 49 mg, 35% yield.1H NMR (400 MHz, MeOD) δ 8.10 (d, J = 
9.1 Hz, 1H), 7.59 – 7.40 (m, 5H), 6.97 (d, J = 9.1 Hz, 1H), 6.90 (s, 1H), 4.60 (s, 1H), 4.18 (s, 2H), 
3.94 (s, 3H), 3.64 (d, J = 8.0 Hz, 2H), 3.46 (dd, J = 14.1, 8.1 Hz, 4H), 3.39 – 3.31 (m, 2H), 3.18 – 
2.96 (m, 2H), 2.23 (dd, J = 19.2, 11.7 Hz, 4H), 2.15 – 1.92 (m, 4H), 1.69 – 1.53 (m, 4H), 1.41 – 
1.27 (m, 2H). 13C NMR (100 MHz, MeOD) δ 175.0, 171.4, 167.8, 165.3, 159.9, 154.0, 141.9, 
131.2, 130.5, 129.1, 128.7, 125.3, 113.8, 103.0, 98.2, 60.5, 55.1, 51.0, 40.2, 38.2, 35.3, 32.0, 28.4, 
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28.0, 25.0, 24.8. HRMS (ESI): m/z calcd for C30H41N7O4 [M + H]
+, 564.3298; found, 564.3307. 
HPLC purity 95.02%; tR= 16.600. 
N1-hydroxy-N7-(2-((7-methoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-
2yl)amino)ethyl) heptanediamide (14a): 49 mg, 40% yield. 1H NMR (400 MHz, MeOD) δ 8.10 
(s, 1H), 7.17 (s, 1H), 6.94 (m, 1H), 4.62 (d, J = 62.4 Hz, 2H), 3.94 (s, 3H), 3.86 (s, 2H), 3.73 – 
3.55 (m, 2H), 3.47 (s, 1H), 3.29 (m, 5H), 3.15 (dd, J = 14.9, 7.5 Hz, 2H), 2.97 – 2.77 (m, 4H), 2.45 
– 2.17 (m, 3H), 2.24 – 2.02 (m, 3H), 1.61 (s, 2H), 1.42 – 1.22 (m, 2H). 13C NMR (100 MHz, 
CDCl3) δ 178.5, 174.4, 166.0, 165.6, 159.2, 153.1, 129.78, 117.7, 115.8, 106.9, 59.6, 53.5, 50.7, 
46.8, 42.1, 39.7, 39.3, 36.0, 32.0, 29.8, 28.4. HRMS (ESI): m/z calcd for C24H37N7O4 [M + H]
+, 
487.2907; found, 488.2962. HPLC purity 94.16%; tR= 13.232. 
N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-7-methoxyquinazolin-2-yl)amino)ethyl)-
N6-hydroxyadipamide (15): 52 mg, 38% yield.1H NMR (400 MHz, MeOD) δ 8.03 (s, 1H), 7.52 
(m, 6H), 6.78 (d, J = 40.3 Hz, 2H), 4.61 (s, 1H), 4.36 (s, 2H), 3.87 (s, 3H), 3.60 (m, 4H), 3.46 (m, 
2H), 3.38 (m, 3H), 2.49 – 1.78 (m, 8H), 1.64 (s, 4H). 13C NMR (100 MHz, MeOD) δ 171.25, 
167.79, 165.02, 159.78, 153.88, 139.89, 131.05, 129.70, 129.50, 128.93, 113.70, 111.3, 103.5, 
66.8, 59.84, 55.36, 50.73, 41.6, 39.2, 38.4, 35.38, 32.02, 27.80. HRMS (ESI): m/z calcd for 
C24H37N7O4 [M + H]
+, 550.3142; found, 550.3148. HPLC purity 96.48%; tR= 16.262. 
N1-hydroxy-N6-(2-((7-methoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-
yl)amino)ethyl)adipamide (15a): 41 mg, 35% yield.1H NMR (400 MHz, MeOD) δ 8.08 (s, 1H), 
6.87 (d, J = 33.0 Hz, 2H), 4.68 (s, 2H), 3.88 (d, J = 22.3 Hz, 3H), 3.82 – 3.69 (m, 1H), 3.62 (s, 
4H), 3.46 (s, 2H), 3.22 (m, 2H), 3.28 – 3.17 (m, 1H), 3.19 – 3.01 (m, 1H), 2.89 (d, J = 15.2 Hz, 
3H), 2.42 – 2.19 (m, 3H), 2.09 (d, J = 29.5 Hz, 2H), 1.90 (s, 1H), 1.62 (s, 3H), 1.38 (d, J = 6.5 Hz, 
2H). 13C NMR (100 MHz, MeOD) δ 173.7, 170.0, 167.9, 164.5, 159.2, 153.4, 141.4, 124.6, 113.0, 
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102.3, 97.4, 54.4, 53.6, 52.2, 46.2, 45.5, 41.6, 39.3, 37.5, 34.3, 34.0, 27.5. HRMS (ESI): m/z calcd 
for C23H35N7O4 [M + H]
+, 474.2829; found, 474.2807. HPLC purity 96.40%; tR= 12.879. 
N1-(2-((4-((1-benzylpiperidin-4-yl)amino)-7-methoxyquinazolin-2-yl)amino)ethyl)-
N5-hydroxyglutaramide (16): 52 mg, 39% yield. 1H NMR (400 MHz, MeOD) δ 8.01 (s, 1H), 
7.51 (d, J = 38.6 Hz, 5H), 6.76 (d, J = 47.4 Hz, 2H), 4.49 (d, J = 103.1 Hz, 3H), 3.86 (s, 3H), 3.53 
(d, J = 59.5 Hz, 5H), 3.22 (s, 3H), 2.23 (m, 6H), 1.93 (s, 4H). 13C NMR (100 MHz, MeOD) δ 
174.1, 170.8, 167.9, 165.0, 159.7, 153.6, 141.7, 131.0, 129.0, 129.8, 128.3, 125.4, 115.4, 113.6, 
102.8, 67.9, 59.9, 55.3, 50.7, 40.1, 38.3, 34.8, 31.7, 27.8, 21.6. HRMS (ESI): m/z calcd for 
C23H35N7O4 [M + H]
+, 536.2985; found, 536.2998. HPLC purity 94.34% ; tR= 16.051. 
N1-hydroxy-N5-(2-((7-methoxy-4-((1-methylpiperidin-4-yl)amino)quinazolin-2-
yl)amino)ethyl)glutaramide (16a): 35 mg, 31% yield. 1H NMR (400 MHz, MeOD) δ 8.10 (s, 
1H), 6.87 (d, J = 31.2 Hz, 2H), 4.70 (s, 1H), 3.92 (s, 3H), 3.73 (dd, J = 12.9, 6.5 Hz, 1H), 3.66 (m, 
3H), 3.46 (s, 2H), 3.35 (d, J = 15.5 Hz, 2H), 3.23 (m, 1H), 2.88 (d, J = 14.5 Hz, 2H), 2.46 – 2.21 
(m, 4H), 2.15 (s, 2H), 1.90 (s, 2H), 1.37 (m, 4H). 13C NMR (100 MHz,) δ 175.8, 171.2, 166.0, 
165.2, 153.3, 151.3, 127.6, 113.2, 110.1, 103.0, 57.8, 54.6, 50.5, 46.9, 41.8, 39.2, 36.4, 33.6, 31.4, 
19.0. HRMS (ESI): m/z calcd for C22H33N7O4 [M + H]
+, 460.2672; found, 460.2648. HPLC purity 
95.90%; tR= 12.615. 
N-(1-benzylpiperidin-4-yl)-6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-
4-amine (18): Compound 18 was synthesized according to the previously reported procedure,[103] 
which was treated with Pd/C under H2 gas to get the free amine.HRMS (ESI): m/z calcd for 
C21H32N6O2 [M + H]
+, 401.2264; found, 401.2642. This amine was directly used in procedure C 
while using monomethylsuberate ester to get 19and monomethylpimelate to obtain 20. 
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8-(4-((6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-
yl)amino)piperidin-1-yl)-N-hydroxy-8-oxooctanamide (19): 48 mg, 34% yield over 2 steps. 1H 
NMR (400 MHz, MeOD) δ 7.68 (s, 1H), 7.20 (s, 1H), 4.66 (d, J = 12.0 Hz, 1H), 4.51 (s, 1H), 4.22 
(s, 2H), 4.12 (d, J = 12.7 Hz, 1H), 3.96 (m, 8H), 3.45 (s, 2H), 3.28 (d, J = 19.7 Hz, 3H), 2.83 (d, J 
= 17.7 Hz, 4H), 2.47 (dd, J = 15.0, 7.3 Hz, 2H), 2.36 (s, 2H), 2.16 (m, 4H), 1.65 (m, 6H), 1.40 (s, 
5H). 13C NMR (101 MHz, MeOD) δ 172.6, 171.5, 167.5, 158.5, 155.8, 152.9, 147.6, 103.4, 102.7, 
99.6, 56.3, 55.5, 55.4, 44.7, 43.7, 42.7, 40.7, 32.4, 32.2, 31.5, 30.6, 28.5, 28.3, 25.1, 25.0, 24.3. 
HRMS (ESI): m/z calcd for C29H45N7O5[M + H]
+, 572.3516; found, 572.3530. HPLC purity 
94.71%; tR= 15.347. 
7-(4-((6,7-dimethoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-
yl)amino)piperidin-1-yl)-N-hydroxy-7-oxoheptanamide(20): 62 mg, 45% yield over two steps. 
1H NMR (400 MHz, MeOD) δ 7.72 (s, 1H), 7.23 (s, 1H), 4.66 (d, J = 12.1 Hz, 1H), 4.52 (s, 1H), 
4.26 (s, 2H), 4.12 (d, J = 12.0 Hz, 2H), 3.96 (d, J = 14.8 Hz, 8H), 3.49 (d, J = 39.9 Hz, 4H), 2.86 
(dd, J = 25.3, 14.7 Hz, 4H), 2.64 – 2.29 (m, 4H), 2.27 – 1.92 (m, 4H), 1.83 – 1.50 (m, 6H), 1.50 – 
1.34 (m, 2H). 13C NMR (100 MHz, MeOD) δ 172.5, 171.4, 167.2, 158.5, 155.9, 152.5, 147.7, 
137.0, 103.5, 102.7, 99.2, 56.18, 55.6, 55.5, 49.4, 45.9, 44.6, 43.5, 42.4, 40.2, 32.4, 32.1, 31.4, 
30.6, 28.2, 25.0, 24.8, 24.0. HRMS (ESI): m/z calcd for C28H43N7O5[M + H]
+, 558.3404; found, 
558.3387. HPLC purity 96.04%; tR= 14.311. 
Compounds 21 and 22  
Compound 10 was treated with NHBoc ethylinediamine as the procedure A to get the 
intermediate 11b, which was further treated with 1-methyl-1,4-diazepane in accordance to 
procedure B to yield 18a, followed by procedure C, using monomethylsuberate or 
monomethylpimelate to get 21 and 22.  
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tert-butyl (2-((2-chloro-7-methoxyquinazolin-4-yl)amino)ethyl)carbamate (11b): 
78% yield. 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 9.0 Hz, 2H), 7.08 – 6.88 (m, 2H), 5.39 (s, 
1H), 3.85 (s, 3H), 3.67 (d, J = 3.9 Hz, 2H), 3.57 – 3.37 (m, 2H), 1.40 (s, 9H). HRMS (ESI): m/z 
calcd for C16H21ClN4O3+ [M + H]
+, 353.1380; found, 353.1372. 
tert-butyl(2-((7-methoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-yl)amino)ethyl) 
carbamate (18a): 69% yield. 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.9 Hz, 1H), 6.95 (s, 1H), 
6.85 (s, 1H), 6.63 (s, 1H), 5.52 (s, 1H), 4.04 – 3.93 (m, 2H), 3.86 (s, 3H), 3.62 (d, J = 4.9 Hz, 2H), 
3.44 (d, J = 4.5 Hz, 3H), 2.73 (s, 2H), 2.69 – 2.51 (m, 2H), 2.37 (s, 3H), 2.03 (s, 2H), 1.41 (s, 9H). 
HRMS (ESI): m/z calcd for C22H34N6O3[M + H]
+, 431.2771; found, 431.2746. 
N1-hydroxy-N8-(2-((7-methoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4 
yl)amino)ethyl) octanediamide (21): 36 mg, 29% yield over 2 steps. 1H NMR (400 MHz, MeOD) 
δ 7.97 (d, J = 8.7 Hz, 1H), 7.16 (s, 1H), 7.02 (d, J = 8.6 Hz, 1H), 4.28 (s, 2H), 3.94 (s, 3H), 3.87 
(s, 2H), 3.74 (d, J = 5.6 Hz, 3H), 3.60 – 3.48 (m, 4H), 3.42 (s, 2H), 2.89 (d, J = 7.3 Hz, 3H), 2.39 
(s, 2H), 2.21 (t, J = 7.0 Hz, 4H), 1.55 (m, 4H), 1.29 (s, 4H). 13C NMR (100 MHz, MeOD) δ 175.5, 
167.49 164.98 159.76 153.4, 124.9, 114.1, 103.6, 99.8, 55.3, 55.1, 48.2, 48.0, 47.8, 47.6, 47.4, 
47.2, 46.9, 46.0, 43.5, 42.6, 41.3, 37.5, 35.6, 34.0, 28.5, 28.4, 25.4, 24.7, 24.0. HRMS (ESI): m/z 
calcd for C25H39N7O4[M + H]
+, 502.3142; found, 502.3128. HPLC purity 96.21%; tR= 13.810. 
N1-hydroxy-N7-(2-((7-methoxy-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-4-
yl)amino)ethyl)heptanediamide (22): 43 mg,36% yield over 2 steps. 1H NMR (400 MHz, 
MeOD) δ 7.98 (d, J = 9.1 Hz, 1H), 7.14 (d, J = 1.9 Hz, 1H), 7.00 (m, 1H), 4.27 (s, 2H), 3.93 (s, 
5H), 3.88 (s, 1H), 3.88 – 3.66 (m, 4H), 3.52 (m, 5H), 3.42 (s, 2H), 2.90 (s, 3H), 2.39 (s, 1H), 2.24 
(dd, J = 10.9, 7.1 Hz, 5H), 1.84 (dd, J = 13.7, 6.5 Hz, 2H). 13C NMR (100 MHz, MeOD) δ 174.99, 
171.13, 168.17, 164.87, 159.67, 153.28, 125.03, 114.13, 103.56, 99.82, 55.19, 43.67, 42.61, 41.15, 
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37.62, 35.26, 31.88, 24.93, 24.60. HRMS (ESI): m/z calcd for C24H37N7O4[M + H]
+, 488.2985; 
found, 488.2960. HPLC purity 96.80%; tR= 13.370. 
7-(benzyloxy)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-2-(4-methyl-1,4-diazepan-1-
yl)quinazolin-4-amine (24) was synthesized from 1a, by following procedure A  (23) and 
procedure B (24), then benzyl group was removed using Pd catalyzed hydrogenolysis, mixture of 
compound 24 (600 mg, 1.2 mmol) and 10 wt% Pd(OH)2/C (90 mg) in ethanol (100 ml) was stirred 
for 40 hours at room temperature under hydrogen balloon. The reaction mixture was filtered and 
concentrated to provide the debenzylated product 4-((1-isopropylpiperidin-4-yl)amino)-6-
methoxy-2-(4-methyl-1,4-diazepan-1-yl) quinazolin-7-ol (25)as brownish yellow solid, 90 %.  
N-hydroxy-7-((4-((1-isopropylpiperidin-4-yl)amino)-6-methoxy-2-(4-methyl-1,4-
diazepan-1-yl)quinazolin-7-yl)oxy)heptanamide (26): Procedure D, Ethyl heptanoate (80 µl, 
0.4 mmol) was added to the ice cold solution of compound 24 (200 mg, 0.4 mmol) in DMF and 
K2CO3 (280 mg, 2 mmol), reaction mixture was warmed to room temperature and then at 60 
oC. 
After 6 h reactions, mixture was evaporated to get the residue and dissolved in DCM and washed 
with brine, organic layer was vacuum dried and eluted in flash column using reverse phase silica 
at 40 % ACN/H2O to get the intermediate ester, which was then dissolved in 2 ml of MeOH and 
treated with 50% NH2OH/water mixture (1 ml) overnight to afford the targeted product. Reaction 
mixture was dried and purified using reverse column and further by HPLC using ACN (0.1% 
HCOOH) /H2O (0.1% HCOOH) as eluent. 94 mg, 40% overall yield. 
1H NMR (400 MHz, MeOD) 
δ 7.61 (s, 1H), 7.06 (s, 1H), 4.14 (s, 3H), 3.97 (d, J = 14.7 Hz, 6H), 3.50 (s, 4H), 3.15 (s, 3H), 3.05 
(s, 3H), 2.74 – 2.57 (m, 3H), 2.38 (s, 3H), 2.22 – 2.03 (m, 3H), 1.90 (d, J = 24.1 Hz, 3H), 1.63 (d, 
J = 48.4 Hz, 4H), 1.48-1.42 (m, 3H), 1.40-1.31 (m, 6H). 13C NMR (100 MHz, MeOD) δ 170.9, 
164.2, 158.0, 155.5, 152.0, 146.6, 110.9, 108.5, 101.5, 70.3, 57.4, 56.8, 56.6, 53.1, 46.4, 44.3, 32.4, 
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29.8, 29.2, 28.8, 26.8, 25.1, 24.1, 20.3. HRMS (ESI): m/z calcd for C30H49N7O4 [M + H]
+, 
572.3924; found, 572.3925. HPLC purity 96.80%; tR= 13.370. 
8-((4-((1-benzylpiperidin-4-yl)amino)-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-7-
yl)oxy)- N-hydroxyoctanamide (30): Targeted analog 30 was synthesized from the anthranillic 
acid starting material.7-(benzyloxy)-N-(1-benzylpiperidin-4-yl)-2-(4-methyl-1,4-diazepan-1-
yl)quinazolin-4-amine (27): prepared according to the procedure A and B.1H NMR (400 MHz, 
CDCl3) δ 7.90 (d, J = 3.6 Hz, 1H), 7.26-7.18 (m, 5H), 7.12 (s, 1H), 6.98 (d, J = 3.9, 1H), 5.87 (s, 
1H), 4.39-4.12 (m, 5H), 3.92 (s, 3H), 3.63 (s, 2H), 3.20 (d, J = 4.6 Hz, 2H), 3.04 (d, J = 2.4 Hz, 
2H), 2.52 (d, J = 2.4 Hz, 2H), 2.28 (s, 3H), 1.82-1.66 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 
163.0, 159.0, 158.6, 138.4, 129.1, 128.2, 127.0, 122.2, 112.1, 104.8, 104.3, 63.1, 58.8, 57.2, 55.3, 
52.4, 48.2, 46.6, 45.9, 45.8, 32.0, 27.6. MALDI-TOF: m/z for C27H36N6O [M + H]
+ is 461.9. 
4-((1-benzylpiperidin-4-yl)amino)-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-7-ol (28): 
Aryl demethylation using BBr3 was employed.[111] BBr3 solution in DCM (1 ml, 1M) was added 
to the ice cold solution of compound 27 (450 mg, 1 mmol), resulting solution was allowed to be 
in normal rt and stirred the reaction mixture under inert atmosphere. Reaction was monitored using 
mass spec (MALDI-TOF), after completion of the reaction at about 48 h, water was added to the 
mixture and basified with NaHCO3, extracted with DCM, washed with brine and dried to obtain a 
pale yellow solid and used for next steps without purification. MALDI-TOF: m/z for C26H34N6O[M 
+ H]+ is 447.8, ratio of the product was over 90% to starting material. 
8-((4-((1-benzylpiperidin-4-yl)amino)-2-(4-methyl-1,4-diazepan-1-yl)quinazolin-7-
yl)oxy)- N-hydroxyoctanamide (30): Procedure D using 28 as the starting material, afforded the 
desired intermediate as colorless solid. HRMS (ESI): m/z calcd for C35H50N6O3[M + H]
+, 
603.4022; found, 603.4031. Subsequently, compound 29 was dissolved in 2 ml of MeOH and 
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treated with 50% NH2OH/water mixture (1 ml) overnight to afford the targeted product. Reaction 
mixture was dried and purified using reverse column and further by HPLC using ACN/H2O as 
eluent. Fractions collected were concentrated and lyophilized to get brown powder, 54 mg, 23% 
yield over two steps. 1H NMR (400 MHz, MeOD) δ 8.10 (d, J = 9.2 Hz, 1H), 7.65 – 7.53 (m, 4H), 
7.06 (d, J = 2.2 Hz, 1H), 6.94 (d, J = 8.9 Hz, 1H), 3.94 (d, J = 19.0 Hz, 2H), 3.80 (s, 2H), 3.72 – 
3.59 (m, 4H), 3.50 (s, 2H), 3.22 (s, 3H), 2.48 (s, 2H), 2.34 (d, J = 14.2 Hz, 3H), 2.15 (s, 2H), 2.05 
(s, 4H), 1.96 (s, 5H), 1.86 (s, 2H), 1.68 (s, 2H), 1.46 (s, 4H). 13C NMR (100 MHz, MeOD) δ 175.5, 
167.4, 164.9, 159.7, 153.4, 140.3, 129.1, 128.2, 127.0, 124.9, 114.1, 109.0, 103.6, 68.7, 63.7, 55.3, 
55.1, 46.0, 43.5, 42.6, 41.3, 34.0, 28.5, 28.4, 25.4, 24.7. HRMS (ESI): m/z calcd for C33H47N7O3 
[M + H]+, 590.3819; found, 590.3832. HPLC purity 96.26%; tR= 14.192. 
3.4.2 Molecular Docking Analysis 
Protein Preparation and Grid Generation: The coordinates for the HDAC8/MS-344 
complex (PDB ID: 1T67) and G9a/BIX-01294 complex (PDB ID: 3FPD) were downloaded from 
the RCSB Protein Data Bank. In these structures, MS-344 and BIX-01294 are bound to HDAC8, 
G9a respectively. The PDB protein-ligand structures were processed with the Protein Preparation 
Wizard in the Schrödinger suite. The protein structure integrity was checked and adjusted, and 
missing residues and loop segments near the active site were added using Prime. The receptor was 
prepared for docking by the addition of hydrogen atoms and the removal of co-crystallized 
molecules except for Zn2+, as it is near to the active site in the case HDAC. Active site water 
molecules outside 5.0 Å from the ligand were removed. The bound ligands were used to specify 
the active site. A 3D box was generated around each ligand to enclose the entire vicinity of active 
site. The receptor grid for each target was prepared with the help of OPLS_2005 force field. The 
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grid center was set to be the centroid of the co-crystallized ligand, and the cubic grid had a size of 
20 Å.  
Ligand Preparation: the 2D ligand structures were prepared using ChemBioDraw Ultra 
12.0, and the 3D structures were generated by Schrödinger suite. Schrödinger’s LigPrep program 
was used to generate different conformations of ligands. All possible protomers and ionization 
states were enumerated for 14 and bound ligands using Ionizer at a pH of 7.4. Tautomeric states 
were generated for chemical groups with possible prototropic tautomerism.  
Molecular Docking: molecular docking studies were performed by using a GLIDE 
docking module of Schrödinger suite. It performs grid-based ligand docking with energetics and 
searches for positive interactions between ligand molecules and a typically larger receptor 
molecule, usually a protein. Finally, prepared ligands were docked into the generated receptor 
grids using Glide SP docking precision. The results were analyzed on the basis of the GLIDE 
docking score and molecular recognition interactions. All the 3D figures were obtained using 
Schrödinger Suite 2014-3. 
3.4.3 Cloning, Protein Expression and Purification 
Mouse histone methyltransferase G9a (969-1263) cDNA was amplified from the cDNA of 
BALB/c mouse thymus, and the fragment was sub-cloned into a vector with a 6His-sumo tag. The 
mouse G9a (mG9a) was expressed in Escherichia coli BL21 (DE3) by the addition of 1 mM 
isopropyl-1-thio-D-galactopyranoside (IPTG) and incubated overnight at 16°C. 
The 6His-sumo mG9a (969-1263) protein was purified using the following procedure: 
harvested cell pellet was re-suspended in 20 mM Tris (pH 8.0), 500 mM NaCl, 0.1% β-
mercaptoethanol, and 1 mM PMSF. Cells were lysed by sonicating for 15 s with 6 s intervals for 
a total time of 15 min on an ice bath. The supernatant of cell lysate was loaded onto a Ni+ affinity 
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column (Invitrogen) then washed with buffer (20 mM Tris-HCl pH 8.0, 500 mM NaCl, 20 mM 
imidazole, 0.1% β-mercaptoethanol, and 1 mM PMSF). The 6His-sumo tag was cleaved from the 
column by adding Ubiquitin-like-specific protease 1 (ULP-1) at 4 °C for 12 h. Wash buffer was 
then run through the Ni+ column again and the elution buffer collected. Subsequently, advanced 
protein purification was done by HiTrap Q HP sequential Superdex 200 10/300 GL. Elute of every 
step was analyzed by SDS PAGE, stained by Coomassie brilliant blue (CBB). 
3.4.4 MALDI-TOF-MS 
The in vitro inhibition of G9a by the synthesized compounds were measured by MALDI-
TOF mass spectrum (Bruker MALDI TOF/TOF Analyzer). 400 nM purified G9a, 5 µM 
synthesized histone H3 (1-21) and 10 µM non-radioactive S-adenosyl methionine (Sigma) were 
added in reaction buffer (50 mM HEPES pH 8.0, 5 µg/ml BSA and 0.1% β-Mercaptoethanol) with 
or without inhibitors (5 µM). The reaction was incubated at room temperature for 30 min, and 
stopped by TFA. 1 µl of the sample was mixed with CHCA matrix and m/z peaks were obtained 
at reflection positive mode. The results of mass spectrum were analyzed using the Bruker flex 
analysis software. 
3.4.5 Cell Based Assays 
Cell lines information: 
MDA-MB-231(breast cancer cell line), MCF-7 (breast cancer cell line), A549 (human lung 
cancer cell line), K562 (human immortalized myelogenous leukemia cell line), Hela (human 
cervical cancer cell line), HEK293 (normal cell line). 
Reagents: CCK-8, Trichostatin A and trypsin were purchased from Sigma. 
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Cell line: MDA-MB-231, A549 cell lines were grown at 37°C/5% CO2 in Dulbecco’s 
Modified Eagle’s Medium (from Sigma) supplemented with 10% fetal bovine serum and 2% 200 
mM L-glutamine and 0.5% antibiotic-antimycotic solution (from Sigma). 
Hela, K562 cell lines were grown at 37°C/5% CO2 in RPMI 1640 medium 
(Gibco)supplemented with 10% fetal bovine serum and 0.5% antibiotic-antimycotic solution. 
MCF-7 cell line was grown at 37°C/5% CO2 in Eagle"s Minimum Essential Medium 
supplemented with 10% fetal bovine serum and 0.5% antibiotic-antimycotic solution. 
3.4.6 HDAC Activity Assay 
The manual assay was developed by Thomas’s group.[112] HeLa cells were seeded into 
white 96-well cell culture plates (corning costar 3596) at a density of 8000-10000 cells/well (total 
volume 81 µl culture medium) and incubated under standard cell culture conditions(37°C，5% 
CO2). After 24 h, 9 µl inhibitors with different concentration were added to the HeLa cells and 
incubation was continued for 3 h under cell culture conditions. After this treatment period, 10 µl 
of a 2 mM stock solution of the substrate Boc-K(Ac)-AMC was added into the 96 well plates with 
Hela cells and inhibitors. Cell culture plates were incubated under standard cell culture conditions 
for an additional 3 h before addition of 100 µl/well lysis/developer buffer mix (50 mMTris–HCl, 
pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2, 1 vol% Nonidet-P40, 2.0 mg/ml trypsin, 10 
µM TSA). After final incubation for 3 h under cell culture conditions, fluorescence was measured 
at excitation of λex = 355 nm and emission of λem = 460 nm on the Perkin–Elmer Wallac Victor 
V 1420 multilabel plate reader (Perkin–Elmer, Wellesley, USA). A549 and K562 cell lines used 
the same method, respectively. IC50s were calculated using GraphPad Prizm statistical package 
with sigmoidal variable slope dose response curve fit. 
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3.4.7 G9a H3K9me2 Cellular Assay 
Cells were seeded at 8000-10000 cells (100 µl) in black-walled 96-well plates (Thermo 
165305) and exposed to various inhibitor concentrations for 48 h. After the incubation, the media 
was removed and 100 µl fixation and permeabilization solution (2% formaldehyde in PBS) for 
fixation was added for 30 min. And then use 200 µl 0.1% Triton X100 in PBS washing solution to 
wash (allow wash to shake on a plate shaker for 5 min). After five washes, cells were blocked for 
1 h with 150 µl blocking buffer to each well (1%BSA in PBS) (allow blocking at rt with moderate 
shaking on a plate shaker). After 1 h, remove the blocking buffer from the blocking step and add 
primary antibody in blocking buffer to cover the bottom of each well. (Three out of four replicates 
were exposed to the primary H3K9me2 antibody, Abcam no. 1220 at 1/500 dilution in 1% BSA, 
PBS for overnight, one replicate was reserved for the background control (only blocking buffer). 
The wells were washed five times with 0.1% Tween 20 in PBS, then secondary IR800 conjugated 
antibody (LiCor) and cell tag 700 stain added for 1 h. (incubate for 1 h with gentle shaking at rt, 
protect plate from light during incubation). After 5 wash with 0.1% Tween 20 in PBS, remove 
wash solution completely from wells. Turn the plate upside down and tap or blot gently on paper 
towels to remove traces of wash buffer. The plates were read on an Odyssey CLX (LiCor) scanner 
at both 800 nm (H3K9me2 signal) and 700 nm (cell tag 700 stain signal) channels. IC50s were 
calculated using GraphPad Prizm statistical package with sigmoidal variable slope dose response 
curve fit. 
3.4.8 Toxicity Assay 
A549, MDA-MB-231, MCF-7 and HEK293 cells were seeded at 8000-10000 cells (100 
µl) in white 96-well plates and pre-incubate the plate for 24 h under standard cell culture 
conditions, respectively. And then the cells were exposed to the different inhibitors with various 
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concentrations for 72 h. Finally, 10 µl of CCK-8 kit solution was added to each well and incubated 
for 3-4 hours under standard cell culture conditions, and the 96 well plates were measured the 
absorbance at 450 nm using Perkin–Elmer Wallac Victor 3V 1420 multi label plate reader (Perkin–
Elmer, Wellesley, USA). EC50s were calculated using GraphPad Prizm statistical package with 
sigmoidal variable slope dose response curve fit. 
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APPENDICES: 1H AND 13C SPECTRA OF COMPOUNDS 
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